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Executive Summary
No Fire, No Smoke:  
The Global State 
of Tobacco Harm 
Reduction 2018
The GSTHR report maps for the first time the global, regional and national 
availability and use of safer nicotine products, the regulatory responses to these 
products, and the public health potential of tobacco harm reduction.
Every six seconds someone dies from a smoking-related disease and the 
problem is likely to worsen; the steep smoking declines in richer countries 
are slowing while in poorer countries smoking is set to rise. Existing forms of 
tobacco control are proving insufficient. While many people give up smoking, on 
their own or with medicinal products, many fail. ‘Quit or die’ is no longer the only 
option for those who cannot give up. Safer nicotine products offer another way. 
There is substantial international, independent evidence that these products are 
demonstrably safer than cigarettes. These potential lifesaving products could 
lead to a global revolution in public health.
The global smoking epidemic
» More people smoke cigarettes than use any other form of combustible 
tobacco products 
» The tobacco cigarette is the most dangerous way of consuming nicotine
» The combustion of tobacco is the problem – combustion releases highly 
dangerous toxins
» People smoke for the nicotine but die from the tar and gases
» Smoking is a major contributor to deaths from non-communicable diseases
» It is the poor who suffer most from smoking and the poorest countries are least 
able to enforce effective tobacco controls
» Many people give up smoking on their own and some with the help of 
medicinal products, but many fail 
» The steep declines in smoking prevalence in higher income countries are 
beginning to slow while in many poorer countries smoking is set to rise
» Existing forms of tobacco control are not enough to help people shift away 
from smoking tobacco
Safer nicotine products and tobacco harm reduction
» Safer Nicotine Products (SNP) deliver nicotine with a significant reduction in risk 
as compared to combusted tobacco products – there is ‘No Fire, No Smoke’
» International evidence shows that these products are safer for the individual 
smoker, immediate family and bystanders than smoking cigarettes 
» The provision of safer ways of delivering nicotine enables people to continue 
using nicotine but to avoid the health risks of smoking
» ‘Quit or Die’ is no longer the only option for those who cannot give up 
nicotine. SNP - including e-cigarettes, heat-not-burn products and Swedish 
snus offer another way – ‘Quit or Try’
» The rapid rise in the use of SNP has been driven by consumer demand often 
in the face of public health or government opposition
» Flawed science, misleading public information and sensational media 
reporting are all sowing seeds of doubt about SNP among consumers, 
politicians and the general public
» Banning these products, or subjecting them to onerous regulation or high 
taxation effectively deny access to potentially lifesaving products 
» SNP could not only effect a global revolution in public health but also at no 
cost to governments
Key figures
Smoking
» Every six seconds a person dies from a smoking-related disease
» Half of all those who smoke will die prematurely from a smoking-related 
disease
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» Over six million people die from a smoking-related disease every year
» More people die from smoking cigarettes than from malaria, HIV and 
tuberculosis combined
» The WHO estimates that by the end of the century one billion people will have 
died from a smoking-related disease
» The global cost of smoking-related diseases in terms of health care and lost 
productivity is estimated by the WHO at USD $1 trillion annually
Safer nicotine products
» E-cigarettes are estimated to be 95% safer than smoking cigarettes
» Snus is not inhaled, so there is no risk of respiratory disease which accounts for 
nearly half of all smoking-related deaths; and no risk to bystanders. There is 
no significant association with premature deaths, diabetes, pancreatic and oral 
cancers, heart disease or strokes
» It is estimated that by 2021, over 55 million people will be using e-cigarettes or 
heat-not-burn tobacco products and that the global market will be worth USD 
$35 billion
» Use of heat-not-burn products in Japan has seen cigarette sales fall by 27% in 
two years, an unprecedented national decrease in smoking
» In Sweden snus has been instrumental in reducing smoking related mortality 
to the lowest in the EU
» If the EU ban on snus is lifted, then around 320,000 premature deaths a year 
could be prevented in the EU
» As Norwegian smokers switch to snus, the smoking rate among young 
Norwegian women has dropped to a world record of 1%
» Over 50% of the UK’s 3 million e-cigarette users are ex-smokers
» 39 countries have inappropriately banned SNP including countries whose 
smoking prevalence is predicted to rise
» 62 countries regulate e-cigarettes under tobacco legislation.
The report – key themes
The GSTHR report is founded on the principle of harm reduction. Harm 
reduction refers to policies, regulations and actions focussed on reducing health 
risks, usually by providing safer forms of hazardous products or encouraging 
less risky behaviours, rather than simply banning products or behaviours. Harm 
reduction is a proven public health strategy.
How does tobacco harm reduction work in practice? It works through the 
provision of SNP allowing people to be able to consume nicotine without 
also inhaling the cancer-producing chemicals found in cigarette smoke. New 
products include e-cigarettes which first appeared in the mid-2000s. More 
recently, heat-not-burn devices have been developed that work by heating 
tobacco below the level of combustion sufficient to release the nicotine but with 
significantly reduced levels of toxins. Smokeless Swedish snus has been around 
for about 200 years but has enjoyed a renaissance in the light of the evidence 
that it makes a significant contribution to tobacco harm reduction. 
SNP and health. Independent national scientific, clinical and parliamentary 
reviews have concluded that:
» There are no circumstances in which it is safer to smoke than to use SNP
» There is a continuum of risk, with cigarettes the highest and non-combustible 
products the lowest risk
» People who switch from smoking to vaping can experience an improvement in 
health 
» Switching to vaping can help people quit smoking
» There are currently no known long-term adverse health effects of vaping or 
snus
» While young people will experiment with e-cigarettes, there is no evidence 
that this leads to regular cigarette smoking. Smoking rates among young 
people are falling.
» There is no evidence for adverse effects from passive vaping – hence no risk to 
bystanders
» There are no known short or long term adverse effects from using nicotine 
meaning that being ‘dependent’ on nicotine of itself is not a health risk
Harm reduction is more than just health and safety – there is an important 
human rights aspect. The preamble to the World Health Organization 
Constitution 1946 states that “The enjoyment of the highest attainable standard 
of health is one of the fundamental rights of every human being without 
distinction of race, religion, political belief, economic or social condition”. This 
includes smokers and their right to information, services and products that may 
assist them to achieve that objective. 
Smokers should not be denied access to harm reduction products that will 
help them avoid disease and early death from smoking. This is recognised in 
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the Framework Convention on Tobacco Control 2005 which states that harm 
reduction is one of the defining strategies of tobacco control: “A range of 
supply, demand and harm reduction strategies that aim to improve the health of 
a population by eliminating or reducing their consumption of tobacco products 
and exposure to tobacco smoke”.
Consumers of SNP. In only a few years there has been rapid uptake in the use 
of the newer SNP in many countries while in both Sweden and Norway snus has 
replaced smoking over a relatively short space of time. In Japan the uptake of 
heat-not-burn products has seen the biggest ever drop in cigarette sales. This 
indicates an appetite for SNP such that where they are available – and if they are 
attractive and suitable alternatives to smoking – many smokers will choose them 
over smoking. 
A key question is whether use of SNP drives down smoking and improves public 
health. The strongest evidence so far comes from Sweden where the uptake 
of snus and the decline in smoking has given this country the lowest smoking 
related mortality in Europe.
The uptake of SNP has mostly occurred in the absence of government, tobacco 
control and public health endorsement. It has been the ordinary consumers 
whose interest in SNP has driven this and who have been active in offering help 
and advice to those who wish to switch from smoking.
Regulation and control. The advent of new SNP presents challenges to tobacco 
control regimes at both a national and international level. A consumer can vape 
nicotine reasonably freely in the USA, UK and New Zealand, but faces fines or 
imprisonment in Thailand and Australia. 
Legislators and politicians are no less immune than health professionals or 
ordinary consumers to being confused by contradictory research findings or 
influenced by the work of anti-harm reduction organisations and sensationalised 
media reporting. 
To use the law to deny or inhibit access to SNP denies the robust and 
independent evidence base, and paradoxically perpetuates use of cigarettes 
(which are freely available the world over) and ensures continuing profits for 
tobacco companies. 
Appropriate regulation should ensure consumer safety and confidence, 
encourage product innovation, and favour use of SNP over cigarettes. 
The harm reduction vision. It is imperative to keep eyes on the prize – an end to 
smoking - and not allow over-proscriptive regulation and control to deny access 
to safer products. SNP have the potential to be one of the most dramatic public 
health coups of modern times. While most global public health interventions 
come at great financial cost, this strategy costs governments, international 
agencies and NGOs nothing. 
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Scope and terminology
This Global State of Tobacco Harm Reduction (GSTHR) report was conceived 
against the backdrop of the major changes in tobacco harm reduction of the last 
decade. It takes its inspiration from the Global State of Harm Reduction report, 
which was first published by the International Harm Reduction Association (now 
called Harm Reduction International) back in 2006 and which is about to go into 
its sixth iteration.  
It tracks the progress or otherwise of drug harm reduction throughout the world.
In the same vein, the GSTHR report is the first attempt to map global, regional 
and national changes in the availability and use of safer nicotine products and 
the regulatory response, with the aim of updating this information on a biennial 
basis.
The information in the GSTHR will be useful for policy-makers, policy analysts, 
consumers, legislators, regulators, civil society organisations, media, public 
health workers, academics and researchers, as well as manufacturers and 
distributors.
The report focuses on those products that are considered to be safer 
alternatives to combustible tobacco products such as cigarettes, cigars,  
and pipes. In policy terms, these safer products are generally considered to 
be tobacco harm reduction products, because they deliver nicotine 
with a significant reduction in risk as compared to combusted tobacco 
products. 
There are many different terms for tobacco harm reduction products, 
including alternative nicotine products, new or novel nicotine products, next 
generation products, modified risk products, reduced risk products, and 
electronic nicotine delivery systems (ENDS). For the purpose of consistency, 
this report refers to safer nicotine products (SNP) when referring to all the 
tobacco harm reduction products: electronic-cigarettes (e-cigarettes), heat-
not-burn (HNB) products and Western-style smokeless tobacco, particularly 
Swedish pasteurised snus. Forms of smokeless tobacco, such as betel quid, 
paan and gutkha, are not covered in this report. However, the products that 
currently have the most global reach are e-cigarettes. It is the current state of 
these products in terms of epidemiology, health research, use and control that 
is most reflected in this report.
Website 
An interactive GSTHR website is available at www.gsthr.org, where you will find  
a downloadable PDF version of the report, country-by-country profiles, and slide 
versions of some of the infographics and tables. There is also a short summary of 
the report available with translations in various languages.
Updating
It is expected that this report will be updated every two years. However, the web-
site will be updated regularly and therefore it would be very helpful if you could 
notify us of any new information, or information that may need to be corrected. 
Please contact us at www.gsthr.org/update and complete the online web form.
Data sources and report limitations
A wide range of data sources have been used to gather evidence on the 
prevalence of smoking, regulations and on the availability and use of SNP and 
legal and regulatory provisions.
The most recent World Health Organization (WHO) statistics have been used to 
outline smoking prevalence and related mortality globally and on a country-by-
-country basis. These data are readily available online.
Websites that interpret data have also been used as reference data in this report, 
including: Our World in Data,1 an online data resource produced by the Oxford 
Martin Programme on Global Development at the University of Oxford; and 
The Tobacco Atlas,2 an online resource that maps the nature and magnitude of 
tobacco use and is produced in partnership with the American Cancer Society 
and Vital Strategies. Information on the regulation of e-cigarettes has largely 
been gathered via Vapetrotter,3 a commercial website with a store directory and 
a database of vaping laws in each country, which is regularly updated.
1  Oxford Martin Programme on Global Development, University of Oxford, Our World in Data 
 https://ourworldindata.org/smoking 
2 American Cancer Society, Tobacco Atlas https://tobaccoatlas.org
3 Vapetrotter https://www.vapetrotter.com/laws/
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Key contacts from academia, public health, policy institutes, industry and 
advocacy organisations in various countries have kindly provided information on 
e-cigarettes, snus and the availability of heat-not-burn products, where this has 
not been openly available from published sources. 
Methodologies of estimates, survey dates, sample sizes, representativeness 
and categorisations of types of smoker or SNP users vary between studies, and 
this makes it very difficult to compare like with like in many cases. There is no 
standard approach to gathering data on SNP. Therefore, while the data displayed 
are accurate for each country, it may well have been gathered differently, or 
analysed differently across countries. Where we know this is the case, it is noted 
in the text. Readers are therefore advised to use caution if comparing one 
country’s profile with another.
There are large gaps in the data on SNP, and the situation in terms of regulation 
and estimates of the prevalence of their use is changing all the time. The rapid 
growth and continuing development of SNP means that the whole landscape, 
from market analysis to control regimes, is very fluid and dynamic. 
While every effort has been made to provide accurate information including on 
the legal status of SNP, Knowledge-Action-Change cannot be held responsible 
for any action taken on the basis of information contained in the report. The 
purpose of the report is to convey information in a consolidated format that may 
be relevant to interested parties, but no commercial or other decisions should 
be made on the basis of the compendium due to the limitations advised above. 
Use and quotation of material from the report
Copyright in original material in No Fire, No Smoke: The Global State of  
Tobacco Harm Reduction 2018 rests with Knowledge-Action-Change, with the 
exception of graphs and tables and text where other sources are acknowledged. 
Users of the report and the website are free to reproduce material, subject to fair 
usage, without first acquiring permission of the copyright holder, and subject to 
acknowledgement of the source.
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Forewords
Nancy Sutthoff
For all the political, public health, scientific, clinical and media discussions 
about safer nicotine products, there is little thought given to the consumers 
of these products, their reasons for utilising them, why they have found them 
to be effective and why they fight for the right to continue to use them. Which 
is interesting, because the genesis of tobacco harm reduction was entirely 
consumer driven. Those that would tell you that vaping is a “big tobacco 
construct” cannot believe that something so disruptive, so widespread and so 
popular could possibly be anything other than a revenue-raising campaign 
from the marketing department of a major corporation. Frankly, this is insulting  
to the thousands of us who have found the technology – on our own, through 
our own research - as a means of self-determination of our own health and 
wellbeing.  
For some it was about the negative health effects of smoking, for others it was 
about the financial impact of increased taxes on tobacco that were negatively 
impacting the family budget. But for ALL of us, it was about making an individual, 
informed choice about our wellbeing. Most of us had tried “medically approved” 
nicotine replacement therapy for smoking cessation offered by the health system 
and had failed. Yet we persisted and found both vaping and the solution we 
needed.
But the switch is not just about health. While many may have begun to vape 
to switch from combustible tobacco, many now continue to vape as a lifestyle 
choice using a consumer product rather than a smoking cessation aid or  
a medicine. There have been entire communities built upon the shared journey 
of vape from a diverse cross-section of society.  I have been at vape meets where 
government ministers, teachers, ex-gang members and housewives have sat 
together and had discussions that range from the weather to the latest sport 
scores, over a pint or glass of wine. As a social construct, vaping has created  
a support system and community that is egalitarian and tolerant.
Perhaps those opposed to tobacco harm reduction should think hard about how 
condoms prevent the spread of sexually transmitted infections and unwanted 
pregnancies, about how vaccinations have wiped polio off the face of the planet, 
or even all the different ways that their road travel is now far safer from seat belts 
to crash helmets and then get back to us about what harm reduction and self-
determination of wellbeing really means. The door is open, and we are waiting 
to have that conversation on equal, neutral territory.
Nancy Sutthoff is Co-founder and Co-Director of Aotearoa Vapers Community 
Advocacy (AVCA) in New Zealand (www.avca.org). She is also the President of 
the governing board of INNCO (the International Network of Nicotine Consumer 
Organisations (www.innco.org)): an international group of over 30 consumer 
organisations that work towards advocating for the rights of users of alternative 
nicotine consumption technologies.
David Sweanor
Our world has over a billion people smoking cigarettes, spending roughly 
US$800 billion annually. Add in all those smoking other tobacco products (bidis, 
kreteks, etc.) and we face a seemingly unbeatable adversary as we seek to 
tackle the myriad diseases caused from the inhalation of smoke. But look more 
creatively, and we are facing not an insurmountable challenge so much as a 
tremendous opportunity.
At a time when new disruptive technology is upending so many markets, the 
technology of the cigarette (setting fire to dried leaves) is from the Stone Age. 
And unlike many other areas, where new products meet needs many of us 
did not know we had (who really had a pressing need to check what friends 
in another country were doing while out walking the dog?), the consumers of 
cigarettes are already highly dissatisfied with the status quo. Many want to stop 
smoking because they know the product is killing them.
Fortunately, we now have rapidly accumulating evidence that a range of non-
combustion products can replace cigarettes. Together smokeless Swedish snus 
(which has actually been around for over 200 years), e-cigarettes and heated 
tobacco devices have led to massive declines in smoking in countries such as 
Japan, Norway, South Korea, the UK, France and Iceland. 
These breakthroughs have largely occurred despite opposition from regulators, 
major health bodies and anti-smoking groups. Which raises the question of just 
how rapidly we could consign cigarettes to the ashtray of history by facilitating 
better options, better consumer information and the use of risk-proportionate 
regulation?
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We have the ability right now to redirect market forces to solving the cigarette 
pandemic. As with past transformations, the problem is actually a solution 
awaiting those with the vision to see it and the willingness to seize the 
opportunity.
David Sweanor is Chair of the Centre for Health Law, Policy and Ethics and an 
Adjunct Professor of Law at the University of Ottawa. He has worked on tobacco 
and health issues since the early 1980s and played a key role in a wide range of 
Canadian and global tobacco control precedents. Recently, he has spent much  
of his time focused on appropriate policies for reduced risk products. 
Martin Jarvis
More than 40 years have passed since Michael Russell’s key insight: that 
cigarette smoking is fundamentally a form of nicotine-seeking behaviour.  
This led to his celebrated dictum that “people smoke for nicotine, but they 
die from the tar”. That should have made tobacco use the poster boy for harm 
reduction approaches: nicotine, while not harmless, does not contribute much 
to smoking’s effects on health. Cleaning up its contaminated delivery system, 
the cigarette, should radically mitigate the resulting burden of morbidity and 
mortality.
Unfortunately, there were numerous missteps and own-goals before tobacco 
harm reduction could begin to take on a semblance of plausible reality. Low-tar 
cigarettes offered the promise but not the reality of reduced exposure; nicotine 
replacement products, at least as formulated and marketed by pharmaceutical 
companies, reduced withdrawal and modestly assisted cigarette cessation, but 
did not offer consumers a satisfying way of using nicotine; in 1992, the European 
Union, aided and abetted by tobacco control activists, implemented an EU-
wide ban on Swedish-type snus (the only real-world example of tobacco harm 
reduction in action); a ban that still stands some 25 years later. Most importantly, 
researchers had no success in developing alternative, non-combustible, forms of 
nicotine delivery that could compete with cigarettes.
Everything began to change in the early 2000s with the launch of the first 
electronic cigarettes.  Developments in battery technology (driven by the needs 
of the mobile phone industry) and sophisticated electronic controls initiated  
a technological revolution which is still gathering pace, and began a process of 
market disruption in the way consumers ingest nicotine. Increasingly effective 
vaping devices which permit consumers to titrate their nicotine intake have 
gained market share and have now been joined by heat-not-burn products 
which mimic cigarette pharmacokinetics but with much reduced toxicant yields.
The challenge now does not come so much from achieving viable non-
combustible alternatives to the cigarette, although a process of continued 
evolution towards better products seems inevitable.  The more intractable 
questions, about a transition away from cigarettes to non-combustibles, concern 
governments and regulatory authorities. Does the new generation of nicotine 
devices represent just the same old evil tobacco industry in a new disguise? 
Should vaping be encouraged or banned? How should it be taxed, how 
promoted, and what form should product regulation take? Is vaping among 
young people a major concern, and if so, how can they be protected? These 
issues have provoked bitter debate and schism and no consensus is yet in view. 
There is an urgent need for evidence and for informed discussion. This report 
forms a valuable contribution to that process.
Martin Jarvis is Emeritus Professor of Health Psychology at the Department of 
Behavioural Science and Health, University of London. He was for many years  
a close colleague of Michael Russell in his smoking research group. Over the past 
40 years, he has researched and published widely on nicotine and tobacco. He 
was Specialist Adviser to the UK House of Commons Health Committee’s inquiries 
into tobacco and health and into smoking in public places. He is a trustee of UK 
Action on Smoking and Health (ASH). He was for some years a member of the 
WHO’s study group on Tobacco Product Regulation. He received the John Slade 
award of the Society for Research on Nicotine and Tobacco. 
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Key acronyms and abbreviations
ASH  –  Action on Smoking and Health (UK)
AFNOR – Association Française de Normalisation 
BAT – British American Tobacco
BSI – British Standards Institute 
CDC – Center for Disease Control and Prevention (USA)
CDER – Center for Drug Evaluation and Research (USA)
CEN – European Committee for Standardisation 
COP – WHO Framework Convention on Tobacco Control, Conference of the 
Parties 
COT – Committee on Toxicity, Carcinogenicity and Mutagenicity of Chemicals in 
Food, Consumer Products and the Environment (UK) 
CTP – Center for Tobacco Products (USA)
ENDS – Electronic Nicotine Delivery Systems
ESTOC – European Smokeless Tobacco Council
FCTC – WHO Framework Convention on Tobacco Control 
FDA – US Food and Drug Administration
GSTHR – The Global State of Tobacco Harm Reduction
HNB – Heat-not-burn
HPHCs – Harmful and potentially harmful constituents
IARC – International Agency for Research on Cancer
ISO – International Organisation for Standardisation 
JTI – Japan Tobacco International
LMIC – Low and middle-income countries 
MHRA – Medicines and Healthcare products Regulatory Agency (UK)
MRTPA – Modified Risk Tobacco Product Application
NCD – Non-communicable diseases
NGO – Non-governmental organisation
NRT – Nicotine Replacement Therapy
ONS – Office for National Statistics (Great Britain)
PAHs – Polycyclic aromatic hydrocarbons
PMI – Philip Morris International
PMTA – Pre-Market Tobacco Application (USA)
RCP – Royal College of Physicians (UK)
SDA – UN 2030 Sustainable Development Agenda
SNP – Safer nicotine products
TPD – Tobacco Products Directive (EU)
TPSAC – Tobacco Products Scientific Advisory Committee (USA)
TSNAs – Tobacco-specific nitrosamines
WCO – World Customs Organization
WHO – World Health Organization
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Chapter 1
Introduction: tobacco 
harm reduction
‘Harm reduction’ refers to policies, regulations and actions that are focused on 
reducing health risks, usually by providing safer forms of hazardous products, or 
encouraging less risky behaviours, rather than simply focusing on eradication of 
products or behaviours.
Arguably, harm reduction as a purely medical intervention (and not at the time 
called harm reduction) can be traced as far back as the 1920s. Following the 
first legal bans on the unauthorised possession of opiates, some doctors in both 
the USA and the UK prescribed morphine or heroin to dependent patients to 
help them manage their condition. In 1926, a committee of UK doctors agreed 
that as a treatment of last resort, it was legitimate medical practice to prescribe 
morphine, heroin or cocaine to a drug-dependent patient.4 
Consumer-led drugs harm reduction emerged in the 1960s, with the rise of 
recreational drug use across North America and Europe, and the development 
of lay advice about how to use drugs in a safer way.5 Alcohol harm reduction 
goes back to early provisions to regulate the content of alcoholic drinks, in order 
to reduce contamination and risk of poisoning. Later, there were attempts to 
modify drinking practices in drinking venues (for example during the First World 
War), and by the 1970s, there was interest in making drinking safer for drinkers 
and those affected by drinking. 
Our everyday lives are replete with examples of potentially dangerous 
products or behaviours being modified – often by manufacturers, regulators or 
consumers – to enable use of the product while reducing risk of harm. Consider, 
for example, the design of motor vehicles and roads to make travel safer, 
laws that separate drinking and driving, and driver licensing and education. 
Or the introduction of products offering safer options, such as refrigerators 
and improved food storage, leading to a reduction in disease due to food 
contamination. This is harm reduction in practice, though rarely in name. It is 
notable too that many interventions to reduce risk emanate from manufacturers 
and consumer demand, or from regulators, but not necessarily from public 
health practitioners.
But, harm reduction as a health strategy came to prominence during the HIV/
AIDS epidemic of the 1980s. The phrase came to be associated with those in gay 
communities on the American west coast and in New York, who banded  
together in grassroots action groups to help protect their health in the face of 
fear and vilification from society at large. This was encapsulated in the slogan 
‘safer sex’ which acknowledged that sexual abstinence was not a moral or 
feasible method for preventing HIV transmission, and that condoms and safer 
sexual behaviour were key.
Once it became clear that those people who injected drugs were similarly at risk, 
new movements arose around the world to campaign for health interventions 
such as needle and syringe exchanges, opiate substitute therapy, overdose 
prevention and drug consumption rooms, that would help preserve the lives of 
those who, for whatever reason, continued to inject drugs.
Drug harm reduction is defined by Harm Reduction International as “Policies, 
programmes and practices that aim to reduce the harms associated with the 
use of psychoactive drugs in people unable or unwilling to stop. The defining 
features are the focus on the prevention of harm, rather than on the prevention 
of drug use itself, and the focus on people who continue to use drugs”.6 
This means that harm reduction is more than just health and safety, more 
than just the equivalent of wearing seats belts or crash helmets. It sits at the 
intersection of public health and human rights as expressed in the WHO Ottawa 
Charter on Health Promotion, which states that “People cannot achieve their 
fullest health potential unless they are able to take control of those things which 
determine their health”.7 In the ‘carrot and stick’ approaches to encouraging 
4 Departmental committee on morphine and heroin addiction, Ministry of Health. Rolleston report. Ministry of 
Health, UK, 1926
5 Stimson, G.V., Minimising harm from drug use. In Strang, J. and Gossop, M. (eds) Heroin Addiction and Drug 
Policy: The British System. Oxford University Press, 1994
6 Harm Reduction International, What is harm reduction? A position statement  
 https://www.hri.global/what-is-harm-reduction
7 World Health Organization. Ottawa Charter for Health Promotion. WHO, 1986. Available at 
 http://www.who.int/healthpromotion/conferences/previous/ottawa/en/
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changes in human behaviour, harm reduction is firmly at the carrot end of the 
strategy, with an ethos that sustainable changes in behaviour originate in, and 
are continued, only if they fit with what people both want and are able to do. 
“Harm reduction is actually more than just health and safety… It sits at the 
intersection of public health and human rights”.
Smoking lagged behind other areas regarding harm reduction because there 
were few reduced risk options for smokers, with the exception of snus in 
Scandinavia and US smokeless tobaccos. From the 1980s onwards, the main 
tobacco harm reduction product was nicotine replacement therapy (NRT): the 
provision of controlled doses of pure nicotine via gums, patches, lozenges, 
inhalers and sprays.  NRT was first used in the USA in 1984. It is now the 
medically approved way to consume nicotine without tobacco and is on the 
WHO’s List of Essential Medicines. Though still banned or tightly regulated in 
some countries, in others NRT is widely available, and in many places, it can be 
obtained without prescription.
Since the mid-2000s, however, a new harm reduction front has opened. We have 
seen the dramatic rise of electronic cigarettes (e-cigarettes), together with the 
realisation of significant public health gains from the switch from combustible 
tobacco to smokeless tobacco (snus) in Sweden,8 and a proliferation in the range 
of newer products, such as heat-not-burn (HNB) devices.   
“The tobacco harm reduction proposition is straightforward: smokers risk 
disease and premature death; most smokers say they want to stop smoking 
and many have tried; many find it hard to stop and many are unable or un-
willing to give up nicotine. The provision of safer ways of delivering nicotine 
enables people to continue using nicotine but to avoid the health risks of 
smoking”.9
The tobacco cigarette remains the most dangerous of all nicotine delivery 
systems. Harm reduction products have greatly expanded the choice for  
consumers who wish to continue to enjoy nicotine without the risks inherent in 
cigarettes, or who are looking for a more acceptable way to quit smoking than 
that provided by cold turkey, counselling, medicinal products, or NRT. With these 
products, quitting smoking can be pleasurable, rather than burdensome. It also 
provides governments with an additional tool to reduce harms from smoking, 
alongside measures to reduce supply and demand, such as tobacco taxes, age 
restrictions, advertising restrictions and bans on smoking in public places.  
“The tobacco cigarette remains the most dangerous of all nicotine delivery 
systems”.
These technological advances in nicotine delivery have been accompanied in 
some countries by developments and changes in the profile of manufacturers 
and distributors, product innovation, investment in research and development, 
and a market driven by product availability and consumer choice. In turn, this has 
raised challenges for governments in terms of appropriate regulatory models, 
resulting in conflicts between the aims of international tobacco control and the 
individual right to health. 
The idea of tobacco harm reduction can be traced to Professor Michael Russell, 
a UK psychiatrist. He observed that people smoke for the effects of nicotine, but 
that illness and premature mortality result from the tar that they inhale. Russell 
pointed to the health gains that might be achieved if the tar in cigarettes could 
be reduced, while maintaining nicotine levels.10
“A case is advanced for selected nicotine replacement products to be made 
as palatable and acceptable as possible and actively promoted on the open 
market to enable them to compete with tobacco products. They will also need 
health authority endorsement, tax advantages and support from the anti-
smoking movement if tobacco use is to be gradually phased out altogether. 
“It is essential for policy makers to understand and accept that people would 
not use tobacco unless it contained nicotine, and that they are more likely 
to give it up if a reasonably pleasant and less harmful alternative source of 
nicotine is available. It is nicotine that people cannot easily do without, not 
tobacco. 
8 Foulds J. et al. (2003). Effect of smokeless tobacco (snus) on smoking and public health in Sweden.  
Tobacco Control, 12:349-359 
9 Stimson, G.V. (2016) A tale of two epidemics: drugs harm reduction and tobacco harm reduction in the United 
Kingdom. Drugs and Alcohol Today, 16 (3), p. 203-11
10 Russell, M.J. (1976) Low-tar medium nicotine cigarettes: a new approach to safer smoking.  
British Medical Journal. 1, p. 1430–3
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“It will be assumed throughout that our main concern is to reduce tobacco-
related diseases and that moral objections to the recreational and even 
addictive use of a drug can be discounted provided it is not physically, 
psychologically or socially harmful to the user or to others”. 
Michael Russell, British Journal of Addiction, 1991.11
Tobacco harm reduction has travelled a separate but parallel road to drugs, sex 
and alcohol harm reduction. There might be some as yet unexplored synergies: 
Michael Russell, for example, started his work at the Addiction Research Unit 
at the Institute of Psychiatry in London at the same time that the unit was 
researching heroin prescribing as a way of reducing risks for heroin users.
Tobacco harm reduction was advocated by the UK Royal College of Physicians 
(RCP) in the 2007 report Harm reduction in nicotine addiction. The report argued 
that “Harm reduction in smoking can be achieved by providing smokers with 
safer sources of nicotine that are acceptable and effective cigarette substitutes” 
and suggested the potential for rebalancing the market in favour of the safest 
nicotine products.12 At the time the report was written, the only safer nicotine 
option for most smokers was NRT. The exception was in Sweden, where snus –  
a moist, pasteurised low-risk oral tobacco – is popular amongst men and  
accounts for Sweden’s low prevalence of lung cancer. The RCP put snus forward 
as proof of concept for tobacco harm reduction.
The following quotes demonstrate an increasing global recognition for 
tobacco harm reduction.
“We suggested [in 2007] that making effective, affordable, socially acceptab-
le, low-hazard nicotine products available to smokers as a market alternative 
to cigarettes could generate significant health gains by allowing smokers to 
stop smoking tobacco without having to stop using nicotine to which they are 
addicted. As most of the harm caused by smoking arises not from nicotine 
but from other components of tobacco smoke, the health and life expectancy 
of today’s smokers could radically be improved by encouraging as many as 
possible to switch to a smoke-free source of nicotine”.
Royal College of Physicians, Nicotine without smoke, 2016.13
“We will help people quit smoking by permitting innovative technologies 
that minimise the risk of harm. We will maximise the availability of safer 
alternatives to smoking”.
UK Department of Health, Towards a smoke-free generation, 2017.14
“The BMA’s ambition is to achieve a tobacco-free society, where there is  
significantly reduced mortality from tobacco-related diseases. Given that  
e-cigarettes are now the most popular device used in attempts to quit  
smoking, and that many people have used them to successfully quit tobacco 
use, they have significant potential to support this ambition, and help reduce 
tobacco-related harm”. 
British Medical Association, E-cigarettes: balancing risks and opportunities, 
2017.15
“These individuals [who cannot quit smoking] should be encouraged to 
switch to the least harmful form of tobacco product possible; switching to the 
exclusive use of e-cigarettes is preferable to continuing to smoke combustible 
products”.
American Cancer Institute, Position statement on e-cigarettes, 2018.16
11 Russell, M. J. (1991) The future of nicotine replacement. British Journal of Addiction. 86(5), p. 653-8. Available at 
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1360-0443.1991.tb01825.x 
12 Tobacco Advisory Group, Royal College of Physicians. Harm reduction in nicotine addiction: helping people 
who can’t quit. London, RCP, 2007. p. 241 
13 Tobacco Advisory Group, Royal College of Physicians. Nicotine without smoke: Tobacco harm reduction.  
London, RCP, 2016. p.11. Available at https://www.rcplondon.ac.uk/file/3563/download?token=Mu0K_ZR0
14 UK Department of Health. Towards a smoke-free generation: a tobacco control plan for England. DH, 2017. p.5. 
Available at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/
file/630217/Towards_a_Smoke_free_Generation_-_A_Tobacco_Control_Plan_for_England_2017-2022__2_.pdf
15 British Medical Association. E-cigarettes: balancing risks and opportunities. BMA, 2017. p. 11. Available at 
https://www.bma.org.uk/collective-voice/policy-and-research/public-and-population-health/tobacco/ 
e-cigarettes
16 American Cancer Institute, Position statement on e-cigarettes (2018)
 https://www.cancer.org/healthy/stay-away-from-tobacco/e-cigarette-position-statement.html
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“If long term smokers who have been unable to quit smoking tobacco 
cigarettes switch to e-cigarettes, thousands of lives could be saved”.
 Trent Zimmerman MP, Chair of the Australian parliamentary committee  
report into the use and marketing of electronic cigarettes and personal  
vaporisers in Australia, 2018.17
“If the great majority of tobacco smokers who are unable or unwilling to quit 
would switch without delay to using an alternative source of nicotine with 
lower health risks, and eventually stop using it, this would represent  
a significant contemporary public health achievement”.
WHO, Electronic nicotine delivery systems and electronic non-nicotine  
delivery systems, 2016.18
“‘Tobacco control’ means a range of supply, demand and harm reduction stra-
tegies that aim to improve the health of a population by eliminating or reducing 
their consumption of tobacco products and exposure to tobacco smoke”. 
WHO, Framework Convention on Tobacco Control, 2003.19
Conclusion
We end this chapter by putting forward what might be called the tobacco harm 
reduction proposition, which states that:          
» Harm reduction is based on the principle of trying to reduce the risk of using 
certain products or engaging in certain behaviours or activities;
» It recognises the reality of aiming to reduce risk rather than believing that risk 
can eliminated;
» There are examples of harm reduction in many areas of daily life, such as road 
safety;
» But in the context of public health it has particular resonance, existing as it 
does at the crossroads between public health and human rights;
» The pioneering examples operating at this intersect were the grassroots 
activity among the gay and drug-using communities, looking to protect 
their health through safer sex and drug-using strategies in the face of official 
marginalisation and discrimination;
» In the same way that unsafe sex and drug injecting leaves the individual at 
risk of life-threatening disease, the cigarette, as the most dangerous nicotine 
delivery system, similarly puts the smoker at risk of disease and death;
» However, there is increasing international recognition that new options now 
exist for the smoker who cannot or does not want to stop consuming nicotine, 
but wants to switch away from smoking. 
But, before we examine those new and safer options in detail, we look at the 
key driver for the report, the imperative behind all forms of tobacco control and 
the issue on which all those involved in public health can agree: the need to 
counteract the devasting impact of the global smoking epidemic.
17 Trent Zimmerman MP. Foreword to the Australian parliamentary committee report into the use and marketing 
of electronic cigarettes and personal vaporisers in Australia. March 2018, p.5. Available at  https://www.aph.
gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/ElectronicCigarettes/Report 
18 World Health Organization. Framework Convention on Tobacco Control: Electronic nicotine delivery systems 
and electronic non-nicotine delivery systems (ENDS/ENNDS): a report by WHO. WHO, 2016. p.2. Available at 
www.who.int/fctc/cop/cop7/FCTC_COP_7_11_EN.pdf 
19 World Health Organization. Framework Convention on Tobacco Control. WHO, 2003. Article 1, para (d) p.4. 
Available at whqlibdoc.who.int/publications/2003/9241591013.pdf
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Smoking tobacco
results in the world’s
deadliest preventable
diseases, prematurely
ending the lives of half
of all smokers.
One person dies from
a smoking-related
disease every six
seconds.
More people die from
smoking cigarettes
than from malaria,
HIV and tuberculosis
combined.
The US Surgeon
General’s report on
tobacco published in
2014 estimated that
in the 50 years since
1964, 20 million
American citizens had
died from a smoking-
-related disease.
Smoking-related death
and disease disprop-
ortionally affects those
living in poverty and
deprivation in richer
countries, and those
with mental health
and other substance
use problems.
The need for tobacco harm reduction
is apparent from global data on smoking.
The statistics relating to smoking-related
mortality and morbidity across the world
are grim:
World Health Organisation.WHO report on the global tobacco epidemic. WHO, 2008. Available
at
US National Cancer Institute and World Health Organisation. The Economics of Tobacco and Tobacco
Control. National Cancer Institute Tobacco Control Monograph 21. NIH Publication No. 16-CA-8029A.
Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer
Institute; and Geneva, CH: World Health Organisation; 2016
1
2
www.who.int/tobacco/mpower/mpower_report_tobacco_crisis_2008.pdf
Smoking cigarettes
is a major cause of
lung and oral cancer,
progressive respirato-
ry diseases such as
emphysema, and
heart disease.
Over six million
people die from
a smoking-related
diseases every year.
The WHO estimates
that by the end of the
century one billion
people will have
succumbed to
a smoking-related
disease.1
The global cost
of treating smoking-
-related diseases
in terms of healthcare
and lost productivity
is estimated by the
WHO at US$1 trillion
annually.2
Chapter 2:
The continuing global  
epidemic of cigarette 
smoking
“The WHO estimates that by the end of the century one billion people will 
have succumbed to a smoking-related disease”.
There are large differences between countries in the overall levels of smoking, 
and in the levels of smoking between men and women. According to WHO data 
for 2015, in 26 countries the prevalence of daily smoking amongst men is above 
40 percent: in Indonesia, a staggering 65 percent of adult males smoke;  
61 percent in East Timor; 57 percent in Tunisia; 51 percent in the Russian 
Federation and in Kiribati; 48 percent in Syria; 46 percent in Georgia and 
Armenia, 45 percent in Laos, Greece and Latvia; 44 percent in the Maldives 
and Egypt; 43 percent in the Solomon Islands and Ukraine; 42 percent in 
China, Papua New Guinea and Cyprus; 42 percent in Lesotho; 41 percent in 
Albania and Mongolia; and 40 percent in Bosnia and Herzegovina, Montenegro, 
Bangladesh, Belarus and Micronesia.3 
These high levels persist despite major global initiatives led by the WHO to 
reduce smoking, and despite the investment of billions of dollars in tobacco 
control to reduce demand and supply.
The prevalence of smoking is lower globally among women than amongst men. 
This global picture of the differences in daily smoking prevalence between men 
and women is shown in Figs 2.1 and 2.2. 
3 These data indicate of the national challenge to reduce smoking-related harms. Country profiles can be seen at 
www.gsthr.org
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Figure 2.1
WHO estimate of daily (tobacco) smoking prevalence age 15+ male
Source: WHO report on the global tobacco epidemic, 2017, Country profiles http://www.who.int/tobacco/
surveillance/policy/country_profile/en/
In many higher income countries, levels of smoking have fallen since the early 
1970s, and are now low by international standards as shown by Figure 2.3 (and 
defined as under 20 percent of adults smoking). This is largely due to greater 
public awareness of the importance of a healthier lifestyle including exercise, 
nutrition, diet, lower alcohol consumption, as well as the introduction  
of various tobacco control measures including advertising bans, smoke-free 
environments and higher taxation.  
The WHO statistics in figures 2.1 – 2.3 demonstrate the comparison between 
countries based on 2015 data. Prevalence data changes over time – for example 
the latest UK Office for National Statistics report says  15.1% of people aged  
18 years and above smoked cigarettes, considerably lower than the WHO adult 
smoking estimate. 
Figure 2.2
WHO estimate of daily (tobacco) smoking prevalence age 15+ female
Source: WHO report on the global tobacco epidemic, 2017, Country profiles http://www.who.int/tobacco/
surveillance/policy/country_profile/en/
However, despite reduced and lower levels of smoking in many countries,  
population growth adds to the increase in the total global number of smokers.4 
This increase in the overall smoker numbers can be seen in Fig 2.4 which also 
forecasts further increases up until 2025.
In countries that have experienced steep falls in smoking prevalence over the 
years, the graphs have begun to level off, for example in Australia,5 suggesting 
there remains a substantial number of people who, for whatever reason, are 
determined to carry on smoking. The WHO trend data to 2025 predicts only 
very modest falls in smoking levels in several countries and predicts some rapid 
increases, mainly in Africa, the Middle East, some parts of Eastern Europe and  
republics of the former Soviet Union. Some of the more extreme examples 
no data 10% 20% 30% 40% 50% 60% 5% 10% 15% 20% 25% 30% 35%no data
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include Cameroon (from 14 percent to 43 percent); Republic of Congo (from  
14 percent to 48 percent) and Bahrain (from 25 percent to 60 percent).6
Figure 2.5, from WHO data, shows the steep gradient of increases in smoking 
prevalence estimates in specific African countries, where the projected increases 
(both sexes) in daily smoking are 5 percent and higher.
Figure 2.3
Lowest prevalence of smoking in high income countries (2015)
Source: WHO report on the global tobacco epidemic, 2017, Country profiles http://www.who.int/tobacco/surve-
illance/policy/country_profile/en/. Note: more recent national surveys may show different figures. Country data 
available at www.gsthr.org.
Figure 2.4
Increasing number of smokers worldwide 
Sources: The Economist. 2017. Where is smoking on the rise? Available at: https://www.economist.com/graphic-
-detail/2017/01/23/where-smoking-is-on-the-rise  
Figure 2.5
African region – increasing daily tobacco prevalence trends (male and female)
Note: These charts are projection estimates. The projection indicates a likely endpoint if the country maintains its 
tobacco control efforts at the same level that it has implemented to date.
Source: WHO global report on trends in prevalence of tobacco smoking 2015. Fitted daily smoking rates aged 15 & 
over. Point estimate (2015).
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How well equipped is any low or middle-income country (LMIC) to deal with the 
smoking epidemic? No government is likely to reject, in principle, measures to 
reduce deaths and disease caused by smoking. But the degree to which coun-
tries can implement and enforce policies rather than simply signing up to good 
intentions is notably split between the ‘developed’ and the ‘developing’ world. 
As the authors of Global Tobacco Control,7 Cairney and Mamudu, point out, 
effective national implementation of the provisions of the 2005 WHO Framework 
Convention on Tobacco Control (FCTC) to which most countries signed up (see 
chapter six) is very much dependent on the overall public health climate.
“We identify the most relevant characteristics of the policy processes within 
‘leading’ countries with the most comprehensive tobacco control: their depart-
ment of health has taken the policy lead (replacing trade and treasury depart-
ments); tobacco is ‘framed’ as a pressing public health problem (not an eco-
nomic good); public health groups are more consulted (often at the expense 
of tobacco companies); socioeconomic conditions (including the value of 
tobacco taxation, and public attitudes to tobacco control) are conducive to 
policy change; and, the scientific evidence on the harmful effects of smoking 
and second hand smoking are ‘set in stone’ within governments. These factors 
tend to be absent in the countries with limited controls. We argue that, in the 
absence of these wider changes in their policy environments, the countries 
most reliant on the FCTC are currently the least able to implement it”.8
The numbers who die from smoking-related diseases are represented on the 
global map in Fig 2.6 and it is important to be clear that it is the smoking of 
tobacco that is the problem. The Global Burden of Disease Study9 calculates that 
in 2016 there were an estimated 6.3 million smoking-related deaths annually: 
884,000 from second-hand smoke, and 48,000 from oral tobacco (none of which 
were related to snus).
There is a wider global concern here which relates to the UN 2030 Sustainable 
Development Agenda (SDA). The preamble states that, “This Agenda is a plan 
of action for people, planet and prosperity. It also seeks to strengthen universal 
peace in larger freedom. We recognize that eradicating poverty in all its forms 
and dimensions, including extreme poverty, is the greatest global challenge and 
an indispensable requirement for sustainable development”, and that “nobody 
will be left behind”.10
Goal 3 of the agenda is to “ensure healthy lives and promote well-being  
for all at all ages” with a sub-goal (3.4) of reducing premature deaths from  
non-communicable diseases (NCD) by one third by 2030. But as the recent WHO 
NCD report notes, “Country actions against NCDs are uneven at best. National 
investments remain woefully small and not enough funds are being mobilized 
internationally… There is no excuse for inaction, as we have evidence-based 
solutions”.11 The top three causes of NCD mortality are cardiovascular disease, 
cancer and respiratory disease; all closely associated with cigarette smoking. 
When the American Cancer Society published the first edition of the Tobacco 
Atlas in 2002, the authors wrote, “The publication of this Atlas marks a critical 
time in the epidemic. We stand at the crossroads with the future in our hands”.  
In the fifth edition (2015), they added “These words are as true today as they 
were then”. 
Given the devastating global public health impact of smoking, and concerns 
over a potential increase in the number of smokers in many parts of the world, 
it is undoubtedly logical for governments to embrace measures to enable the 
marketing of products which have the potential to switch smokers to less harmful 
alternatives. Regrettably, governments have been slow to follow this path, 
despite calls by many scientific, medical and policy commentators.
 “Consumers have shown us that it is possible for the world to move away 
from smoking for ever”.
The Atlas authors wrote about standing at the crossroads and now the promise 
of tobacco harm reduction has carved out a new path to take. Back in 2002, 
smokers had just two roads to choose from: one called ‘Quit’ and the other 
7 Cairney, P. et al. Global Tobacco Control – Power, Policy, Governance and Transfer. Palgrave Macmillan UK, 2012
8 Cairney, P. and Mamudu M.H. (ND) The WHO Framework Convention for Tobacco Control: What would have to 
change to ensure effective policy implementation? 
9 Gakidou E. et al (2017). Global, regional, and national comparative risk assessment of 84 behavioural, environ-
mental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global 
Burden of Disease Study 2016. Lancet. 390, p.1345-1422
10 United Nations. Transforming our World: The 2030 Agenda for Sustainable Development. UN, 2015. Available at  
https://sustainabledevelopment.un.org/post2015/transformingourworld/publication
11 World Health Organization. Time to deliver: report of the WHO independent high-level commission on  
non-communicable diseases. WHO, 2018. p.4
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called ‘Die’. Now, smokers who cannot, or do not wish to either quit or die 
have a third route to a smoke-free lifestyle. It has the potential to substantially 
reduce the global toll of death and disease from smoking, and to affect a global 
public health revolution - and all at no cost to governments. This route could be 
described as ‘Quit or Try’. 
Figure 2.6
Mortality – number of deaths attributable to tobacco smoking (2016)
Source: WHO report on the global tobacco epidemic, 2017, Country profiles http://www.who.int/tobacco/
surveillance/policy/country_profile/en/
In fact, it is consumers themselves who have led the charge to develop and 
embrace alternative forms of nicotine, in products that both work and are 
desirable, mostly in the form of e-cigarettes. Consumers have shown us that it is 
possible for the world to move away from smoking forever. 
0.2M 0.4M 0.6M 0.8M 1M 1.2M 1.4M 1.6Mno data
Conclusion 
That smoking has been in decline in much of the developed world is to be 
welcomed. But the fact that the steep drops since the 1970s have begun to 
level out in some countries demonstrates that despite all the efforts of tobacco 
control, even in the West, there are still millions of people who continue to 
smoke, most notably among the poorest and most vulnerable.
The situation is even more serious in LMIC, where most smoking deaths occur 
and where population growth is set to increase rather than decrease the 
smoking population. And it is precisely these poorer countries that simply  
do not have the resources to make serious inroads into their smoking problem. 
Overall, at the current levels, the WHO estimated in 2008 that by the end of  
the century, a billion people would have died from smoking at an annual cost  
to the global economy of US$1 trillion amounting to a projected total of  
US$92 trillion by 2100.
Yet there is now a proof of concept which offers a way for governments to 
tackle smoking-related deaths and disease and move towards the aspirations 
of the Sustainable Development Agenda, with no drain on national finances. 
Current SNP have the potential to replace and eradicate smoking. The history, 
development and growth in use of these products is the subject of the next 
chapter.
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Chapter 3:
Safer nicotine products – 
a global picture
From the mid-16th century, when it first reached the courts of Europe, to the mid- 
19th century, tobacco was primarily smoked in pipes or chewed. The cigarette 
first appeared in France around 1850. For the next forty years, cigarettes were 
hand rolled, but demand grew to the point where mechanisation was required. 
In 1881, an American inventor, James Bonsack, was granted a patent in the USA 
for a revolutionary machine. It chopped the tobacco and dropped a certain 
amount into a long tube of paper, which would then be rolled, pushed out and 
then sliced into individual cigarettes. The machine operated at thirteen times the 
speed of a human cigarette roller, transforming cigarette production and giving 
birth to the modern tobacco industry. 
Figure 3.1
James Albert Bonsack’s cigarette rolling machine,
invented in 1880 and patented in 1881 
Source: https://commons.wikimedia.org/wiki/File:Bonsack_machine.png
In America, prior to 1900, cigarette smoking came behind chewing tobacco, 
pipes, roll-your-own tobacco and cigars as a way of consuming tobacco. The 
development of the safety match in 1899 allowed for a convenient and portable 
way of lighting cigarettes, while the power of advertising was first demonstrated 
in 1913 by Reynolds’ national campaign promoting Camel cigarettes. Camel  
became the first national cigarette brand and the first cigarette to be pre-
-packaged. By 1916, Reynolds’ share of the cigarette market surpassed those of 
the Liggett and Lorillard companies. By 1920, Reynolds were number one in the 
cigarette category, having also eclipsed American Tobacco.1
During this period, the most dramatic rise in cigarette consumption came in the 
two World Wars, when cigarettes became part of military rations. Cigarettes now 
outstripped all other forms of tobacco consumption.2
Today, there are around one billion smokers in the world, consuming an 
estimated 5.8 trillion cigarettes a year.3  A lit cigarette burns at 600°-800°C. At 
those temperatures, you can melt zinc, aluminium, tin and lead. The temperature 
can rise to around 900°C when puffing, nearly the melting point of silver.  
A cigarette contains around 600 ingredients and when it is burned, it releases 
some 7,000 chemical substances, about 70 of which are known carcinogens.4 
Most smokers interviewed by researchers, or who complete self-report surveys, 
say they want to quit, although Phillips and colleagues suggest this can be  
a “second order preference”: what many smokers mean is that they wish they 
wanted to quit.5 There may also be a powerful response set, in that given the 
social pressure to quit, many feel obliged to affirm this. But many people do quit 
smoking, with or without any interventions, or try and fail. There can be many 
reasons why people fail to quit when they want to, but purely from a neuro- 
-biological point of view, one key reason is that nicotine as delivered in  
cigarettes has powerful reinforcing properties.
1 AdAge. R.J. Reynolds Tobacco Co. (Reynolds American). 
http://adage.com/article/adage-encyclopedia/r-j-reynolds-tobacco-reynolds-american/98855/
2 Burns, D.M. et al. Cigarette smoking behaviour in the United States.
3 American Cancer Society, Tobacco Atlas https://tobaccoatlas.org/
4 American Lung Association, Smoking Facts. Available at  
http://www.lung.org/stop-smoking/smoking-facts/whats-in-a-cigarette.html
5 Phillips, C. V. et al. (2015) Smoking or quitting; choice, true preferences, tobacco harm reduction, and other 
neglected considerations. Available at  
https://epology.files.wordpress.com/2014/11/phillips-nissen-rodu-smoking-or-quitting-neglected-considerations.
pdf
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According the US National Institute on Drug Abuse: 
“A transient surge of endorphins in the reward circuits of the brain causes  
a slight, brief euphoria when nicotine is administered. Nicotine increases  
levels of the neurotransmitter dopamine in these reward circuits which 
reinforces the behaviour of taking the drug”. When cigarette smoke enters 
the lungs, nicotine is absorbed rapidly in the blood and delivered quickly to 
the brain, so that nicotine levels peak within 10 seconds of inhalation. But 
the acute effects of nicotine also dissipate quickly, along with the associated 
feelings of reward; this rapid cycle causes the smoker to continue dosing to 
maintain the drug’s pleasurable effects and prevent withdrawal symptoms”.6 
However, over the last decade, there are other options for ingesting nicotine 
which are not only less reinforcing than nicotine delivered in a combustible 
cigarette,7 but do not involve the high-level release of toxic chemicals. Just to 
repeat, this report calls them safer nicotine products (SNP) and they break down 
into three main types: e-cigarettes, heat-not-burn (HNB) devices and an option 
that is very far from new but enjoying a renaissance: smokeless tobacco, in the 
form of snus from Sweden. 
To encourage people away from smoking, the new devices need to be easy to 
use and cost effective, but must also offer choice. These days, choice is what 
people expect – of beer in a pub, coffee in cafes, or butter in the supermarket. 
And just as design is critical to the marketing of smart phones, wearables and 
similar technology, the design of new nicotine devices is important. SNP design 
needs to fit into the modern technological zeitgeist; indeed, the look and feel  
of many SNP is light years from dried leaves wrapped in bits of paper.
E-cigarettes 
A brief history
On 25th May 1927, one Joseph Robinson filed a patent in New York, which was 
granted in May 1931. It was for an ‘Electrical Vaporizer’, whereby an electrical ele-
ment contained in a cylinder would be heated to vaporise a compound through 
a mouthpiece. In his patent application, Robinson did not make clear the pra-
ctical application of his invention. The likely purpose was for inhaling medicinal 
products but in any event, it does not appear to have gone into production.8
If there was a godfather of e-cigarettes, it was probably Herbert Gilbert,  
a business studies graduate and 40-a-day smoker. In 1963, he filed a patent 
application for a ‘Smokeless Non-Tobacco Cigarette’. Interviewed by James 
Dunworth in 2016, Gilbert said he had a eureka moment. “The problem,  
as I concluded, was that when you burned leaves and wood, even if you did it in 
your back yard, it yielded a result that no one wanted to take into their lungs”.9 
This led him to construct a device which was very similar to the basic modern-
day e-cigarette; a long, cylindrical body, a battery, a heat source and  
a flavour cartridge. The most crucial difference, however, was that Gilbert’s 
device was nicotine-free. The device never made it to market and existing 
prototypes perished in a warehouse fire. 
If Gilbert’s invention had gone into production, the fact that it did not deliver 
nicotine would probably have caused it to fail anyway. Yet Gilbert believed other 
forces were at work. As he explained to Dunworth, those he showed it to could 
have put it into production, “but they chose to wait for the patent to expire and 
then file their own versions”. Moreover, timing is everything and in the 1960s, 
with tobacco promotion at its height and cancer denial in full swing, it was not 
in the interests of the tobacco industry to be promoting a ‘safer cigarette’; the 
lawyers would not allow the fruits of the industry’s own damning research to see 
the light of day for fear of the consequences.
A significant next step came from outside the industry. Phil Ray, a space engineer 
at NASA, was best known for pioneering the microprocessor. In 2016, the vaping 
site Ashtray Blog interviewed Dr Norman Jacobson, who worked with Ray on  
a project to develop a new nicotine delivery system.10  
Ray was a smoker and did not want to give up nicotine, but wondered if the 
harm could be reduced by simply inhaling nicotine without the smoke. Jacobson 
6 National Institute on Drug Abuse. Tobacco, Nicotine, and E-Cigarettes. NIDA, 2018 
7 Foulds, J. et al (2015) Development of a questionnaire for assessing dependence on electronic cigarettes among 
a large sample of ex-smoking e-cigarette users. Nicotine and Tobacco Research. Feb;17(2), p186-92.  See also 
https://ec.europa.eu/health/scientific_committees/opinions_layman/tobacco/en/about.htm#7 
8 Google Patents. US 1806646 https://www.google.com/patents/US1806646
9 Dufton, E. (2016) James Dunworth’s Interview with Herbert A. Gilbert, Inventor of the E-Cigarette. Points: The Blog 
of the Alcohol & Drugs History Society. Available at https://pointsadhsblog.wordpress.com/2016/02/11/ 
an-interview-with-herbert-a-gilbert-inventor-of-the-e-cigarette/
10 Dunworth, J (2013) Vaping 1970’s Style: An Interview with One of the Pioneers. Ashtray Blog. Available at 
https://www.ecigarettedirect.co.uk/ashtray-blog/2014/06/favor-cigarette-interview-dr-norman-jacobson.html
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was Ray’s doctor. He conducted a small clinical trial, with eight smokers, to see 
what would happen. The trial used a plastic device, shaped like a cigarette, 
which contained paper soaked in nicotine. Nicotine’s low volatility meant that all 
the user had to do was inhale from one end to draw out the nicotine, without any 
combustion or heating at all. In that sense, it was more like a Nicorette inhaler 
than a modern-day e-cigarette. 
But the trial proved that the idea offered benefits: the levels of carbon monoxide 
in the subjects’ blood were dramatically reduced to levels seen in non-smokers; 
they inhaled about half the nicotine from the average pull, and the subjects 
either smoked less or quit for up to two years after the trial. 
In 1979, Dr Jacobson delivered these preliminary results to a meeting of the 
American College of Chest Physicians in Houston under the title, ‘Nicotine 
inhalation or vaping’, the first time the word ‘vaping’ had seen the light of day. 
As part of their research, Jacobson and a colleague came to England in the early  
1980s to meet with Michael Russell, one of the world’s foremost tobacco resear-
chers who, as we have seen, became convinced of the benefit of tobacco harm 
reduction measures. A company, Advance Tobacco Products Inc, with Jacobson 
as CEO, was also established in the early 1980s to commercialise the product.  
It appeared in 1985 under the trade name Favor (as in ‘do yourself a favour’).
Unfortunately, Favor failed on three counts. Firstly, nicotine evaporates very qui-
ckly, so the shelf-life of the cartridges was too short to be a practical alternative 
to smoking. Secondly, nicotine degrades to cotinine, which leaves a bitter taste 
unless refrigerated, which again makes it difficult to market. And finally, in February 
1987, the US Food and Drug Administration (FDA) banned it outright, deeming it 
to be a new drug (nicotine removed from tobacco) delivered by an unproven drug 
delivery system.11 This was just the beginning of a battle between the FDA and 
purveyors of SNP, which shows little sign of abating. Eventually, the patent for Fa-
vor was sold to a Swedish company, which converted the device to a nasal spray.
Through the 1980s and 1990s, several patents for similar devices, often citing 
Herbert Gilbert’s original invention, were lodged in the USA, mainly by existing 
tobacco companies.12 But the real tipping point for the e-cigarette revolution did 
not emerge from the secret vaults of Big Tobacco or Silicon Valley, but around 
10,000 miles away across the Pacific in China.
The story of Hon Lik 
Hon Lik was born in northern China in 1951. He graduated from the Liaoning 
College of Traditional Chinese Medicine and began his career working in 
plant agriculture, trying to devise easier ways for people to ingest traditional 
Chinese herbal remedies like ginseng. And like millions of Chinese men, he 
was a heavy smoker – two or three packs a day – and had been trying to quit 
using nicotine patches, to little effect. His father was a heavy smoker too, and 
would die from lung cancer. 
11 Center for Drugs and Biologics, Dept. of Health and Human Services, Office of Compliance. Michels, D.L. (1987). 
Regulatory Letter: Favor Smokeless Cigarettes, Regular Favor Smokeless Cigarettes, Menthol Favor Smokeless 
Cigarettes, Lights Favor Smoke-free Cigarettes, Regular Favor Smoke-free Cigarettes, Menthol Favor Smoke-free 
Cigarettes Lights. Philip Morris Records. Available at https://www.industrydocumentslibrary.ucsf.edu/tobacco/
docs/#id=xggy0038
12 Dufton, E. (2015) The Strange and Complicated History of Patenting the E-Cigarette. Points: The Blog of the Al-
cohol & Drugs History Society. Available at https://pointsadhsblog.wordpress.com/2015/01/22/the-strange-and-
-complicated-history-of-patenting-the-e-cigarette/
 The article points out that pharmaceutical companies have also lodged patents based on the same technology  
as e-cigarettes in order to deliver medicines
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Hon Lik recounts that the idea of delivering nicotine in a vapour came to him 
in a dream. One night he went to bed forgetting to remove his patch. Nicotine 
can generate vivid dreams13 and he dreamt he was drowning in a deep sea, 
when suddenly the sea vaporised and he found himself floating in a brightly 
coloured fog. From that, he says he reasoned that the steady delivery of nicoti-
ne through a patch was not satisfying enough. He reckoned that vaporising the 
nicotine would simulate more of the cigarette experience. He was right.
“In 2001, I devised a system on a large console, using food additives as solvents.  
At the time I was working on vaporisation by ultrasound, but the droplets for-
-med were too big to resemble tobacco smoke. This technology is used for 
example in some household humidifiers; it consists of making a metallic diap-
hragm vibrate at an ultrasonic frequency in a liquid to create micro-droplets 
which then, upon contact with room-temperature air, form a sort of cold vapour”.14
The challenge was to scale the mechanism down to a miniature size, suitable 
for a hand-held cigarette-sized device, and achieving the right dose of 
nicotine, while also getting the right odours from harmless additives.
In 2003, he came up with the idea of using a high frequency, piezoelectric, 
ultrasound-emitting element to vaporise a pressurized jet of liquid 
containing nicotine. Piezoelectricity is the electric charge that accumulates 
in certain solid materials (such as crystals, certain ceramics, and biological 
matter such as bone, DNA and various proteins) in response to applied 
mechanical stress. The principle has many practical applications, from sonar 
to ceramic cartridges on vinyl record decks, igniting cigarette lighters and 
push-start propane barbecues. Hon Lik’s design created a smoke-like vapor 
that delivered nicotine. Arguably the crucial step forward from previous 
efforts was that the nicotine was protected from vaporisation until it was 
heated. Here was a stable nicotine delivery system and a smoke-like vapour 
wrapped in a device that looked like a cigarette. 
Hon Lik filed the first patent in 2003. The company Hon worked for, Golden 
Dragon Holdings, changed its name to Ruyan, meaning ‘like smoke’, and 
the first e-cigarette went on sale in China in 2004. Ruyan now markets 
e-cigarettes, e-pipes and e-cigars globally. And unlike many inventors, Hon 
Lik profited from the fruits of his dream, selling his intellectual property rights 
to Imperial Tobacco for a reported $7.5m in 2013.15
Types of e-cigarettes
There are now many types of e-cigarette. They range from entry level disposable 
types, which cannot be customised and are known as ‘closed systems’, through 
to mechanical modified types, or ‘mods’, which the vaper is able to fully 
customise and are at the top end of what are known as ‘open systems’. The 
higher up the device scale you go, the more control the vaper has over the 
whole vaping experience. The product scene is extremely varied and complex, 
with many different devices, device components and flavours, and a bewildering 
lexicon of jargon and terminology, which, like everything else in this industry,  
is changing and evolving. What follows is therefore a snapshot of where we are 
in 2018.
All e-cigarettes have three basic elements; a battery, which heats up a coil or 
atomiser, turning the flavoured e-liquid or juice into a vapour, which is then 
inhaled.
E-liquid comprises four ingredients: vegetable glycerine, propylene glycol, 
nicotine, and flavouring. Some liquids can contain no nicotine. Vegetable 
glycerine (VG) is a thick, naturally sweet liquid that provides the vapour from 
the liquid. Propylene glycol (PG) is a thin liquid, which acts as the flavour 
carrier. Some people are allergic to PG and e-liquid without that ingredient is 
available. The VG/PG ratio is the ratio of VG and PG in a liquid. The higher the VG 
percentage, the more cloud and the smoother the vape, but there is less flavour. 
Higher PG gives less cloud, more ‘throat hit’ and possibly more flavour. Throat 
hit refers to the feeling a smoker gets when inhaling nicotine. The problem that 
most smokers switching to vaping report is the fact that they do not feel the 
same kind of throat hit that they would with a regular cigarette. The flavourings 
are the same as used in food and confectionery production and the range of 
flavours available for vaping runs into the thousands.16 17
13 Page, F. et al (2006). The effect of transdermal nicotine patches on sleep and dreams. Physiology and Behaviour. 
30;88(4-5), p. 425-32
14 Mawsley (2017). Hon Lik speech at ISoNTech. Planet of the Vapes. Available at  
https://www.planetofthevapes.co.uk/news/vaping-news/2017-08-03_hon-lik-speak-at-isontech.html
15 Gustafsson, K. (2013) Imperial Tobacco Agrees to Acquire Dragonite’s E-cigarette Unit. Bloomberg. Available at 
https://www.bloomberg.com/news/articles/2013-09-02/imperial-tobacco-agrees-to-acquire-dragonite-s-e-cigaret-
te-unit
16, 17  è
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First generation e-cigarettes
First-generation e-cigarettes, called ‘cigalikes’, were designed to closely 
resemble an ordinary cigarette and are comprised of a battery, a combination 
disposable cartridge of e-liquid, and the heating element or atomiser, called 
a cartomiser. Most users at this level want the convenience of just using the 
device and disposing of the cartridge, but some brands are refillable. Some 
cigalike manufacturers have started to sell mini refillable tanks, or clearomisers 
(so named because you can see how much liquid is left). In general terms, each 
cartridge is roughly equivalent to a pack of cigarettes and last around 200 puffs. 
This type of e-cigarette is the most popular for many of those starting to vape, 
because it looks and feels like smoking a cigarette and is convenient to use.
Second generation e-cigarettes  – ‘Tank system’ e-cigarettes
Second-generation e-cigarettes are the next level up for those looking for larger 
tanks. Some offer adjustable airflow for more and different flavours, some hold 
more liquid and have larger battery capacity for a longer charge, and some have 
adjustable power features. This type of device has been dubbed an eGo style, 
after the eGo battery developed by the Joytech company in China, now the 
world’s leading brand in this type of battery. 
Depending on the system itself, the larger battery gives more power, generating 
more vapour production, more flavour and a stronger throat hit. In this type of 
device, the tank and the atomiser are separate items.
Figure 3.3
First generation e-cigarette
Figure 3.4 
Second generation e-cigarette
Figure 3.5
Third generation e-cigarette
16 Zhu, S. el al (2014) Four hundred and sixty brands of e-cigarettes and counting: implications for product regula-
tion. Tobacco Control 2014; 23iii3-iii9  
In January 2014, the researcher identified 466 brands and 7764 unique flavours. From a previous search conduc-
ted in 2013, they calculated that around 10 new brands and 240 new flavours were appearing each month. If pro-
duct development has continued at that rate, in 2018 there could now be over 700 brands and 15,000 flavours.17 
Page, F. et al (2006). The effect of transdermal nicotine patches on sleep and dreams. Physiology and Behaviour. 
30;88(4-5), p. 425-32
17 Any company wanting to make their SNP (such as e-liquid or device) available on the UK market is obliged to 
notify the Medicines Healthcare products Regulatory Agency (MHRA). In 2017, 32,000 products were notified to 
the MHRA; 90% were e-liquids and 10% devices
There are three main types of device: 
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Third generation e-cigarettes (‘mods’) – Mechanical mod-style 
e-cigarettes
While many e-cigarette users probably do not label themselves as ‘vapers’ 
and are content just to walk into their local store, supermarket, gas station or 
vape shop to buy a basic device, there is a strong ‘hobbyist’ element among 
vapers. People in this group want maximum control over their devices, maybe 
mixing their own liquids, building coils, experimenting with battery wattage and 
voltage and tank sizes to fine-tune their vaping experience. This would be akin to 
building your own computer from component parts.
E-cigarettes have developed along two lines. Closed systems have disposable 
cartridges, rather like a fountain pen with cartridges and are simple to use. Open 
systems allow the user to customise their use with different parts, including 
mouthpieces, atomisers and batteries, refillable tank and a choice of liquids.
Tobacco heating systems or HNB products 
Tobacco heating systems, also known as heated tobacco products, tobacco 
heating products – and more generally (and hereafter in this report) as HNB pro-
ducts – work on the principle of heating tobacco below the level of combustion. 
A HNB device heats tobacco to a temperature of no more than 350°C, which is 
sufficient to release the nicotine but with significantly reduced levels of toxins.18
Tobacco for use in a HNB device is prepared differently than in a cigarette: the 
tobacco is powdered and mixed with glycerine, guar gum, and other ingredients. 
There are three methods in which tobacco is heated in these products. In the first 
method, tobacco is directly heated by a blade inserted into a small tobacco stick, 
which then heats the tobacco and releases the vapour. The second method is to 
indirectly heat the air, which in turn heats the tobacco, similar to the way  
a fan oven works. In the third, a liquid is heated to generate a vapour, which then 
passes through tobacco before being inhaled, picking up nicotine and flavours. 
This method is a similar process to placing food in a steamer.
Unlike the e-cigarette market, the major tobacco companies like Philip Morris 
International (PMI), British American Tobacco (BAT) and Japan Tobacco Interna-
tional (JTI) currently dominate the global market in these new products because 
the process of developing HNB alternatives to cigarettes is extremely expensive. 
For decades now, the industry has been trying to develop a product that is de-
monstrably safer than smoking, but still ticks the boxes of consumer satisfaction 
18 Committee on Toxicity. COT Meeting: 4 July 2017 (2017). Available at 
https://cot.food.gov.uk/cot-meetings/cotmeets/cot-meeting-4-july-2017
Figure 3.6
IQOS (PMI)
Figure 3.7
glo (BAT)
Figure 3.8
Ploom (JTI)
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(nicotine hit and flavour) and can credibly defend itself against inevitable politi-
cal and public health opposition. As far back as 1958, a tobacco executive wrote 
that whoever came up with such a product could dominate the whole market.19 
In 1988, Reynolds launched an early version of a HNB product: the Premier 
cigarette. It worked by heating and aerosolising tobacco flavour and was intended 
to reduce or eliminate the health risks associated with smoking. But despite an  
estimated investment of up to US$1 billion, the product failed. Smokers complained 
about a charcoal-like aftertaste, and although it looked like a conventional 
cigarette, special instructions were required to teach smokers how to light it. 
Reynolds estimated it would take two or three packs for a smoker to acquire a taste 
for Premier, but in practice, many smokers only smoked one cigarette and then 
shared the rest of the pack. It was withdrawn from the market in 1989, less than  
a year after its introduction. Reynolds tried a further launch in 2002, this time in 
India, one of the world’s largest smoking markets. But it failed within 12 months.20
Reynolds tried again in 1994 with another HNB product called Eclipse, which 
heated the tobacco instead of burning it by using a carbon tip wrapped in 
glass fibres. It was only available nationally in the USA from 2003-07, but remains 
available in some local US markets. It did seem to tick all the boxes, but in terms 
of general acceptance, may have been a product ahead of the time. It was 
rebranded as Revo in 2015, but has since been shelved.21 PMI also made initial 
attempts to develop and commercialise heated tobacco products in the late 
90s and early 2000s, but these products were unsuccessful due to drawbacks 
in technological capability and low consumer satisfaction.22  The technical 
challenge has been considerable, involving how to remove or significantly lower 
five types of carcinogenic compounds: nitrosamines, the significant cancer-
causing agents in tobacco smoke; aldehydes, formed by the burning of sugars 
and cellulose in tobacco; polycyclic aromatic hydrocarbons (PAHs), which form 
in the cigarette behind the burning tip; carbon monoxide, which binds with 
red blood cells and strongly affects cell respiration; and traces of heavy metals 
present in tobacco as a result of fertilisers used on the plant. 
Smokeless tobacco
Many parts of the world have versions of smokeless tobacco, which can be che-
wed, inhaled as snuff, or placed under the lip. However, some varieties contain 
substances other than tobacco, which have been associated with oral cancers. 
Chewing tobacco is one of the oldest methods of consuming tobacco. 
Indigenous peoples of the Americas, in both North and South, chewed the 
leaves of the plant long before the arrival of Europeans, frequently mixing them 
with the mineral lime, similar to the way coca leaves are chewed. 
Tobacco chewing became widespread in the main tobacco growing areas of the 
American south and is still in vogue among some young males in the southern 
states, although its popularity was already on the wane before the Second World 
War. 
Dipping tobacco is a type of finely ground or shredded, moistened smokeless 
tobacco product. It is used by placing a lump, pinch, or ”dip” of tobacco 
between the lip and the gum.
Dipping tobacco evolved from the use of dry snuff in early American history. 
Up until the late 1700s, dry snuff was taken nasally. Then early Americans began 
to take snuff orally by chewing the end of a twig until it resembled a brush, 
and then ”dipping” the twig in the snuff and placing it in their mouths until the 
snuff dissolved. This evolved into modern day moist snuff, with Copenhagen 
introduced in 1822, and Skoal introduced in the USA in 1934, betraying the 
Scandinavian roots of this type of smokeless, oral tobacco product. Dipping 
tobacco is typically flavoured, most commonly with mint and wintergreen, but 
also grape, cherry, apple, orange, lemon/citrus, peach and watermelon.
Snus
Of all the smokeless tobacco products, it is snus which has captured most 
attention, because of its success in reducing the prevalence of lung cancer and 
other tobacco-related diseases in Sweden.23 Swedish snus dates back to the 
18th century and is distinct from other types of smokeless tobacco products 
19 Parker-Pope, T. (2001) ‘Safer’ Cigarettes: A History. NOVA  
Available at http://www.pbs.org/wgbh/nova/body/safer-cigarettes-history.html
20 Wikipedia. Premier (cigarette) https://en.wikipedia.org/wiki/Premier_(cigarette) 
21 TVECA, Reynolds pursues another restart with revamped heat-not-burn cigarette Eclipse (2017)               
https://www.tveca.com/content/reynolds-pursues-another-restart-revamped-heat-not-burn-cigarette-eclipse
22 Philip Morris International, Sustainability Report 2017 (2017). Available at  
https://www.pmi.com/docs/default-source/pmi-sustainability/pmi-sustainability-report-2017.pdf
23 Foulds, J. et al (2003). Effect of smokeless tobacco (snus) on smoking and public health in Sweden.  
Tobacco Control 12; 4, p. 349-59
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because of its composition, the manufacturing methods, and the specific 
standards for reducing several unwanted substances implemented by all major 
manufacturers.24 Swedish snus is the dominant form of smokeless tobacco in 
the Nordic countries, although all major manufacturers are based in Sweden. 
In recent years, some smokeless products have been launched in North 
America marketed as “snus”, in addition to Swedish snus. However, the chemical 
properties of some of these products are distinct from traditional Swedish snus, 
and they are not manufactured according to the same quality standards as those 
produced by the major Swedish manufacturers.
Swedish snus
Figure 3.9
Snus
Swedish snus is a moist to semi-moist smokeless tobacco product, made from 
ground tobacco leaves and food-approved additives. Because the tobacco is 
ground into a powder instead of being cut, the final product is intended to be 
placed in the mouth, rather than chewed. 
“Of all the smokeless tobacco products, it is snus which has captured most at-
tention, because of its success in reducing the prevalence of lung cancer and 
other tobacco-related diseases in Sweden”.
Snus production involves a heat-treatment process, which substantially 
decreases the microbial activity in the final product. This contributes to its 
chemical stability and shelf-life. The manufacturing methods and ingredients 
have essentially remained the same over the past 200 years. However, 
production changes introduced over the past few decades by the major 
manufacturers have resulted in substantial decreases in the levels of unwanted 
substances in Swedish snus including potentially carcinogenic tobacco-specific 
nitrosamines (TSNAs) and PAHs. 
Loose snus is a moist powder, which can be portioned and packed into  
a cylindrical or spherical shape with the fingertips or a purpose-made cylindrical 
device. The result is often referred to as a pris (pinch), buga, prilla, or prell 
(slang). Some users (usually long-time users) simply pinch the tobacco and place 
it under their upper lip (‘farmer’s pinch’ or ‘living snus’). Over time, the demand 
for loose snus has been replaced by portioned varieties. The discrete nature of 
this more recent formulation has helped increase demand for snus.
Today, the dominant snus brands come in small teabag-like sachets. There 
are two varieties of portion snus. ‘Original portion’, introduced in 1973, is the 
traditional form. The sachet material is moisturised during the manufacturing 
process, resulting in a brown, moist pouch. ‘White portion’ is a milder-tasting 
and slightly slower-release form. The sachet material is not moisturised during 
the manufacturing process, resulting in a white, dry pouch. The tobacco within 
the portion material has nearly the same moisture content as original portion 
snus, but the nicotine and flavour are somewhat slower in delivery due to the 
drier sachet. ‘White portion’ refers to the style, not the colour, as many white 
portion snus manufacturers use a black material instead of white. Examples have 
included General Onyx and Grovsnus Svart (Black) and Blue Ocean (Blue).
The nicotine content of snus varies between brands, with the most common 
strength being 8 mg of nicotine per gram of tobacco. In recent years, snus 
manufacturers have released stark (strong or sterk) and extra stark (extra strong 
or extra sterk) varieties with greater nicotine content. Stark varieties contain, on 
average, 11 mg of nicotine per gram of tobacco, while extra stark varieties may 
contain up to 22 mg of nicotine per gram of tobacco.
Unlike in the European Union, snus has never been banned in the USA. Although 
Swedish snus was previously only available by mail order in the USA, an 
increasing number of tobacco retailers have now begun to stock it. R J Reynolds 
and Philip Morris USA, and the US Smokeless Tobacco Company now produce 
similar products called Camel snus, Marlboro snus, and Skoal snus, respectively.  
24 Moist snuff is fire-cured as opposed to snus which is pasteurised
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Swedish Match, the leading manufacturer of Swedish snus, is currently selling it 
in Canada, and several regions throughout the USA.
‘Safer’ cigarettes
Over the years, tobacco companies have sought to introduce a ‘safer’ cigarette, 
for example ones that produced less tar. Such efforts failed. In 2017, the US 
FDA announced the launch of a public conversation on the idea of forcing the 
tobacco companies to reduce the nicotine content of combustible cigarettes to 
‘non-addictive’ levels. The FDA based its view on simulation modelling research, 
published in the New England Journal of Medicine, where the authors estimated 
that “approximately 5 million additional smokers […] would quit smoking within 
a year after implementation of the hypothetical policy, a number that would 
increase to a total of 13 million additional former smokers […] within 5 years[…]. 
By 2060, smoking prevalence drops from 7.9 percent in the baseline scenario to 
1.4 percent”.25 
The former director of UK Action on Smoking and Health (ASH), Clive Bates, 
has detailed the many reasons why this is unlikely to work. He considers that 
smokers would not buy the new product in sufficient numbers to make a positive 
population level health impact, but does concede that it could be “an important 
signal of a direction of travel – the end of combustible tobacco products as 
nicotine delivery products. This could make it an ‘agency threat’ – a big stick that 
has influence in setting direction and pressing companies and their investors to 
respond”.26 
However, to dramatically reduce the nicotine content of a cigarette could equally 
result in the accelerated growth of an illicit market, an unintended consequence 
noted by the FDA in its press release announcing the consultation process.27
The global e-cigarette market
On 20th July 2006, US Customs received a tariff enquiry asking about the import 
duty on a device described as “a spherical, metal tube with a plastic mouthpiece 
tip on the end which measures approximately 5 ½” in length. Inside the tube are 
a sensor, electronic atomizer, integrated circuits and a lithium ion battery. The 
spherical cartridge is attached to a plastic mouthpiece tip and contains nicotine 
and propylene glycol”. The device was a Ruyan Electronic Cigarette, and the 
letter came from Mark Weiss, a patent attorney from Scottsdale, Arizona who  
initially considered importing the Ruyan into the USA. Instead, in that same year, 
he founded NJOY, one of the first companies to manufacture and sell  
e-cigarettes in the USA. By the time NJOY was founded, British businessman 
Greg Carson had already introduced the ‘Electro-Fag’ into Europe in 2005 – and 
the rest is history. In 2012, Phil Hodson, founder of E Lounge Vaping, the UK’s 
first dedicated e-cigarette retailer, told online magazine Raconteur “It’s going to 
be huge”.28 And he was right. But how huge?
The growth of safer nicotine products
In 2013, the investment bank Goldman Sachs identified e-cigarettes as one 
of the eight emergent themes in the global economy capable of what it 
termed ‘creative destruction’, representing a whole new and totally disruptive 
technology, offering consumers a far safer product and forcing companies 
to either adapt or die.29 The market research company Nielsen identified 
e-cigarettes as the fastest-growing product in British supermarkets in 2014, with 
sales up by almost 50 percent.30 
Increasing interest in SNP is encouraging many tobacco companies to shift the 
nature of their operations. Once, companies were engaged in manufacturing  
a single agricultural product – the tobacco cigarette – with little need for signifi-
cant product innovation. In the last decade, however, many of the major tobacco 
companies have invested substantial sums in research and development of SNP. 
The science and technology of these new products involves, amongst other 
things: heating technology; battery design; consumer electronics; materials 
science; biotechnology; inhalation science; and flavour chemistry.
25  Apelberg B.J. et al (2018). Potential public health effects of reducing nicotine levels in cigarettes in the United 
States. The New England Journal of Medicine. 378 p.1725-1733 
26 Bates, C. and Wade, C. (2017) Reducing nicotine in cigarettes. Available at https://clivebates.com/documents/
ReducedNicotineOct2017.pdf
27 Gottlieb, S. (2018) Statement from FDA Commissioner Scott Gottlieb, M.D., on pivotal public health steps to dra-
matically reduce smoking rates by lowering nicotine in combustible cigarettes to minimally or non-addictive levels. 
FDA, 2018. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm601039.htm
28 Sims, J. (2012) From ‘electro fag’ to e-cigarette. Raconteur  
https://www.raconteur.net/lifestyle/from-electro-fag-to-e-cigarette
29 Boroujerdi, R.D. The Search for Creative Destruction. Goldman Sachs, 2013. Available at http://www.goldman-
sachs.com/investor-relations/financials/archived/annual-reports/2013-annual-report-files/search.pdf
30 Smithers, R. (2014) E-cigarettes and sports nutrition products lead grocery sales boost. The Guardian. Available at 
https://www.theguardian.com/business/2014/dec/30/e-cigarettes-sports-nutrition-supermarkets-sales-rise-uk
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It is not only the tobacco industry feeling the heat as the e-cigarette market 
grows. Sales of NRT have fallen in some markets where e-cigarettes have  
a strong showing, to the extent that pharma giant GlaxoSmithKline considered 
getting into this rival market, but quailed in the face of potential  
controversy.31 32 33
The consensus of analysts suggests that most of the metrics of the market in 
SNP will continue to grow. However, there are some signs that the initial surge 
of smokers switching away from cigarettes, at least in Great Britain, has begun to 
level off. Growth could be further slowed if product development is hindered by 
legislation and regulation (e.g. banning online sales) and taxation.
Figure 3.10
Regional e-cigarette market size estimates 2018
Source: ECigIntelligence, 2018
Trying to accurately represent market analysis in such a fast-moving and dynamic 
environment is challenging, even more so when attempting growth forecasts – 
 whether in terms of financial value, units sold, market share, or numbers of 
consumers. Some measures such as units sold might at first seem easy to 
acquire, but many market measures depend on sales till data, which do not 
necessarily include small independent shops and online sales. 
Largest markets for e-cigarette products
North America is by far the largest e-cigarette market, followed by Western 
Europe, Eastern Europe, Asia Pacific, and then the rest of the world.34
The market share for different products varies in different countries. For example, 
possibly due to their relatively low cost, cigalikes enjoy a 50 percent share in  
a very small market like Azerbaijan, followed by 43 percent in Austria, 42 percent 
in the USA, 39 percent in China, and 38 percent in Ecuador. The USA accounts 
for 70 percent of the US$500m global market for the relatively new pod mod 
systems (a system similar to using coffee pods like Nespresso), with only UK, Italy, 
Poland, and France having a market share greater than 9 percent.
“In 2012, Phil Hodson, founder of E Lounge Vaping, the UK’s first dedicated  
e-cigarette retailer, told online magazine Raconteur, ‘It’s going to be huge’.   
And he was right”.
In the more mature e-cigarette markets, open systems are still dominant,  
the top five markets being USA, UK, Italy, Germany and France, followed by 
China, Russia, Poland, Canada and Malaysia. But, according to Euromonitor 
analysis, open systems do face future challenges. The analysis speculates 
that the ability to customise devices is likely to appeal to early adopters, who 
are frustrated by the inflexibility of cigalikes, which once offered the only 
safer option. Those early adopters are likely to continue populating the niche 
market in ultra-flexible devices. However, new products might appeal more to 
31 Kelland, K. (2015) GSK’s nicotine patches and gum feel the heat from e-cigarettes. Reuters. Available at  
https://www.reuters.com/article/gsk-ceo-ecigarettes-idUSL6N0UU3TU20150116 
32 Weinbren, E. (2015) Smoking cessation: NRT v e-cigarettes. Chemist and Druggist. Available at  
https://www.chemistanddruggist.co.uk/feature/nrt-v-e-cigarettes
33 Fox, L. (2015) GlaxoSmithKline’s Patch and Gum Sales are Suffering Due to E-Cigs. Ecigarette Reviewed.  
Available at https://ecigarettereviewed.com/GSK-nrt-losing-sales-e-cigs
34 Data in this section sourced from Global tobacco; key findings. Part II; vapour products. Euromonitor International, 
October 2017
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newer consumers who do not want basic cigalikes, but are not interested in 
customising devices. For those consumers, closed system products are likely to 
be more attractive, offering both convenience and choice. But it would be wrong 
to assume that those using SNP stick to one type of product. Some consumers 
will use a range of different e-cigarettes, HNB products and snus to suit both 
their mood and the environment they find themselves in. 
Overview of e-cigarette industry structure
The e-cigarette industry has grown at an astonishing rate in the past five to ten 
years, from its earliest days as almost a cottage/craft business to a multi-billion 
dollar global enterprise. It is still a rapidly evolving industry, with a complex 
ecology of layered acquisitions. These involve parent and subsidiary compa-
nies, some of which are owned by the traditional tobacco companies, but are 
mostly independently run, with multiple brands and sub-brands. Currently, the 
pharmaceutical industry is hardly represented in the sector, but there are some 
exceptions. One of the leading e-liquid companies in the UK, Blend & Bottle, is 
owned by BSMW, itself a subsidiary of the pharmaceutical company Thornton 
and Ross. The US market is by far the most mature, followed by the UK, but  
a similar business landscape can be mapped across other markets.
There are companies that manufacture their own devices, device components 
and liquids, while others just produce liquids. Some manufacture their own devi-
ces and liquids, but also ‘white label’, rebadging devices and liquids from other 
companies and/or selling white label products to others.  Some companies use 
the company name as a brand for devices, for instance, but have other brands 
for other elements of the business. Some companies have established niches 
in the market. In the UK, for example, MultiCig dominate the service/gas station 
market. There are also subsidiary services. For example, Vapourized also have  
a consultancy service, which advises other companies on liquid compliance. 
There are also scientific companies which specialise in testing products for safety 
and compliance. 
Some manufacturing companies also have their own wholesale and distribution  
networks, either devoted exclusively to their own products or wholesaling 
products across the board. Others focus solely on distribution. At the consumer 
retail level, there are companies that are not only manufacturing and distributing 
products, but also running a vape shop franchise business. Finally, there are 
stand-alone shops. As you would expect these days, at all levels of the business, 
from manufacturer to high street vape shops, most offer online purchasing 
options.
Retail
At the retail level, the primary high street sites are supermarkets, convenience 
stores and service stations. These sites are where potential consumers are most 
likely to first encounter e-cigarettes, as these outlets are where they are used to 
buying their cigarettes. As new consumers, they may want an experience close 
to cigarettes, and could therefore be attracted to the basic cig-a-like disposable 
device. Due to lack of space and lack of product knowledge on the part of the 
staff, this type of outlet (together with pharmacies) tend to stock basic products 
and are unable to give much, if any, advice to consumers. 
In the UK, there are around 50,000 convenience stores, as opposed to around 
2,000 vape shops, so the business potential of serving around three million 
UK vapers is significant. Because UK retailers must display cigarettes behind 
closed cabinets, some owners are now moving the cabinets out of sight and 
replacing them with vaping stands, displaying a much wider range of products. 
Pharmacies are also beginning to offer more choice. This is important for these 
stores. Once, consumers may have moved to purchase from a vape shop, as it 
offered them more options. Instead, they may now return to the convenience 
store, as it offers more choice, the opportunity to buy other products (such as 
groceries), and is open for longer hours than a vape shop.
Vape shops offer a different experience. The staff are likely to be more informed 
about vaping and the range of devices. The shop itself is often a social space for 
vapers to meet and exchange information. Shops cater for all levels of vaping 
knowledge and experience and this extends into the many online chat forums, 
festivals, exhibitions and publications that cater for the more advanced and 
technical end of the consumer market.35
In France, the main retail channel is the vape shops (around 2,600, 60 percent 
of market share), and then tobacconists (about 25,000, 20 percent market 
share) which is also the only outlet for cigarettes in France. French supermarkets 
35 Retail information drawn from panel discussion on UK retail market at UKVIA Vaping Industry Forum, 2018.
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and convenience stores generally do not sell vaping products. Belgium and 
Switzerland have similar distribution channels.36
Component production
Whether companies are manufacturing their own products or sourcing from 
elsewhere, many of the key components originate from the centre of global 
e-cigarette production located in Shenzhen, in south-east China, which links the 
mainland with Hong Kong. Shenzhen is the e-cigarette industry’s Silicon Valley. 
It is listed in the top thirty global financial centres and, because of its status 
as China’s first Special Economic Zone, has become a magnet for high tech 
start-up companies in many fields, including e-cigarettes. Chinese companies 
who have enjoyed global success include Joyetech, which developed the eGo 
battery, Kangertech, Innokin and ISmoka. The Chinese also boast major e-liquid 
manufacturers, Hangsen and Dekang.
E-cigarette product development and innovation
Apart from a few relatively minor modifications, the combustible cigarette has 
hardly changed in the last hundred years. But the advent of SNP (except for 
smokeless snus-style products) has brought with it a burgeoning technological 
revolution in nicotine delivery. It is commonplace now for innovations in mobile 
technology to lead to the development of multi-function devices, such as smart 
phones and watches. In 2015, the US company Vaporcade launched Jupiter,  
a combined phone/vaping device,37 and other similar innovations are probably 
in the pipeline. But looking at more conventional developments, aimed at fines-
sing or tweaking som e of the existing problems with devices from a consumer 
satisfaction perspective, examples would include:
» Products to improve the basic cigalike, by ensuring the stick remains charged, 
is always full of liquid, with lights telling the user when they have completed 
a vape session – and to more closely mimic the tank experience enjoyed by 
users of open systems;
» Products with extended battery life and on-the-go charging;
» Products which pay more attention to the look and feel of the device, 
in much the same way as mobile phone companies focus on design 
aesthetics;
» E-liquids designed to work with newer closed system devices;
» Localised and craft liquids mimicking the appeal of locally-sourced foods and 
the craft beer industry; 
» Products from closed system manufacturers offering personalisation elements 
(like device colour ranges) to offset the lack of customisation afforded by open 
systems.
Avoiding a Kodak moment: global tobacco companies  
take up the challenge
As with most modern disruptive technologies, it was the new start-up 
companies that took the lead in commercialising e-cigarettes, leaving the 
tobacco industry playing catch-up. It was not until six years after the launch 
of e-cigarettes in the USA that Lorillard became the first tobacco company 
to launch an e-cigarette in 2012. This was through its acquisition of the 
Blu brand from Jason Healy, the Australian entrepreneur who founded the 
company in 2009. Subsequently, Lorillard was taken over by Reynolds, which 
was then taken over by BAT. The Blu brand was sold to Imperial Brands. It is 
not uncommon for tobacco companies to take a stake in the new SNP market 
by acquiring pioneering companies. In the UK, some of the top brands 
such as 10 Motives, Logic and Vype, as well as Blu, are subsidiaries of major 
tobacco companies.38
In the USA, the world’s most mature and valuable market for e-cigarettes, it is 
estimated that the value of the e-cigarette business in 2018 will be US$5.1bn. 
US$3.5bn of this would be the value of the market still dominated by the 
independent sector. US$1.5bn would be held by the tobacco industry, which 
largely controls the cigalike end of the market. In mid 2018, the independent 
company JUUL has over 70 per cent share e-cigarette market.39 One analyst 
company calculated a 97 percent growth in the e-cigarette market in the USA 
during the last quarter through to the end of January 2018, with 88 percent 
36 Ouest France, Les ventes de cigarettes électroniques repartent à la hausse (2018) 
https://www.ouest-france.fr/economie/les-ventes-de-cigarettes-electroniques-repartent-la-hausse-5794660 
37 Cigbuyer.com, Vaporcade Jupiter – A Smartphone You Can Vape (2015) 
https://www.cigbuyer.com/vaporcade-jupiter-smartphone-you-can-vape/
38 The Grocer, 10th February 2018, p.46
39 Bloomberg, E-cigarette maker JUUL is raising $1.2 billion (2018)  
https://www.bloomberg.com/news/articles/2018-06-29/e-cigarette-maker-juul-labs-is-raising-1-2-billion 
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of that growth attributable to JUUL. Overall, it is likely that in the US tobacco 
companies have no more than an 18 -25 percent share of the SNP market.40
Currently, the major companies have taken differing views on where they 
invest most heavily in SNP. Imperial Brands appear to be focussing their 
effort in the e-cigarette market; JTI and BAT seem equally committed to both 
e-cigarettes and HNB products, while PMI are moving ahead in the HNB 
field. But while market analysts are often prepared to predict market trends 
five to ten years ahead, in this ever-changing environment the companies are 
much more cautious in their strategic planning. One guesstimate puts the 
investment to date at around US$10bn.41
Of the major companies PMI have invested most heavily, some US$3bn 
since 2008 with a further US$1.7bn of additional spend planned. In 2009 
the company opened a new R&D facility in Switzerland dedicated to smoke-
free products, followed in 2010 by a new R&D and manufacturing facility 
in Singapore. New factories have also opened in Germany and Italy, while 
existing cigarette factories in Greece and Romania have been re-tooled to 
produce new smoke-free products. BAT has invested US$2.5bn since 2012 in 
developing new products and JTI announced a three-year projected spend 
of US$1bn to 2021.  
E-cigarettes (Disposables and Closed system)
Mass Market (Retail convenience store, Food, Drug stores)
Online
Other Retail (incluging kiosks)
Vapors/Tanks/Mods & Personal Vaporizers (Open System)
Convenience Store, Food, Drug and Mass Retail)
Online and other retail outlets
Vepe Shops
Total
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Market shares:
Type: Open Systems 68%, Closed Systems and Disposables 32%
Consumer sectors: Mass market retail 27%, Other retail 7%–20%, Online 15%–20%, Vape Shops  41%
Cigarette Manufacturers: mostly mass retail (27%) where they are 65% (Vuse, MarkTen, Blu and Logic) => total market share of approximately 18%–25%
40 Wells Fargo. Nielsen; tobacco ‘all channel’ data thru [to] 5/19. 29th May 2018
41 Various contributors. Panel on ‘Rethinking Nicotine’. Global Forum on Nicotine, 2018 
42 Used with permission of Professor David Levy and taken from his presentation at Global Forum on Nicotine 2018 
entitled Modelling future impact of the uptake of e-cigarettes and other safer nicotine products. 
Figure 3.11
US market consumer channels and industry shares42
Source: Data presented by David Levy at Global Forum on Nicotine conference 2018
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HNB products
HNB products are available in 36 countries43. The HNB market is different to the 
e-cigarette market, it is currently dominated by Japan and its uptake of the Philip 
Morris product IQOS. JTI are planning to go nationwide in Japan in 2018 with 
their HNB product Ploom TECH, to compete with IQOS and BAT’s product Glo. 
Other markets like Romania, Switzerland and Portugal currently lag behind. It is 
estimated that Japan will continue to dominate the HNB market over the next 
few years, both in terms of absolute value of the market and total market share in 
relation to cigarettes.   
Already in 2018, HNB products have 14 percent of the total Japanese cigarette 
market (forecast to rise anything from 20–40 percent by 2021 depending 
on the analyst). This growth has seen a consequential and dramatic dip in 
cigarette sales recorded by the main company JTI. Overall, HNB products 
are forecast by Euromonitor to constitute 45 percent of the global SNP sales 
market in value over the next few years. More information on Japan will be 
found in Chapter 4.
Is the market in SNP on a continuous 
upward growth curve?
As with any economic forecasting, market analysts will have differing views as to 
the future state of commodity markets. This is particularly evident when making 
predictions about SNP, especially with uncertainties about global regulations.
In 2012, the global market value for e-cigarettes was estimated by Euromonitor 
at US$2bn.44 In 2018, their estimate for the global market was around US$14bn 
(higher than the E Cig Intelligence estimate of US$8.6bn).
Euromonitor now combines estimates for e-cigarettes and HNB into a single 
‘vapour product category’. In 2016, the figure for all vapour products had 
jumped to around US$12.3bn. 
At the moment, this puts vapour products behind all forms of tobacco products 
– not just cigarettes at US$683.4bn, but also smoking tobacco (US$26.8bn), 
cigars (US$25.8bn) and smokeless tobacco (US$12.5bn). Though still small 
in comparison with the cigarette market, the growth rates are significant: 
Euromonitor reports growth in vapour products sales value of 818 percent over 
the period 2011 to 2016. 
But by 2021 Euromonitor estimates, the all-product vapour market will be more 
valuable than the market for all tobacco products except cigarettes, with a global 
value of around US$34bn.
There was a 43 percent growth in the value of the global market in 2015, but 
this had slowed to 34 percent in 2016. Analysts attribute this slowdown to the 
fact that in the strongest markets, like the USA, consumers were moving away 
from market leader cigalikes (as found in many service stations and convenience 
stores) towards more closed system products or pod mods, which combine the 
convenience of cigalikes with the greater flavour ranges and nicotine strengths 
offered by self-fill systems.
The chart below shows estimates from Euromonitor showing the continuing 
growth of the combined e-cigarette and HNB markets.
Snus
The Scandinavian snus market is estimated to have amounted to slightly more 
than 375 million cans in 2016, up by approximately four percent from the 
previous year. Over the past several years, consumption has been moving 
from traditional loose products to pouch products, which at the end of 2016 
accounted for approximately 80 percent of volumes in Scandinavia. 
Sweden is the largest snus market in Scandinavia, with approximately one million 
consumers. It is estimated that some 20 percent of Swedish men use snus on  
a regular basis. The overall percentage of women using snus is lower but growing.
43 Andorra, Greece, Poland, Bulgaria, Guatemala, Portugal, Canada, Israel, Romania, Canary Islands, Italy, Russian 
Federation, Colombia, Japan, Serbia, Croatia, Kazakhstan, Slovakia, Curacao, South Korea, Slovenia, Cyprus, 
Lithuania, South Africa, Czech Republic, Monaco, Spain, Denmark, Netherlands, Switzerland, France, New 
Zealand, Ukraine, Germany, Palestine, United Kingdom
44 Data in this section sourced from Global tobacco; key findings. Part II; vapour products. Euromonitor International, 
October 2017 
45 Statistics Norway, Snus more used than cigarettes. Statistics Norway, 2018. Available at 
https://www.ssb.no/en/helse/artikler-og-publikasjoner/snus-more-used-than-cigarettes
46 Norwegian Institute of Public Health. Evaluation of harm reduction as a strategic element in tobacco work. NIPH, 
2017
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In Norway, the snus market volume has grown by more than 20 percent over the 
past three years to the point where there are now more daily users of snus (12 
percent) than cigarette smokers (11 percent).45 Most snus use is among males 
in the 16–34 age groups, contrasting with very low levels of smoking in 16–24 
age group. Fewer people smoke in the youngest age group than any other, with 
smoking prevalence among women aged 16–24 down to one percent.
Figure 3.12 
Global market size for vapour (e-cigarette and HNB) products 2011–2021
Source: Euromonitor International. Passport tobacco 2017: new insights and system refresher. January 2018 
It is clear that a mixed economy of vapour products is emerging.
Swedish Match sells Swedish snus in the US under the General brand, priced in 
line with premium priced moist snuff products. ZYN is the company’s brand for 
its nicotine pouches without tobacco and was launched for sale in a selection of 
shops from December 2016. 
An almost identical product to Zyn is Zonnic, from the pharmaceutical company 
Niconovum. It was launched in 2008 and released onto the Norwegian market  
a few years later. Zonnic is sold as a non-prescription product and can be bought 
at pharmacies and in kiosks and grocery stores. As it is regulated as a medicine, 
the producer can advertise it.46  Niconovum also manufacture Nicopads (mouth 
powder containing nicotine) which consist of a white, dry powder packed into 
small pads. The powder contains nicotine salts leached from tobacco leaves, to 
which aroma (lemon/mint), acid regulators, sweeteners, stabilisers and fillers are 
added. 
In 2016, the US moist snuff market is estimated to have grown by approximately 
three percent, and amounted to approximately 1.5 billion cans, with the pouch 
segment accounting for approximately 15 percent of this market.  The US snus 
market is growing but is still quite small and amounted to approximately 55 
million cans in 2016.
Conclusion
The cigarette has been the dominant nicotine delivery system for the past 
hundred years and remains so today. However, the arrival of global e-cigarettes 
and HNB devices onto the market, and renewed interest in Swedish snus, have 
created a hugely disruptive landscape for the tobacco industry, allowing many 
new independent players into the business such as NJOY, JUUL, Kangatech and 
Hangsen to name but a few.  
The new and safer options these companies provide very much fit into the 
zeitgeist of new technology. They offer consumers who want to continue using 
nicotine unprecedented choice. Consumers can choose whether they want 
simple and convenient devices or wish to create their own user experience. They 
have a choice of nicotine strengths and a bewildering array of flavours.  None  
of these options are possible simply by burning some dried leaves wrapped  
in paper.
Everything about the new industry is dynamic and very fluid, making current 
estimates of market size, value and other metrics and forecasts of future growth 
hardly an exact science. It is clear, however, that these new technologies are 
here to stay. Over-zealous and disproportionate regulation could impede their 
growth. The only reasonable prediction at this stage is that the global industry 
is still on a learning curve. The industry will continue creating products that 
consumers want in the hope and expectation of encouraging more take-up 
of the widest range of options, and drawing more people away from smoking 
cigarettes.
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Despite all the caveats, the data does tell the story of how these new products 
have gained a foothold in many global markets in a remarkably short space of 
time. It is also important to examine this phenomenon in relation to changes  
in consumer awareness and knowledge of the products, and how this is shaping 
the market. The next chapter examines these factors in some detail.
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Chapter 4:
Consumers 
of safer nicotine 
products
The uptake of SNP has been driven by a combination of products, manufacturers 
and consumers:  the availability of older (snus) and the development of newer 
(e-cigarettes and HNB) products, coupled with smokers’ interest in alternatives to 
smoking.
In comparison to conventional tobacco control initiatives, this has occurred  
without any overall public health plan – without encouragement from governments, 
tobacco control experts or tobacco control NGOs. Only one country to date – the 
UK – has given strong policy support to this development, but this came after the 
initial spread of electronic cigarette use. Other governments are beginning to be 
supportive, but again after initial consumer interest. Until recently, no government 
had run a health promotion anti-smoking campaign that supported the use of 
e-cigarettes. In its 2017 ‘Stoptober’ campaign, Public Health England (PHE) did 
endorse the use of e-cigarettes as  a legitimate route to quitting.1
Indeed, in many countries tobacco control leaders have been caught by surprise 
by the rapid uptake of SNP, have been antipathetic to these products and have 
tried to block their availability or discourage their use. 
As we will argue in Chapter 7, this consumer interest is entirely consistent with 
a public health philosophy of enabling people to take control of their health, 
yet has been led by people themselves, not by public health experts. As one 
commentator put it, “E-cigarette makers, vaping stores, vaping forums and 
vapers are the new frontline in helping people switch from smoking. It is an 
example of public health objectives being delivered without the involvement  
of public health professionals”.2
“E-cigarette makers, vaping stores, vaping forums and vapers are the new 
frontline in helping people switch from smoking. It is an example of public 
health objectives being delivered without the involvement of public health 
professionals”.3
The story of SNP has yet to be fully told. Market data (as shown in Chapter 3) 
provide one measure of the uptake of products, but public health analysts are 
usually more interested in epidemiological data showing the numbers of people 
who use SNP, or the percentage of the population using them. Such data are still 
thin on the ground and they only give a snapshot at a point in time. Even rarer 
is information about trends in use over time and how this relates to changes in 
levels of smoking and longer-term health outcomes.
Starting to use e-cigarettes4
“About ten years ago my bad habit of smoking was beginning to annoy me, 
coughing in the morning and problems with breathing when I was active,  
so I decided to see if I could get rid of the cigarettes. First, I tried to just quit,  
I just put them away and said that’s it, lasted for about two to three weeks 
then I was back to the cigs. I should mention that I managed to cut down on 
my use, but it didn’t do anything for my health, so I tried to use some nicotine 
gum and patches, but it was like they gave me an urge to smoke more.
“After trying to stop for about two years a workmate introduced me to a strange 
looking pen with some liquid in and he told me I should try this. I tried  
a few puffs and was at first: ‘I’m never gonna get used to this’ – but he told me 
I could keep it (it was an eGo styled pen with a CE4 style tank) and he gave 
some apple flavoured E-juice also. After looking at it for a few days I thought 
what the heck, let’s see if I can’t get used to it. After a couple of days, I started 
1 Public Health England, Stoptober campaign website  
https://www.nhs.uk/oneyou/stoptober/home?gclid=CjwKCAjwxo3OBRBpEiwAS7X62TMrdcX8YnoOh3G-4NQW_
YzpdvFHuIaxADGfGEqBQvwPtuZIHz15nxoC4kAQAvD_BwE#GVG3ULMld2Jj9uOr.97
2 Stimson, G. (2016) Public health should step aside. Vapers are now leading the fight against smoking. Spectator 
(Health). Available at 
https://health.spectator.co.uk/public-health-should-step-aside-vapers-are-now-leading-the-way-against-smoking/
3 Stimson, G. (2016) Public health should step aside. Vapers are now leading the fight against smoking. Spectator 
(Health). Available at 
https://health.spectator.co.uk/public-health-should-step-aside-vapers-are-now-leading-the-way-against-smoking/
4  Testimony of a Danish vaper provided by DADAFO, the Danish vapers association
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to like the feel and taste of the e-cig and I managed to use it sometimes when 
I had the need for a smoke. It was around January 2010.
“I gradually used the e-cig more and more instead of cigs but it took me 
about two months to totally quit the cigs – so 13th April 2010 I smoked my last 
cigarette. And wow, only after a couple of weeks I started to smell way better 
and shortly after my taste got better, but most importantly I stopped coughing 
in the morning and my breathing got way better. The switch to vaping has 
been a life changer for me and I can’t thank my work mate enough for the 
introduction to vaping!”
Danish vaper
But these bare facts will tell only part of the story. Description of how the 
changes in the use of tobacco and nicotine occur requires other kinds of 
information, using the tools of anthropology, history, and cultural studies, 
in addition to social and behavioural studies.  It requires in-depth studies of 
how changes in tobacco users have occurred in different places over time. In 
the case of the cigarette, itself a disruptive innovation, we know that it took 
several decades for it to displace other ways of using tobacco. And indeed, in 
many countries, as is the case in India (Chapter 6), smoking cigarettes has not 
displaced the use of other types of tobacco. Few smoking researchers have 
turned their attention to how changes in the route of administration of nicotine 
have occurred in the past and are occurring now.
These changes are important to understand at a personal level, including, as 
in the example of the Danish vaper, the significance of advice and help from 
friends. A huge amount of information about e-cigarettes is also available on 
social media. For example, one e-cigarette forum in the UK gets 10,000 visits 
a day,5 a French site attracts 30,000 visits a day6 while an Australian site gets 
75,000 visits a day from people across the globe.7 Smokers are turning to vapers 
for advice on switching from smoking, and vapers have access to massive 
sources of information and support from other vapers – a genuine example of 
community public health in action.
There is a serious lack of curiosity among tobacco control researchers concerning 
the processes by which changes in the prevalence of smoking occur. At the end 
of this chapter, we give some mini-case studies to show how smoking is rapidly 
disappearing in Norway, how the decline in smoking in Sweden has been accom-
panied by dramatically low levels of smoking-related diseases, how Japanese 
smokers rapidly switched to HNB and how the tobacco market is collapsing, and 
how many UK smokers rapidly embraced e-cigarettes. These case studies merely 
scratch the surface of the complexity of changes in smoking and nicotine use.
“Smokers are turning to vapers for advice on switching from smoking, and 
vapers have access to massive sources of information and support from other 
vapers – a genuine example of community public health in action”.
Global estimates of e-cigarettes and HNB use
According to the market analyst company Euromonitor, in 2011 there were 
an estimated seven million people who “were regular dual or sole users 
of e-cigarettes and vapour products” around the world – for this estimate 
Euromonitor combines data on e-cigarettes and HNB. That figure rose to around 
35 million in 2016 and is estimated to rise to around 55 million by 2021.8 
Euromonitor base their growth estimate of 55 million partly on the assumption 
that the market in HNB products will continue at the current rate, although there 
are signs that the rapid growth in the Japanese market is beginning to slow. 
Much caution is required in forecasting what will happen in the SNP market 
because of the uncertainties over both regulation and consumer uptake.
While the current figure of around 35 million is a fraction of the world smoking 
population, when matched against the smoking population in the 61 markets 
where Euromonitor International collect data, those using mainly e-cigarettes 
or HNB are equivalent to about seven percent of that smoking population. 
Euromonitor estimates that the total vaping population will grow to around ten 
per cent of the smoking population by 2021. This is a remarkable growth in the 
short period since these products have been available: even more so that this 
has been driven by consumer interests and not by public policy.
5 Personal communication, Oliver Kershaw
6 Personal communication, Jacques le Houezec
7 Data from Vapetrotter https://www.vapetrotter.com
8 Euromonitor. Global tobacco: key findings part II; vapour products. Euromonitor, 2017, p.11
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Figure 4.1
Estimated numbers of people using vapour products (e-cigarettes and heat-not-
-burn) globally (millions)
Source: Euromonitor International, Passport Tobacco 2017: New Insights and System Refresher January 2018
There are no global estimates on the use of US style smokeless tobacco, though 
the US National Survey on Drug Use and Health estimates that there are around 
eight million consumers of smokeless tobacco in the USA.9 There are an estima-
ted one million adult male and 200,000 adult female snus users in Sweden. 
Country level data on e-cigarette users
For the first time we have tried to bring together the extant information on the 
prevalence of use of e-cigarettes, and this is summarised in Figure 4.22 at the 
end of the chapter. This information is also available online, on a country-by-
-country basis where it exists, at www.gsthr.org. 
We have tried to gather information on current or daily use, as well as on the 
numbers who have ever used e-cigarettes. However, there are large gaps – we 
have only been able to obtain recent, reliable data from 36 countries, and much 
of the information comes from one major EU survey. Clearly global interest in  
e-cigarettes by consumers and some policy makers has not been matched by 
government or academic surveys to explore even the extent of use. Readers 
must be aware of limits to the comparability of the sources. Surveys can suffer 
from numerous differences, due to variations in sampling methods and questions 
asked. We therefore suggest caution in making country comparisons.10  
9 Rodu, B. (2014) How many Americans use smokeless tobacco? Rstreet. Available at 
https://www.rstreet.org/2014/08/08/how-many-americans-use-smokeless-tobacco/ 
10 Farsalinos, KE. et al (2016). Electronic cigarette use in the European Union; analysis of a representative sample of 
27,460 Europeans from 28 countries. Addiction. Nov;111(11) p. 2032-2040. Available at  
https://www.ncbi.nlm.nih.gov/pubmed/27338716 
11 Great Britain is England, Scotland and Wales. The United Kingdom (UK) is England, Scotland, Wales and Northern 
Ireland – vaping prevalence in the UK is approximately five percent. 
12 European Commission. Attitudes of Europeans towards tobacco and electronic cigarettes. Special Eurobarometer 
458. EC, 2017. Available at: http://ec.europa.eu/commfrontoffice/publicopinion/index.cfm/Survey/getSurvey 
Detail/instruments/SPECIAL/surveyKy/2146
Overall, as a percentage of the total adult population, levels of current use of 
e-cigarettes in different countries range between one percent and 6 percent.
Levels of sometime experience with e-cigarettes range up to 27 percent of the 
adult population in Greece, and 20 percent or above in Estonia, Czech Republic, 
France, Cyprus, Latvia, and Austria. 
Clearly there are many smokers who are interested in these products. But there 
is also a large gap between those who have shown enough interest to have tried 
an e-cigarette at some time, and those who have gone on to currently use them. 
The highest prevalence of vaping is found in Great Britain11 where approximately 
six percent of the adult population currently vapes. 
There are limitations with all surveys on vaping, but one of the most extensive 
datasets is from Eurobarometer 458. The European Commission used this public 
opinion gathering resource to conduct an extensive survey of e-cigarette use 
across the EU as part of a wider review of smoking habits.12 The key findings 
were that across the 28 countries of the EU in 2017:
» Around 15 percent of those aged 15 or over had tried an e-cigarette at least 
once – compared to 12 percent in 2014;
» Two percent of the population are current users and this has remained stable 
since 2014; 
» Almost one in twenty current smokers now currently use e-cigarettes or similar 
devices (four percent), and four percent of ex-smokers; 
» Current use of e-cigarettes among people who have never smoked is rare. At 
most, one percent of e-cigarette users in any EU country are people who have 
never smoked.
Figure 4.2, generated from Eurobarometer data shows the prevalence of smoking 
cigarettes compared with the prevalence of e-cigarette use across the EU. 
41CHAPTER 4CONSUMERS OF SAFER NICOTINE PRODUCTS
E-cigarette use in the USA
Collating data from various national representative sources, the National 
Academy of Science report13 indicates that:
» Between 8.5 and 12.6 percent of the adult population has tried e-cigarettes;
» Current use (in the past 30 days) is estimated very widely at between 2.4 
and 5.5 percent;
» Although the data are hard to interpret, e-cigarette use in the USA has 
begun to level out;
» About 20 percent of current users reported using e-cigarettes daily and  
nearly 70 percent were dual users, not just of combustible tobacco  
products but also smokeless products like snus;
» E-cigarette use is mainly found in younger age groups and decreases with 
age – and more men use e-cigarettes than women;
» US data reveals significant racial and ethnic differences with majority use 
among (non-Hispanic) whites, followed by Hispanic, Black, Asian and 
Native Indian;
» In general, as frequency of use increased, so the consumer was more likely 
to use the more flexible devices with refillable tanks and more likely to use 
e-liquid containing nicotine;
» About two-thirds of current users were using flavoured liquids.
An earlier analysis considered e-cigarette use among US adults based on the 
Population Assessment of Tobacco and Health (PATH) study,14 while another 
looked at reasons for use among a national representative sample.15 Taken 
together, and adding to the National Academy of Sciences review,  
the studies concluded:
» Most e-cigarette consumers were either current, or recent former, smokers;
» The main reason for dual use or switching was concerned with personal 
health considerations and the health impact on others, followed by conve-
nience, curiosity, flavour and cost;
13 National Academy of Sciences. Public health consequences of e-cigarettes. National Academies Press, 2018
14 Rodhu, B. and Plurphanswat, N. (2017). E-cigarette use among US adults: Population Assessment of Tobacco and 
Health (PATH) Study. Nicotine and Tobacco Research, p. 1-9
15 Patel, D. et al. (2016) Reasons for current e-cigarette use among US adults. Preventative Medicine. 93, p. 14-20. 
Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316292/
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Figure 4.2 
Comparison of current smoking and vaping levels
The second chart develops a simple metric giving the ratio of current e-cigarette users to current smokers. This shows that the highest is the UK at 0.29. In other 
words, there are 29 e-cigarette users for every hundred smokers in the UK. In many other EU countries, the ratio is above 0.10.
Figure 4.3 
Ratio of current vapers to current smokers
Source: European Commission (2017). Special Eurobarometer 458: Attitudes of Europeans towards tobacco and electronic cigarettes Available at: http://data.europa.eu/euodp/en/data/dataset/S2146_87_1_458_ENG 
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» The study by Patel16 also revealed variations in reasons for use by product 
type, including greater likelihood of citing cessation/health among tank 
users compared with disposable users. Research suggests that tank 
systems may deliver more nicotine than disposable e-cigarettes and that 
some e-cigarette users find disposable varieties less satisfying than tank 
systems.17 This aligns with research showing that e-cigarette users who use 
tanks are more likely to be former smokers than those who use disposable 
or cartridge style e-cigarettes.18
Australia – e-cigarettes are used despite nicotine being illegal
As we discuss in Chapter 6, in Australia a legacy ban means that nicotine for 
use in e-cigarettes is illegal unless obtained on a prescription. Nevertheless, 
despite prohibition, there is substantial use of e-cigarettes. The 2016 
National Drug Strategy Report19 found that:
» Almost one-third of smokers had tried e-cigarettes at some time;
» Current use of e-cigarettes was 1.2 percent of people aged 14 or older 
reporting that they currently use e-cigarettes (this compares for example 
with 5 percent in the UK);
» Current e-cigarette use was most common among smokers aged 18–24;
» One in 20 smokers currently use e-cigarettes and only 1.5 percent use 
them daily;
» Those aged 50 or older were more likely to use e-cigarettes as a cessation 
device, with more than half specifying that they used them to help them 
quit smoking;
» About one in five used e-cigarettes because they thought they were less 
harmful than regular cigarettes. 
The lesson from Australia is that while bans might make access difficult and 
result in fewer people using e-cigarettes than in countries with more liberal 
laws, bans do not deter interest in e-cigarettes.
The numbers using e-cigarettes are still small in many countries, but are still 
substantial given the limited time in which these products have been available, 
the lack of endorsement by most governments and discouragement from public 
health leaders, often seized upon by media in search of a story.
Why do people use e-cigarettes?
First experiences with e-cigarettes20
“I bought my first e-cigarette, a cigalike, in a marketplace in July 2012. Until 
that day, I was convinced, that I would be the last smoker on earth, since  
I had already tried all the different quitting methods, all without success. 
I even tried Zyban, in the hope for a ‘quick fix’ – and that almost led me to 
commit suicide. If I hadn’t stopped taking the pills, I wouldn’t be here today...
This new ‘gadget’ I bought in 2012 – ‘the electronic cigarette’ as it was called 
– was the first step on the road to a ‘smoke-free living’, but it wasn’t until 
February 2013 [that] I could finally break my smoking habit, thanks to an 
eGo-battery and the CE4 atomizer. I started out with 36 mg/ml nicotine, and 
I felt no need to smoke. After three smoke-free days, everything around me 
started to smell of smoke – and I had to wash down all the walls in the house, 
the curtains, the blankets, all my clothes – because of the pungent smell of 
tobacco smoke.
“I’m down to 3-6 mg/ml nicotine - and I enjoy vaping. I can easily go for days 
without vaping, and for me it hasn’t been the craving for nicotine that keeps 
me vaping – it’s the sensation and the pleasure that comes from vaping –  
like a really good cup of coffee or a nice glass of red wine.
“I started smoking when I was 16, and kept on smoking a pack-a-day for the 
next 16 years and I’ve been 100 percent smoke-free for almost six years now, 
thanks to vaping. I still find pleasure in vaping, as I did with smoking – 
but I feel so much better – both physically and mentally. And I’ve found 
reassurance in vaping, found so many new friends, who also saw the potential 
in vaping.
16 Patel, D et al. (2016) Reasons for current e-cigarette use among US adults. Preventative Medicine. 93, p. 14-20. 
Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316292/
17 Farsalinos, K. et al. (2014). Nicotine absorption from electronic cigarette use: comparison between first and new-
-generation devices. Scientific Reports. 4:4133
18 Dawkins, L. et al (2015). First- versus second-generation electronic cigarettes: predictors of choice and effects on 
urge to smoke and withdrawal symptoms. Addiction. 110(4) p. 669-677 
19 Australian Government. National Drug Strategy Household Survey. Australian Institute of Health and Welfare, 2017
20 Testimony provided by DADAFO, the Danish vapers association
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“Today, I’m fighting for smokers and vapers rights – every day – trying to slay 
misinformation, and educate people about ‘the truth about vaping’”. 
Danish vaper
New Zealand
Penelope Truman from Massey University and colleagues conducted the first 
survey of New Zealand vapers, sampling a broad range of regular vapers who 
had completely switched from smoking, reflecting the estimated 63,000 daily 
vapers in New Zealand. In line with most consumer surveys, most vapers were 
white males aged 20–50. Vaping was a means of smoking cessation, smoking 
reduction, or avoidance of or mitigation of relapse to smoking, while cost was 
also a factor. First time vapers tended to start with devices that looked like  
a cigarette then moved on to explore more powerful devices. They also 
moved away from tobacco and menthol flavoured e-liquid over time.
The majority of those who still smoked only did so occasionally, and those 
who still smoked regularly had reduced their tobacco consumption by around 
50 percent on a conservative estimate. Unlike nicotine patches and other 
smoking cessation methods, vaping appears to be pleasurable for many. 
Finding a pleasurable form of vaping may prove important for complete 
smoking cessation, since those who were smoking as well as vaping seemed 
less likely to report that they liked vaping. Exploration of different types of 
e-cigarette, different nicotine strengths, and different flavours of e-liquid 
was common and may be an important aspect of a successful vaping 
experience.21
Eurobarometer also gives insights into why people use e-cigarettes. It might 
seem obvious but the top reason across the EU for using e-cigarettes is to stop 
using tobacco. The clear majority of people using e-cigarettes did so to stop, or 
to reduce tobacco use (61 percent). Following this the next reason was because 
they thought e-cigarettes were less harmful than cigarettes (31 percent), or less 
expensive (25 percent). Only six percent said they started because they felt using 
e-cigarettes was cool or attractive. 
The flavour was relatively unimportant as a reason to start using e-cigarettes 
– only 12 percent mentioned this as a factor. However flavour is an important  
factor in continued use, and in the previous Eurobarometer survey (2014) flavour 
was an important  factor in choice of e-cigarette. Flavours preferred by current 
e-cigarette users in the 2016 survey were fruit (47 percent), tobacco (36 percent), 
then menthol/mint (22 percent). Women preferred tobacco flavour more, and 
men preferred fruit. Older respondents preferred tobacco flavour compared 
with the younger respondents who preferred fruit (72 percent) and candy 
flavours (11 percent).
Figure 4.4 
Top four reasons for starting to use e-cigarettes
Source: European Commission (2017). Special Eurobarometer 458: Attitudes of Europeans towards  
tobacco and electronic cigarettes Available at: http://data.europa.eu/euodp/en/data/dataset/ 
S2146_87_1_458_ENG
However, a recent study of 15,000 US vapers indicated the importance of flavour 
in encouraging smokers to switch. The proportion of first e-cigarette purchases 
that were fruit-flavoured increased from 17.8 percent of first purchases made 
before 2011 to 33.5 percent of first purchases made between June 2015 and 
June 2016. Tobacco-flavoured first purchases almost halved during this time 
(46.0 percent pre-2011 to 24.0 percent between 2015 and 2016). Fruit/fruit 
beverage, dessert/pastry and candy, chocolate, or sweets all showed percentage 
increases over time and were the most popular currently used e-cigarette 
flavours. Tobacco and menthol flavours, the two most popular flavours for 
21 Truman, P. et al. (2018) An online survey of New Zealand vapers. International Journal of Environmental Research 
and Public Health; 15 (2) p. 222
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initiating e-cigarette use prior to 2013, now rank as the fifth and sixth most 
popular currently used e-cigarette flavours, respectively. The authors conclude 
that current moves in the US to ban e-liquid flavours in the mistaken belief they 
have a special appeal for young people could in fact dissuade smokers from 
switching.22
Safer nicotine products and changes 
in the prevalence of smoking
The key questions for tobacco harm reduction are whether SNP can replace and 
displace cigarette smoking, the way this occurs, and whether there are long-term 
health gains from this. In other words, do SNP help drive down smoking and 
smoking-related disease and premature death? If the ethos of tobacco control 
can be characterised (and possibly caricatured) as ‘Quit or Die’, does the harm 
reduction message of ‘Quit or Try’ really make a difference to individual and 
public health? Does smoking decline lead to less illness and less premature 
death? What is the weight of evidence for safer nicotine products and individual 
and population health?
“Does the use of SNP drive down smoking and improve public health?”
These questions cannot be answered through single epidemiological studies, 
market data, or policy studies. It requires bringing together a historical and 
cultural picture of tobacco use in particular countries, changes in the types of 
tobacco and nicotine used over time, epidemiological studies of tobacco users, 
scenario modelling, and measures on long-term changes in health. This work has 
barely begun. Few smoking researchers have synthesised the complex array of 
national information. 
In this final section of the chapter, we give a brief overview of changes in 
tobacco and nicotine use, by way of national case studies: in Norway, where the 
evidence is that snus has rapidly displaced cigarettes and that smoking is fast 
disappearing; in Sweden, which has undergone a similar process and where 
there are epidemiological data on the low rates of tobacco related disease; 
in the UK, which has the highest uptake of e-cigarettes globally; and finally in 
Japan, which is the most important global example of how HNB products are 
displacing cigarette sales at a hitherto unseen rate.
Case study 1: 
Norway – smoking is fast disappearing and only 
one percent of young Norwegian women smoke
Snus is fast replacing cigarettes as the way that Norwegians consume nicotine.23 
As shown in Figure 4.5 there has been a long-term decline in daily smoking 
from 21 percent in 2008. In 2017, for the first time, the proportion of the popula-
tion using snus – 12 percent – exceeded that of those smoking cigarettes. At 11 
percent, Norway now has one of the lowest levels of daily smoking in developed 
countries. The fall in smoking is even more dramatic amongst younger people. 
Among young people snus became more popular than smoking around  
2009–10, with a decline in smoking to three percent. 
Figure 4.5 
Prevalence (%) of daily smoking and snus use in the Norwegian population
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22 Russell, C et al. (2018). Changing patterns of first e-cigarette flavor used and current flavors used by 20,836 adult 
frequent e-cigarette users in the USA. Harm Reduction Journal; 15 p. 33. Available at  
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-018-0238-6 
23 We are grateful to Karl Lund for contributions to this section
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Figure 4.6 
Daily usage as a percent of population (for those under the age of 25)
Figure 4.7 
Daily usage as a percent of population (women under the age of 25)
 
Source: Statistics Norway/The Norwegian Directorate of Health
Even more dramatic is the changing tobacco habits of young women in 
Norway under the age of 25, with a precipitous fall in smoking among this 
group since 2008, from 17 percent to one percent. 
It is likely that such a fall has not been witnessed anywhere else in countries 
where smoking has been common among women. 
But women have not given up using tobacco – snus use hovers from around 14 
percent to 17 percent. The overall percentage of people using nicotine via either 
snus or smoking has remained about the same over time – it is the choice of 
products that has changed over the last ten years.
How has this come about? The Government of Norway has taken a negative view 
on snus: at a recent European Court of Justice hearing (see Chapter 6) it referred 
to its use as an “epidemic” among young people. In Norway, all tobacco adver-
tising has been banned since the middle of the 1970s. The uptake of snus has 
been within a public climate where messages from government, medical and 
tobacco control organisations have asserted that snus is not a safe alternative to 
smoking cigarettes, where there have been warnings against snus use including 
for smoking cessation, and both smokers and non-smokers over-estimate the 
health risks of snus.24 25
The change in nicotine consumption began at the end of the 20th century. In 
1997-99, about five percent of tobacco consumption was snus, and 95 percent 
was cigarettes. The use of snus accelerated from the turn of the century, linked 
with the availability of pasteurised snus and the new products that came onto 
the market in both Norway and Sweden in the late 1980s. Cleaner to use pro-
ducts in small pouches, a range of flavours and strengths, and smart packaging 
would seem to have been part of the appeal, in a context where people were 
being encouraged to avoid smoking. Overall tobacco consumption – by weight – 
declined by 40 percent between 1997 and 2017.
There appear to be three mechanisms behind the fall in smoking and the rise in 
the use of snus. First, snus is an exit from smoking for established smokers. Over 
24 Øverland, S., et al (2008). Relative harm of snus and cigarettes: What do Norwegian adolescents say? Tobacco 
Control: An International Journal, 17(6), p. 422–425
25 Wikmans, T. and Ramström, L. (2010). Harm perception among Swedish daily smokers regarding nicotine, 
NRT-products and Swedish snus. Tobacco Induced Diseases, 13 p. 8–9
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time, the use of snus at the last quit attempt has risen from ten percent in 2003 
to around 23 percent, overtaking NRT by 2011.26 27  It is the most common way to 
quit smoking in Norway, after unassisted (cold turkey) quits. As with e-cigarettes, 
the preference of snus over NRT might be because snus is non-medical –  
a switch in route rather than a medication. 
Former smokers make up the largest proportion of snus users,28 29 and there 
is evidence that using snus is associated with higher quit rates for smoking 
compared to not using snus30 or using NRT.31 NRT is in fact widely available. It is 
plausible that there is a higher population impact of snus on exits from smoking 
than for other ways of quitting smoking.
Secondly, snus use helps smokers to reduce smoking. Many smokers in Norway 
appear to use snus to reduce the level of smoking, or use it where smoking 
is banned. Those who both smoke and use snus have a weekly cigarette 
consumption 37 percent below that of exclusive smokers.32 The proportion of 
dual users is small.33
Thirdly, snus use has become an alternative way of using nicotine for those who 
might otherwise have started smoking. Norway provides suggestive evidence 
that snus is protective against smoking – in other words, people who want to use 
nicotine and who chose snus are unlikely to progress to smoking. Many young 
snus users have characteristics that usually predict uptake of cigarette smoking.34 
If, as seems possible, they are choosing snus instead, this is an important propo-
sition given concerns about snus as a possible gateway to smoking.
Karl Lund, a Norwegian smoking and snus researcher, summarises the situation:
“In Norway and Sweden, the availability of snus has clearly influenced total 
tobacco consumption through its role in smoking initiation and smoking 
cessation. The combined numbers who have i) quit smoking for snus, ii) 
reduced smoking intensity by snus, iii) picked up snus instead of cigarettes, 
have outnumbered iv) snus users who otherwise would have been tobacco-
free. Health gains from smoking cessation, smoking reduction and smoking 
substitution produced by snus, have more than out-weighed the (marginal) 
health loss in the small fraction of never-smokers taking up snus”.
Norway provides evidence that the availability of snus and consumer choices 
have driven these changes. It is interesting to speculate whether the reductions 
in smoking might have been quicker had there been supportive messages from 
government and health experts.
Case study 2: 
Sweden and snus – low rates of smoking and the 
lowest level of tobacco-related mortality in Europe
It has often been remarked that Sweden provides a unique case study of the 
impact of snus on smoking. Sweden stands out in the EU as the only country 
where snus may be sold legally. This natural experiment, and the large amount 
of long-term epidemiological evidence, provides substantial information on the 
uptake and plausible impact of snus on smoking and tobacco related disease. 
The UK Royal College of Physicians argued in its 2016 report that the use of snus 
in Sweden is proof of concept for the efficacy and effectiveness of tobacco harm 
reduction:
24 Øverland, S., et al (2008). Relative harm of snus and cigarettes: What do Norwegian adolescents say? Tobacco 
Control: An International Journal, 17(6), p. 422–425
25 Wikmans, T. and Ramström, L. (2010). Harm perception among Swedish daily smokers regarding nicotine, 
NRT-products and Swedish snus. Tobacco Induced Diseases, 13 p. 8–9
26 Lund K. E. (2012). Association between willingness to use snus to quit smoking and perception of relative risk 
between snus and cigarettes. Nicotine and Tobacco Research. 14 p. 1221–8
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“The availability and use of an oral tobacco product known as snus in Sweden, 
documented in more detail in our 2007 report (and revisited in Chapter 7), 
demonstrates proof of the concept that a substantial proportion of smokers will, 
given the availability of a socially acceptable and affordable consumer alternati-
ve offering a lower hazard to health, switch from smoked tobacco to the alter-
native product. Particularly among men, the availability of snus as a substitute 
for smoking has helped to reduce the prevalence of smoking in Sweden, which 
is now by far the lowest in Europe. The magnitude of the contribution made by 
the availability of snus over and above conventional tobacco control measures 
is difficult to quantify, but a recent study of the effect of withdrawal of snus from 
the market in Finland in 1995, when both Finland and Sweden joined the EU, 
but only Sweden was allowed to continue its use, estimates that over the  
following ten years the availability of snus reduced smoking prevalence in 
Sweden by an additional 3.7 percentage points. Trends in snus use in Norway 
are similar to, and perhaps stronger than, those in Sweden, and there the use of 
snus is strongly associated with quitting smoking”.35
Snus has been used in Sweden for over 200 years and, historically, tobacco use 
in Sweden was dominated by snus. From the early 1900s (a couple of decades 
after the invention of the cigarette rolling machine) cigarettes started to become 
more popular and the consumption of snus began to decline. From the late 
1960s the trends were reversed and the use of snus increased. According to 
Swedish tobacco expert Lars Ramström:
“An important influence behind this change was the emerging scientific 
evidence of the health risks of smoking which were disclosed in the 1962 report 
of The Royal College of Physicians in London and the 1964 report of the US 
Surgeon General. These new pieces of evidence received a lot of attention in 
Sweden, both in news media and in professional circles. Many smokers who 
were encouraged to escape the health risks of smoking switched to snus”.36
The change was accelerated by the availability of newer types of the Swedish 
pasteurised snus. In 1981, Swedish Match (at that time called Swedish Tobacco 
Ltd) opened a newly built factory where the traditional pasteurisation process 
was made completely closed to avoid contamination. 
Snus overtook cigarettes among men in 1996. The change would seem to have 
been due to consumer interest in the face of opposition from the Swedish 
government and health bodies. It occurred primarily among Swedish men, and 
the reduction in smoking was faster for men than for women. Among men, the 
prevalence of smoking is now a sixth of what it was in 1963, and there has been 
a sharp increase in the use of snus to around 18 percent. Female smoking levels 
continued to increase until 1976, but have since declined, at a slower rate than 
for men however. Unusually for many countries, more women now smoke than 
men. Nevertheless, the use of snus is increasing among women but is still below 
that for men (note that the official statistics for Sweden give somewhat higher 
levels of smoking than the Eurobarometer studies).
Figure 4.8 
Prevalence of daily smoking and snus use in Sweden 1963-2016
Data source: Lars Ramström, Institute for Tobacco Studies, Sweden. Sweden’s pathway to Europe’s lowest level of 
tobacco-related mortality. Poster. World Conference on Tobacco or Health, South Africa, 2018
Sweden now has the lowest level of smoking among men than for any other co-
untry in Europe. According to the European Commission’s Eurobarometer 2017 
report, only five percent of Swedish men now smoke. This is only one fifth of the 
EU average of 24 percent. The Eurobarometer report indicates that all other EU 
countries have a smoking prevalence three to seven times greater than Sweden. 
So, something is clearly different about Sweden – and the clear difference is that 
snus is allowed in Sweden yet banned in the other 27 EU countries.
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35 Royal College of Physicians, Tobacco Advisory Group. Nicotine without smoke: Tobacco harm reduction. RCP, 
2016, p.6
36 Lars Ramström, Institute for Tobacco Studies, Sweden. Sweden’s pathway to Europe’s lowest level of tobacco-
-related mortality. Poster. World Conference on Tobacco or Health, South Africa, 2018
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Figure 4.9 
Prevalence of daily smoking in the EU
Data source: Eurobarometer 458, May 2017 (TableQB4aT2)
Chart reproduced from: Lars Ramström, poster, Global Forum on Nicotine 2017
The changes in the way that tobacco is consumed has, in Sweden as in Norway, 
come about through two mechanisms. The first is the increasing preference  
of snus over cigarettes among those starting to use tobacco. Birth cohort data 
over four decades show that the proportion of men starting to initiate tobacco 
use from smoking dropped, whilst those initiating tobacco through snus 
increased. What is also striking is that during these periods the proportion  
of the population initiating any tobacco use dropped. 
It is sometimes asserted that the use of snus could be a stepping stone to the 
smoking of tobacco. This is not supported by the population level smoking 
and snus data. Neither is it supported by research evidence. The largest study 
is an analysis of a nationally representative sample of the Swedish population 
recruited between 2003 and 2011, covering 60,675 individuals. Those who 
began daily tobacco use using snus were much less likely to subsequently take 
up smoking than those who had not.37
The second mechanism leading to fewer smokers is the use of snus to quit or 
reduce smoking.    Among men, snus is the most commonly used cessation 
product, while among women, nicotine gum or patches are more common. 
Success rates using snus are higher than for those using other means. A very 
high proportion of male (87 percent) and female (86 percent) smokers who take 
up snus use quit daily smoking.38   
“When the tobacco control score is plotted against smoking prevalence 
in different countries, Sweden is an outlier whose record low smoking 
prevalence is not explained by tobacco control activities alone”.
It has been suggested that the fall in smoking in Sweden might not be due to 
the availability of snus but rather to the imposition of tough tobacco control 
measures. However, on key indicators of tobacco control (price, smoking bans, 
treatment availability, health promotion spending, health warnings, advertising 
bans) Sweden is in the middle ranking among European countries and well 
below the UK, Ireland and Iceland.39 When the tobacco control score is plotted 
against smoking prevalence in different countries, Sweden is an outlier whose 
record low smoking prevalence is not explained by tobacco control activities 
alone.
Sweden and tobacco-related mortality
In theory, the reduction in the number of smokers, and the use of lower-risk 
snus, should have an impact on morbidity and mortality in Sweden. Snus does 
not pose a respiratory risk, and across many studies snus is not associated with 
diabetes, pancreatic and oral cancers, heart disease or stroke (see Chapter 5).  
A limitation with the evidence on newer SNP such as e-cigarettes and HNB is the 
absence of long-term data on health outcomes. And it is in this respect that the 
Swedish experience adds considerably to our understanding of the impact of 
tobacco harm reduction on population level health measures. 
37 Ramström L. et al (2016). Patterns of smoking and snus use in Sweden: implications for public health. International 
Journal of Environmental Research and Public Health, 2016 Nov 9;13(11), pii: E1110
38 Ramström L. et al (2016). Patterns of smoking and snus use in Sweden: implications for public health, International 
Journal of Environmental Research and Public Health, 2016 Nov 9;13(11), pii: E1110
39 Tobacco Control Scale http://www.tobaccocontrolscale.org/results-last-edition/
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”Sweden has, for men, the lowest tobacco-related mortality in Europe at 152 
per 100,000. The rate is less than half the EU28 average”. 
Nineteen European countries have tobacco-related death rates that are twice 
that of Sweden.  
Figure 4.10 
Death rate per 100,000 attributable to tobacco, all causes of death, men 30 
years and older
Data source: Lars Ramström, poster, Global Forum on Nicotine 2017. Data source World Health Organization. WHO 
Global Report: Mortality Attributable to Tobacco; WHO: Geneva, Switzerland, 2012; ISBN 978-92-4156443-4
Looking at it another way, we can assess what percentage of all deaths are 
tobacco-related – which gives an indication of the chances of dying of a tobacco-
related disease. Using more recent data from the Global Burden of Disease 
study, it is calculated that in Sweden 11 percent of male and 12 percent of 
female deaths are tobacco-related. In all EU countries the percentage is higher: 
for example, in Greece 26 percent of male deaths are tobacco related; 23 
percent in Spain, Belgium and the Netherlands; 21 percent in Italy and Denmark; 
and 20 percent in the UK and Luxembourg.40
The Swedish experience indicates the human cost of the ban on snus.  
Dr Ramström calculated the potential future premature deaths that could be 
avoided in the EU if the ban on the marketing of snus is revoked: 
“If snus is made available by lifting of the current ban in the EU, and truthful 
public education encourages substitution of snus for cigarettes as in Sweden, 
then around 320,000 premature deaths per year can conceivably be 
prevented among men 30 years and older in the current EU countries”.41
Case study 3: 
E-cigarettes in the United Kingdom – 
rapid consumer uptake and official endorsement
The UK has taken many steps to embrace harm reduction. The use of safer forms 
of nicotine as alternatives to smoking was endorsed by the Royal College of 
Physicians back in 200742 before e-cigarettes were in the public mind, and again 
in 2016.43 The evidence reviews by PHE44 45 that conclude that ‘e-cigarettes are at 
least 95% less harmful than smoking’ have been very influential. Most of the anti-
smoking and health NGOs, and medical bodies endorse the use of e-cigarettes. 
More recently the importance of innovation and less harmful alternatives is 
included in the latest tobacco control plan published by the Department of 
Health.46 This was not the case from the beginning. A handful of vociferous 
40 Lars Ramström, Institute for Tobacco Studies, Sweden. Sweden’s pathway to Europe’s lowest level of tobacco-
-related mortality. Poster. World Conference on Tobacco or Health, South Africa, 2018. Data from database of  
The Global Burden of Diseases, Injuries, and Risk Factors Study 2016, Lancet 2017; 390: 1345–422 available on the 
website of The Institute for Health Metrics and Evaluation
41 Lars Ramström (2017). Poster, Global Forum on Nicotine 2017
42 Royal College of Physicians, Tobacco Advisory Group. Harm reduction in nicotine addiction: helping people who 
can’t quit. RCP, 2007
43 Royal College of Physicians, Tobacco Advisory Group. Nicotine without smoke; tobacco harm reduction. RCP, 
2016
44 McNeill, A. et al (2015) E-cigarettes: an evidence update: a report commissioned by Public Health England. 
PHE publications gateway number: 2015260 2015. PHE, 2015. Available at https://www.gov.uk/government/
publications/e-cigarettes-an-evidence-update
45 McNeill A. et al (2018). Evidence review of e-cigarettes and heated tobacco products 2018. A report 
commissioned by Public Health England. PHE, 2018
46 UK Department of Health, Towards a smoke-free generation: tobacco control plan for England. DH, 2017.  
Available at https://www.gov.uk/government/publications/towards-a-smoke-free-generation-tobacco-control-plan-
-for-england
699
566
469
360
51CHAPTER 4CONSUMERS OF SAFER NICOTINE PRODUCTS
public health leaders opposed e-cigarettes. Early regulatory discussions by 
smoking research academics and leading tobacco control NGOs favoured 
regulating e-cigarettes as medical products; this influenced legislators in 
designing the updated EU Tobacco Products Directive. The legal and regulatory 
policy drive was thrown out by the European Parliament under pressure from 
vaper advocates (See Chapter 7). 
Prevalence of smoking in the United Kingdom
Adult smoking prevalence has been in decline since the 1974 with the most 
rapid decline in the 70s and 80s. Since then the gradient of decline has been 
less steep. The decrease in smoking has come about due to a combination of 
smokers quitting and an increase in the proportion of people who have never 
taken up smoking.47
Figure 4.11 
Proportion of current smokers, all persons aged 18 and over, UK, 2011–2017
 
Source: Annual Population Survey – Office for National Statiscics
Annual Population Survey (APS) data provided by the Office for National 
Statistics (ONS) shows the continued declining trend between 2010 and 2017 
in each of the four UK countries (England, Wales, Scotland and Northern 
Ireland).  Overall smoking prevalence in the UK in 2017 was 15.1 percent, 
which equates to around 7.4 million people in the population, a statistically 
significant decline of more than five percentage points since 2011.  England 
had the lowest level of smoking at 14.9 percent (approximately 6.1 million 
people), Wales at 16.1 percent (approximately 386,000 people), Scotland 16.3 
percent (approximately 677,000 people) and Northern Ireland the highest at 
16.5 percent (approximately 226,000 people).48 Figure 4.11 shows the year on 
year decline for England, Wales and Scotland. Northern Ireland’s overall trend is 
down, but not as consistently as the other three countries.
Prevalence of e-cigarette use in the Great Britain
The anti-smoking charity ASH has conducted repeat surveys on the use of 
e-cigarettes in the adult population in Great Britain (England, Wales, and 
Scotland) since 2012. Sample sizes are substantial at around 12,000 adults  
(18 and over) each year.  
These surveys show a steady increase in the proportion of the adult population 
who use e-cigarettes, up from just under two percent in 2012 to nearly six percent 
in 2017.49 There appears to be some slowing of the increase in 2016 and 2017.
ASH, working with King’s College London, has estimated the prevalence of 
e-cigarette usage in Great Britain by using the findings of the surveys and 
applying these to the most recent population data available in each year.50  This 
shows that in 2017:
» An estimated 2.9 million adults in Great Britain were currently using e-cigarettes; 
» Of the 2.9 million current e-cigarette users, approximately 1.5 million (52%) 
were ex-smokers.
Figure 4.14 plots the data from Figure 4.11 and Figure 4.12 to show the trend 
in e-cigarette use in GB against the trend in smoking in the UK. The trends 
are rather similar to those seen in Norway and Sweden where snus gradually 
replaced smoking – bearing in mind that the process in both countries was over 
a longer period of time.
47 ASH, Factsheet no.1 Smoking statistics. ASH, 2017. Available at  
http://ash.org.uk/category/information-and-resources/fact-sheets/ 
48 Office for National Statistics. Statistical bulletin: Adult smoking habits in the UK: 2017 ONS, 2018. Available at 
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/ 
bulletins/adultsmokinghabitsingreatbritain/2017  
49 At the time of writing, new survey data from the ONS Great Britain – Opinions and Lifestyle Survey (2017) showed 
a slightly lower e-cigarette use prevalence (5.5 percent) for 2017 (2.8 million vapers)
50 ASH. Fact sheet. Use of e-cigarettes (vapourisers) among adults in Great Britain. ASH, 2017. Available at  
http://ash.org.uk/category/information-and-resources/fact-sheets/
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Figure 4.12 
Proportion of e-cigarette users in Great Britain, 2012–2017
Data source: ASH (2017). Fact sheet. Use of e-cigarettes (vapourisers) among adults in Great Britain
Figure 4.13
E-cigarette use in Great Britain
Data source: ASH (2017). Fact sheet. Use of e-cigarettes (vapourisers) among adults in Great Britain51
Use of e-cigarettes is confined largely to current and ex-smokers and use 
amongst never smokers remains very low (at around two to three percent). 
Over time the proportion of current e-cigarette users who smoke tobacco has 
decreased and the proportion of ex-smokers has increased (and overtaken 
smokers). See figure 4.15.
Figure 4.14 
Trends in smoking (UK) and e-cigarette use (Great Britain) 2012–2017
Data sources: 
Smoking statistics: Office for National Statistics Statistical bulletin: Adult smoking habits in the UK: 2017. (ONS, 2018)52 
E-cigarette use statistics: ASH Use of e-cigarettes (vapourisers) among adults in Great Britain. (ASH, 2017)53 
Figure 4.15
Current e-cigarette use by smoking status. Great Britain. 2014–2017
Data sources: ASH (2017). Fact sheet. Use of e-cigarettes (vapourisers) among adults in Great Britain
25%
20%
15%
10%
5%
0%
20
12
19
.6
%
20
13
18
.8
%
20
14
18
.1
%
20
15
17
.2
%
20
16
15
.8
%
20
17
15
.1
%
Smoking UK E-cigarettes use GB
51 ASH. Fact sheet. Use of e-cigarettes (vapourisers) among adults in Great Britain. ASH, 2017. Available at  
http://ash.org.uk/information-and-resources/fact-sheets/use-of-e-cigarettes-among-adults-in-great-britain-2017/ 
52 Office for National Statistics. Statistical bulletin: Adult smoking habits in the UK: 2017 ONS, 2018. Available at 
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/ 
bulletins/adultsmokinghabitsingreatbritain/2017
53 ASH. Fact sheet. Use of e-cigarettes (vapourisers) among adults in Great Britain. ASH, 2017. Available at  
http://ash.org.uk/information-and-resources/fact-sheets/use-of-e-cigarettes-among-adults-in-great-britain-2017/
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Changes in smoking cessation
The data suggest there are large numbers of smokers both trying e-cigarettes 
and using them, and who have quit smoking altogether. Coupled with the rapid 
decline in smoking, to 15.1 percent, this indicates a strong association between 
the rise of e-cigarettes and the ongoing decline in smoking.
There appears to be a new landscape of smoking cessation. E-cigarettes are 
now the most common method used to quit smoking, having overtaken NRT, 
medication and behavioural support by 2013 in England.
Figure 4.16 
Aids used in quit attempt in past 12 months, England, Smoking Toolkit Study
2011–2015
Source: Smoking Toolkit Study. http://www.smokinginengland.info/latest-statistics/
These changes are also reflected in the use of stop smoking services. The UK 
has a network of specialist stop smoking services and help with quitting is also 
provided though a wide range of NHS services. They have seen a rapid drop in 
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customers since 2011-12. In part this might be due to reduced resources, but is 
also likely to be linked to the fact that people now have additional ways to quit.
Figure 4.17 
Smoking cessation services in England lose business – customers declined by 
45% since 2011–2012
Source: Health and Social Care Information Centre. Statistics on NHS Stop Smoking Services in England, April 2014 
to March 2015, April 2013 to 31 March 2014.
Given the interest in e-cigarettes, staff in stop smoking services have had to 
respond to patient requests as to whether using e-cigarettes is a good way 
to quit smoking. After some reluctance to embrace e-cigarettes, some stop 
smoking services now incorporate them into what they offer clients. The first to 
do this was the smoking cessation programme run by Louise Ross, then service 
manager for Leicester City (UK) stop smoking service, which started using 
e-cigarettes in their programme from 2014. The service achieved success with 
other health professionals, including persuading midwives to convince pregnant 
» Total cost of cessation services in England (2014/15) £118million
» Cost per successful quit ~£513
» Total number of clients setting a date to quit 450,582
» Number of successful quits 229,688 (Quit smoking at 4 week follow up 
appointment, not smoked since two weeks after quit date)
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women that vaping is safer than smoking, and convincing GPs to record vapers 
as ex-smokers. The Time to Switch poster went viral round the world within a 
couple of hours of appearing on billboards in Leicester. The call to action on the 
poster was that all smokers should consider switching to vaping, and that vapers 
should consider quitting smoking altogether.
What is remarkable is that in a few years, large numbers of smokers have started 
to use e-cigarettes, and many of them no longer smoke. There are 2.9 million 
current e-cigarette users, of whom 1.5 millon are ex-smokers. Many more have 
tried e-cigarettes but did not continue. This is even more remarkable in that it 
was not a result of any planned public health campaign. Most public health cam-
paigns are top down – governments and health agencies invest money in trying 
to persuade the population to adopt healthier behaviours (e.g. to have lower ca-
lorie intake and exercise more). No public health campaign could have achieved 
such a rapid success as the adoption of e-cigarettes in terms of people reached 
(numbers knowing about the issue), numbers attempting to change their beha-
viour (trying the product), the numbers actively using the product (continuing to 
use the product), and the numbers who successfully use the product to change 
their behaviour. This has the making of consumer-led public health success.
Although this achievement was not policy directed, it occurred in a policy 
environment that became more positive over time, so that now the UK has the 
most e-cigarette friendly environment in the world.
What explains the policy acceptance of e-cigarettes in the UK? The reasons are 
under-explored, and again highlight the need for in-depth analysis on a country 
level. Contributory factors would seem to be:
» Historically, a pragmatic approach to public health issues including harm 
reduction for drugs and sex, and the historical playbook for tobacco harm 
reduction set out by the UK psychiatrist Michael Russell;
» Support for tobacco harm reduction in medical political circles, as in the 2007 
RCP report;
» An academic evidence base tracking changes, and academics driven by 
evidence not rhetoric;
» Support within PHE especially by those who understood the public health 
potential of e-cigarettes;
» Supportive academics in key influential positions within anti-smoking and 
health organisations;
Time to Switch poster
Source: Source: http://www.stopsmokingleic.co.uk/resources/
55CHAPTER 4CONSUMERS OF SAFER NICOTINE PRODUCTS
54 Mark A Levin (2013) Tobacco control lessons from the Higgs Boson: Observing a hidden field behind changing 
tobacco control norms in Japan. American Journal of Law Medicine. 39 p.471-489
55 Tabuchi, T. et al (2017) Heat-not-burn tobacco product use in Japan: its prevalence, predictors and perceived 
symptoms from exposure to secondhand heat-not-burn tobacco aerosol. Tobacco Control. 16 doi:10.1136  
Available at http://tobaccocontrol.bmj.com/content/early/2017/12/15/tobaccocontrol-2017-053947.
abstract?papetoc
56 PMI, Philip Morris International Inc. Presents at the Consumer Analyst Group of New York (CAGNY) Conference 
(2018) https://www.pmi.com/investor-relations/overview/event-details/?eventId=5267394
» Support at high levels within government, especially among advisors to the 
then Prime Minister David Cameron in the ‘Nudge Unit’ (the Behavioural 
Insights Team);
» A handful of key advocates and a larger linked network who campaigned for 
e-cigarettes;
» Vociferous vaper advocates whose energy shifted the EU Tobacco Products 
Directive (TPD) legislation.
“No public health campaign could have achieved such a rapid success as the 
adoption of e-cigarettes in terms of people reached […], numbers attempting 
to change their behaviour[…], the numbers actively using the product […], 
and the numbers who successfully use the product to change their behaviour”.
Case study 4:
Japan – rapid rise in sales of HNB products, 
rapid fall in cigarette sales
Japan provides an exceptional insight into rapid changes in smokers’ 
preferences for using tobacco. According to the WHO, 19 percent of Japan’s 
adult population were daily smokers in 2015, with smoking higher among men 
(at 30 percent) than women (at nine percent). These levels are much lower than 
the extraordinarily high percentage of male smokers back in 1968, at 78 percent. 
But the decline had, until recently, abated. Although we do not have current 
prevalence data, we know that something dramatic has changed in tobacco 
markets. There has been a rapid rise of HNB products to take 14 percent of the 
tobacco market by 2018, and a rapid fall in cigarette sales, by about 13 percent  
a year. E-cigarettes are allowed but only as medical products and none have 
been approved.
In comparison with many other countries, Japan does not have a distinctly 
hostile approach to tobacco. Until 1985, the tobacco industry was a state 
monopoly. The state still owns one-third of Japan Tobacco International (JTI) and 
is the largest shareholder. Unlike Australia, Europe and North America, there are 
no mandatory smoking bans in public places, though recently voluntary bans 
have been introduced by some companies and a street smoking ban introduced 
by some cities.54 
“Japan provides an exceptional insight into rapid changes in smokers’ 
preferences for using tobacco”.
HNB in Japan
In 2014, Phillip Morris International (PMI) introduced IQOS to the Japanese 
market, initially as a test in the city of Nagoya. It was then rolled out across Japan 
in 2016. JTI had started Ploom sales online in December 2013 and launched 
Ploom TECH in March 2016. British American Tobacco (BAT) started selling its 
HNB glo device in December 2016. There was extraordinary interest in IQOS, as 
reflected in internet searches in 2016.55 The Figure 4.18 shows weekly Google 
searches from 2013 to 2017, normalised to 100 to show relative search volume.
Surveys of the adult population show the initial uptake of HNB. In 2015, 1.3 
percent of adults were using e-cigarettes (despite their illegality) but only 0.3 
percent were currently using IQOS and 0.3 percent Ploom TECH. One year later, 
in 2016, these levels had not changed greatly. By 2017, e-cigarette use had 
increased to 1.9 percent, while use of IQOS had increased to 3.6 percent, use of 
Ploom TECH increased to 1.2 percent, and use of the glo was 0.8 percent.
The other sources of information about HNB come from market data. PMI’s 
IQOS uses ‘HeatSticks’ which accounted for 0.4 percent of the tobacco product 
market in December 2015, rising to a 14.1 percent share of the tobacco market 
by December 2017.56 In two years, IQOS has overtaken specific cigarette brands 
– for example PMI’s own Marlboro which has about eight percent of the tobacco 
market. 
“A 27 percent drop in cigarette sales in two years is unprecedented in Japan… 
[and] likely the highest drop in cigarette consumption over that period of time 
seen in any country”.
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Figure 4.18 
Weekly Google search volume for HNB tobacco/e-cigarette 2013–2017 (past  
4 years) in Japan
Graph source: Adapted from Takahiro Tabuchi et al (2017) Heat-not-burn tobacco product use in Japan. Tobacco 
Control.57
The uptake of HNB products is disrupting the traditional Japanese cigarette 
market. JTI is the major tobacco company with around 60 percent of the 
Japanese cigarette market, and unlike some tobacco companies, releases 
monthly information on sales. From 2016 to 2017 its volume of cigarettes sales 
fell 14 percent, with a further fall of 13 percent in 2018 (based on 2016 levels). 
This is an extraordinary collapse in cigarette sales, of 27 percent over two years.
A 27 percent drop in cigarette sales in two years is unprecedented in Japan: 
over the 16 years from 1996 to 2012 domestic cigarette consumption fell by 46 
percent – or just over 2.9 percent a year on average.58 It is likely the highest drop 
in cigarette consumption over that time seen in any country.
Figure 4.19
Trends in current use of HNB tobacco/e-cigarette, both sexes, in Japan
Graph source: Takahiro Tabuchi, Silvano Gallus, Tomohiro Shinozaki, Tomoki Nakaya, Naoki Kunugita, Brian Colwell. 
Tob Control 16 December 2017, doi:10.1136/tobaccocontrol-2017-053947
Figure 4.20
Cigarette volume decline in Japan 2016–2018
Table source, Clive Bates. Data source: Japan Tobacco, Japanese Domestic Cigarette Sales Results
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Euromonitor International expects that HNB will be at least 22 percent of the 
Japanese market for tobacco by 2021 if it continues to drive out cigarettes. What 
is interesting about the Euromonitor tracking is that the total volume of tobacco 
purchased is not expected to change, but the type of tobacco purchased is. This 
is somewhat different to the experience in Sweden and Norway where the switch 
to SNP has been accompanied by longer term declines in tobacco consumption 
– the difference, of course, being that tobacco users in Sweden and Norway have 
a much longer experience with SNP.  
Figure 4.21
Japan: cigarettes and heated tobacco value and cigarettes volume 2011–2021
Source: Euromonitor International: Passport – Global Tobacco: Key Findings Part 2:vapour products. October 2017.
What is remarkable about this change in behaviour among tobacco users in Japan 
is that it came about not through the planned actions of tobacco control – indeed 
as has been observed, tobacco control measures are weaker than in many other 
countries, and Japanese law favours the tobacco industry.59 The change has 
occurred by selling a safer alternative to smoking, smart marketing, and consumers 
switch from smoking to HNB. This ‘intervention’ has not required action on the part 
of public health and tobacco control (except perhaps to help create a climate where 
smokers wish to quit) and it has been at no direct cost to the Japanese taxpayer.
Conclusion
This chapter presents what is possibly the first deep dive into the disparate 
data on global consumer uptake of SNP as far as the data allows, but points to 
a need for much more research in this area.
The cross-sectional data show that in the space of a few years, there has been 
rapid uptake in the use of the newer SNP in many countries. The data from both 
Sweden and Norway shows how over a relatively short space of time, snus has 
replaced smoking. We take this as evidence for an appetite for SNP such that 
where they are available – and if they are attractive and suitable alternatives to 
smoking – smokers will tend to choose them rather than to smoke. Evidence 
from Norway and Sweden also suggest that snus may be protective against 
smoking. Given these significant trends, there are important implications for 
public policy: an end to smoking may be achievable, but not an end to nicotine 
use. The best example is that smoking prevalence among Norwegian women is 
down to one percent, yet still around 15 percent are using snus. 
The survey data are a limited measure of what is happening in each country. 
Some datasets report on the prevalence of e-cigarette use among smokers. By 
itself this can be misleading, because such a measure excludes those people 
who use SNP and who have stopped smoking. More information is needed 
on the changes in the use of e-cigarettes or other SNP over time, and how this 
is linked to changes in the prevalence of smoking, and ultimately changes in 
smoking-related disease. This can be done for some countries for e-cigarettes 
and snus, where for example there are time trend data on the decline in smoking 
and the uptake of SNP (as shown in the Norway and Sweden case studies). 
More work needs to be done on selecting appropriate measures to describe 
the uptake of e-cigarettes and other SNP. Unfortunately, research in this field is 
mainly dominated by individual studies to answer small and specific questions. 
There seems to be a marked lack of appetite or research capacity and 
ambition to undertake overviews which synthesise evidence on a national 
level to answer a key question: does the use of SNP drive down smoking and 
improve public health? 
There – there is now good evidence that the uptake of SNP is associated with 
a decline in smoking. The evidence is stronger still for snus, which has been 
around for longer than e-cigarettes and HNB. 
59 Mark A Levin (2013) Tobacco control lessons from the Higgs Boson: Observing a hidden field behind changing 
tobacco control norms in Japan. American Journal of Law Medicine. 39 p. 471-489, p483
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For the newer SNP, it is still too soon to determine whether these changes are 
followed by improvements in public health. The laboratory evidence that SNP 
are much safer than smoking (which we discuss in Chapter 5) suggests that this 
will be the case. Longer term studies are needed – and the strongest evidence 
yet again comes from Sweden, where the uptake of snus and the decline in 
smoking has given this country the lowest smoking related mortality in Europe.
What is also remarkable is that the uptake of SNP has occurred in the absence 
of government, tobacco control and public health endorsement. It has been the 
ordinary consumers whose interest in SNP has driven the product development 
process and who have been proactive in offering help and advice to an ever-
widening global community.
Figure 4.22 
Global vaping prevalence (%) – various surveys (see notes below) 
Australia ##
Austria*
Belgium*
Bulgaria*
Canada***
Croatia*
Czech Republic*
Denmark*
Estonia*
EU 28*
Finland*
France*
Germany*
Year of survey
2016
2017
2017
2017
2013
2017
2017
2017
2017
2017
2017
2017
2017
Currently vape – total 
adult population
1%
3%
4%
NA
2%
NA
1%
2%
1%
2%
1%
4%
2%
Ever tried/ever vaped – 
 total adult population
8%
21%
16%
NA
9%
NA
20%
16%
21%
15%
17%
24%
12%
Great Britain###
Greece**
Hungary*
Ireland*
Italy*
Japan^
Kazakhstan####
Latvia*
Lithuania*
Luxembourg*
Malta*
Mexico#
Netherlands*
Northern Ireland^^
Poland*
Portugal*
Rep. of Cyprus*
Romania*
Slovakia*
Slovenia*
Spain*
Sweden*
United Kingdom*
United States****
Year of survey
2015-16
2017
2017
2017
2017
2017
2014
2017
2017
2017
2017
2016-17
2017
2016-17
2017
2017
2017
2017
2017
2017
2017
2017
2017
2014-15
Currently vape – total 
adult population
6%
5%
1%
2%
NA
1.90%
1.70%
1%
1%
2%
2%
1%
2%
6%
1%
1%
3%
NA
NA
1%
1%
NA
5%
2%
Ever tried/ever vaped – 
 total adult population
19%
27%
9%
13%
NA
11.40%
7.20%
24%
15%
12%
12%
6%
15%
12%
13%
8%
21%
NA
NA
11%
12%
NA
18%
9%
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Notes:
The data in this table should be viewed as a snapshot for each country at the time that surveys were undertaken. 
Estimates of prevalence cannot necessarily be compared between countries due to the reasons below: 
1. There are significant disparities between survey estimates carried out in the same country.  
2. Surveys have been conducted in different years and there is a rapidly changing picture and prevalence of vaping 
in many countries.      
3. These data are for ’adults’, however this is defined differently in different surveys (e.g. Eurobarometer 15+; 
Farsalinos 18+).      
4. Sample sizes vary from quite small in certain countries (e.g. Eurobarometer survey) to large (e.g. Mexico) 
(ENCODAT 2016–17).      
5. There are differences in the way e-cigarette users are categorised e.g. ’Current use’ can be ’used in last 30 days’ 
(e.g. Reid et al. 2015 [Canada]) or ’every day or some days’ (Zhu et al. 2017 [USA]) OR ’daily or less than daily’ 
(WHO. 2014 [Kazakhstan]) in some cases, with no specific timeframe.
6. In some instances, data have been not available (NA).
Data for this table have been gathered from freely available online sources. There are gaps in the data available – 
readers are invited to send in updated information to the GSTHR team.     
                
Data sources: 
*Reference: European Commission. Special Eurobarometer 458: Attitudes of Europeans towards tobacco and 
electronic cigarettes. EC, 2015. Available at http://data.europa.eu/euodp/en/data/dataset/S2146_87_1_458_ENG
Note: EU 28 – European Union – weighted average for the 28 member states.
Note: Total sample N = 27901, aged 15 and over. Includes an estimate for United Kingdom which is England, 
Scotland, Wales and Northern Ireland.
Description: Eurobarometer data provide a representative sample of approximately 28,000 respondents and 
estimates the prevalence of vaping for the EU overall, as well as per country. Survey dated March 2017.  
    
**Reference: Farsalinos K. et al (2018). Electronic cigarette use in Greece: an analysis of a representative 
population sample in Attica prefecture. Harm Reduction Journal. 15:20 Available at https://harmreductionjournal.
biomedcentral.com/articles/10.1186/s12954-018-0229-7 
Note: This is a regional prevalence, and does not refer to the whole country. However 35 percent of the 
adult Greek population live in Attica.                                                                          
Note from author: The data on number of vapers are extrapolated to the Attica population (one third of the Greek 
population). But the prevalence (five percent of the population) could be reasonably applicable to the whole 
population of Greece. That would mean there are about 450,000 vapers in Greece (in an adult population of about 
nine million).   
Description: A cross-sectional survey of a representative sample of 4058 adults (aged 18 and over) living in Attica 
prefecture (35 percent of the Greek adult population) was performed in May 2017 through telephone interviews. 
Prevalence and frequency of e-cigarette use were assessed according to the smoking status, and logistic regression 
analysis was performed to identify correlates of use.
                                                                                                                            
***Reference: Reid J. L. et al (2015). Who is using e-cigarettes in Canada? Nationally representative data on the 
prevalence of e-cigarette use among Canadians. Preventative Medicine 81 p. 180-183   
Description: The study examined prevalence and correlates of e-cigarette use in the Canadian population, 
using data from the nationally representative 2013 Canadian Tobacco, Alcohol and Drugs Survey (n = 14,565). 
Sociodemographic correlates of e-cigarette use (ever, and in the past 30 days) were examined using logistic 
regression models. Data is from people aged 15 and over.
                                                                                                   
****Reference: Zhu, S. H. et al (2017). E-cigarette use and associated changes in population smoking cessation: 
Evidence from U.S. current population surveys. The British Medical Journal 358:j3262.    
Description: Sample 161,054. Adults aged 18 and over; US Current Population Survey-Tobacco Use Supplement 
(CPS-TUS). 2014-15. Ever users of e-cigarettes were those who ‘ever used e-cigarettes, even one time’. Current users 
of e-cigarettes were ever users who answered ‘every day’ or ‘some days’.
#Reference: Encuesta Nacional de Consumo de Drogas, Alcohol y Tabaco, ENCODAT 2016-2017. Available at 
https://drive.google.com/file/d/1Iktptvdu2nsrSpMBMT4FdqBIk8gikz7q/vie
Description: Data on Mexico (in Spanish) can be found in the National Poll on Consumption of Drugs Alcohol and 
Tobacco. It is official government data and is publicly available. Data on e-cigarette usage is found in the tobacco 
section and a pdf version can be downloaded in this link. Around 59,000 people were polled in the survey.  
    
##Reference: National Drug Strategy Household Survey 2016, tobacco chapter, supplementary data tables. The 
Australian Institute of Health and Welfare, September 2017   
Description: Age from 14 and over. Current use of e-cigarettes was relatively low in the general population with 
only 1.2 percent of people aged 14 or older reporting that they currently use e-cigarettes.  Warning provided about 
very wide sampling errors in the estimates.         
    
###Reference: Office for National Statistics. E-cigarette use in Great Britain. Available at  
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/
datasets/ecigaretteuseingreatbritain      
Note: Great Britain is England, Scotland and Wales. Survey covers adults aged 16 and over.  
 
####Reference: World Health Organisation Global Adult Tobacco Survey (GATS). WHO, 2014. The Republic of 
Kazakhstan, 2014, Country Report. 
Note: Adults are those aged 15 and over. 
     
^Reference: Tabuchi, T. et al (2017) Heat-not-burn tobacco product use in Japan: its prevalence, predictors 
and perceived symptoms from exposure to secondhand heat-not-burn tobacco aerosol. Tobacco Control 16 
doi:10.1136. Available at  https://tobaccocontrol.bmj.com/content/early/2017/12/15/tobaccocontrol-2017-
053947?papetoc=#DC1
^^Reference: Health Survey Northern Ireland, 2016 -17. Available at https://www.gov.uk/government/statistics/
health-survey-northern-ireland-first-results-201617   
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Chapter 5:
Safer nicotine products 
and consumer health 
A chasm exists between those in the global public health community who work 
to reduce the death and disease toll from smoking, and the tobacco industry, 
which both produces the product causing all the damage and actively tries to 
undermine national and international tobacco control efforts. As the sale of 
cigarettes still reaps vast profits for the industry, that chasm remains as wide as 
ever. Does the arrival of e-cigarettes and HNB, and the involvement of some 
tobacco companies in producing SNP do anything to bridge the gap?   
As it transpired, the advent of SNP left the global public health community itself 
divided. Many working in tobacco control regard SNP as a ruse by tobacco 
companies to renormalise smoking, especially in countries where adult smoking 
rates have been in decline for decades – and citing in particular a fear of young 
people being led through a ‘gateway’ to regular smoking.
Others – public health officials, academics, clinicians and consumer advocates 
among them – point to evidence that SNP are significantly less harmful than 
smoking cigarettes for those who cannot or do not want to give up nicotine, 
those who want to cut back on smoking, or quit altogether. From this follows 
the conclusion that a switch to SNP has the potential to save many lives and 
moreover, at no cost to governments or taxpayers.
These debates continue against a backdrop of the emerging scientific 
understanding of much less harmful nicotine products. There has been a major 
increase in the number of publications on e-cigarettes. Our search for articles on 
them shows the increasing interest in the subject over the last ten years. From 
2007-12, there were only 53 publications recorded. Between 2013 and 2017, the 
figure jumped to over 1500.
But more science does not always mean better science (as we will show below) 
or better science communication. Poorly formulated and designed research, 
over-cooked announcements of research results, over-hyped university press 
releases and an uncritical media with an appetite for bad news stories all create 
a perfect storm of confusion among the general public, smokers and users of 
SNP as to the advisability of switching away from smoking to SNP.
Figure 5.1 
Number of Pubmed search results for articles on e-cigarettes 2007–2017
PubMed searches databases of abstracts and publications in biomedicine and life sciences. Search terms were 
e-cigarette OR electronic cigarette OR e-cig in the abstract/title field.
Media-driven confusion
The confusion generated by popular media reporting is exemplified by 
this article from the UK Daily Mail published on 24th February 2017.1 The 
headline and straps were:
Do you use e-cigarettes? You may be at greater risk of a STROKE: Exposure to 
vapours damages chemicals in the brain
» Researchers exposed mice to both e-cigarette vapour and smoke from 
tobacco
» They found the animals were more likely to have a stroke from e-cigarette puffs
» Experts now warn that the popular gadgets are not any safer than cigarettes 
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1  Mail Online (2017). Do you use e-cigarettes? You may be at greater risk of a STROKE: Exposure to vapors damages 
chemicals in the brain. Available at: http://www.dailymail.co.uk/health/article-4255696/Do-use-e-cigarettes-risk-
STROKE.html
61CHAPTER 5SAFER NICOTINE PRODUCTS AND CONSUMER HEALTH
Most consumers get their information about SNP (and other health issues, 
climate change and so on) from the media and friends. Given the extent and 
focus of media reporting, it is perhaps unsurprising that many people are 
confused or concerned about SNP. The real concern for harm reduction is 
that perception of the risk of SNP is actually increasing; more people think 
(incorrectly) that SNP are as dangerous as cigarettes. 
In a global survey conducted by the Foundation for a Smoke-Free World2,  
a majority of those polled in 11 of the 13 countries surveyed thought nicotine 
more harmful to general heath than alcohol, sugar, fat and salt while all those 
surveyed believed the nicotine in e-cigarettes presented a risk of heart disease 
and a range of cancers.
In Great Britain, despite the well-publicised findings (cited below) from PHE and 
the RCP about the relative safety of e-cigarettes, the stop smoking charity ASH 
found that perceptions of harm concerning e-cigarettes worsened between 2013 
and 2017. Over time more people thought that e-cigarettes were more or equally 
as harmful as smoking, and fewer people thought that they were a lot less harmful.
Figure 5.2 
Adult population perception of harm from e-cigarettes relative to smoking 
2013–2017, Great Britain
Source: ASH fact sheet (May 2017) Use of e-cigarettes (vapourisers) among adults in Great Britain.
The chart refers to the population in general, but as ASH stated, more worrying 
is the worsening perception among smokers: 
“The poor understanding among smokers in general about the relative harms 
of e-cigarettes compared to smoking is of concern […]. The proportion of 
smokers who think e-cigarettes are just as, or more, harmful than smoking 
has increased significantly from 9 percent in 2013 to 22 percent in 2017. […] 
Smokers who have never tried e-cigarettes are less likely to accurately believe 
they are a lot less harmful than tobacco smoking than smokers who are cur-
rently using e-cigarettes. Among smokers who have never tried an e-cigarette, 
one in three (30 percent) believe e-cigarettes are more or equally harmful as 
smoking. This is a view that has grown over time among smokers who have 
not tried an e-cigarette with 25 percent holding this opinion in 2016.”3
“The poor understanding among smokers in general about the relative harms 
of e-cigarettes compared to smoking is of concern”.
In the USA, the perception among smokers that e-cigarettes were as, or more harm-
ful than, cigarettes jumped from 11.7 percent in 2012 to 35 percent in 2015 while  
a belief that e-cigarettes were addictive went from 25.3 percent to 56 percent.4
Tobacco products are not all the same: 
a continuum of risk 
How can a smoker be sure that a safer nicotine product is safer than smoking  
a cigarette? 
This chapter considers the main issues surrounding relative product safety, 
starting with e-cigarettes and then snus, for which there is now an extensive 
evidence base. It also covers the evidence regarding HNB products as tobacco 
harm reduction options.
The scientific understanding of SNP brings to attention the fact that not all 
nicotine containing products are equally risky. There is clearly a difference 
between cigarettes and therapeutic nicotine products. But there are also 
differences between different types of tobacco products. This fact is often 
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2 Foundation for a Smoke Free World. Worldwide State of Smoking Survey 2018
3  ASH. Fact sheet. Use of e-cigarettes (vapourisers) among adults in Great Britain. ASH, 2017. Available at  
http://ash.org.uk/category/information-and-resources/fact-sheets/
4  Majeed, B.A. et al. (2017). Changing perceptions of harms of e-cigarettes among US adults 2012-2015. Amerian 
Journal of Preventative Medicine: 52 (3), p.331-338
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ignored or glossed over in campaigns that target tobacco consumption per 
se. The differential risk is reflected in mortality figures: globally an estimated 
six million deaths from smoking a year, and 48,000 deaths from oral tobaccos 
mainly in south Asia.5
The health outcomes from smoking tobacco are well known from the huge 
amount of clinical and epidemiological evidence on disease and premature  
death associated with smoking. The same type of epidemiological evidence 
shows that the health impact of Swedish snus is markedly dissimilar to that of 
smoking tobacco – there is a significant decrease in risk of tobacco-related disease. 
The fact that there are differences in the harmfulness of different tobacco 
products is also apparent from an understanding of the constituents of different 
tobacco products – for example, the complex constituents of tobacco smoke 
compared with e-cigarette emissions. 
The evidence shows that the key difference in health risks is associated with 
combustion. The tobacco cigarette turns out to be the dirtiest and most harmful 
nicotine delivery system. 
Comparing different tobacco products on the basis of clinical, epidemiological, 
and laboratory studies puts cigarettes at the high-risk end, with HNB products, 
snus, e-cigarettes and medicinal nicotine products at the low risk end. 
As Fig 5.3 shows, risk falls dramatically beyond combustible cigarettes, 
indicating that any form of nicotine delivery system that does not involve 
combustion is safer than smoking tobacco. There is a continuum of risk – or 
perhaps it is better described as a ‘cliff drop of risk’. 
Estimating and communicating the risk of safer 
nicotine products
Just how much less harmful are SNP than cigarettes is a matter of scientific 
assessment and science communication. The risk continuum is one way of 
communicating the differences in risk when using different kinds of nicotine-
containing products. The problem in trying to compute a risk continuum, and 
then communicating this, is that there are hundreds of different measures that 
could be considered, derived from laboratory studies, clinical studies of short-
term health impacts, through to long-term epidemiological studies. 
Two landmark reviews brought the evidence together on e-cigarettes and have 
been published in the UK, from Public Health England6 and the Royal College 
of Physicians.7 The first key point is that there are no circumstances in which it is 
safer to smoke than to use e-cigarettes. Their headline conclusions are:
» Vaping is substantially safer than smoking;
» People who switch from smoking to vaping can experience an improvement in 
respiratory health; 
» Switching to vaping can help people quit smoking;
» There are currently no known long-term adverse health effects due to vaping;
» There is no evidence that young people who experiment with e-cigarettes will 
become regular cigarette smokers.
The more cautious and conditional evidence review from the US National 
Academy of Sciences, The Public Health Consequences of E Cigarettes (2018), 
stated nonetheless: “There is conclusive evidence that completely substituting 
e-cigarettes for combustible tobacco cigarettes reduces users’ exposure to 
numerous toxicants and carcinogens present in combustible tobacco cigarettes”.
And while opposed to SNP, the WHO briefing on e-cigarettes conceded that  
“it is very likely that average ENDS use produces lower exposures to toxicants 
than combustible products”.8  
Public Health England has asserted that “based on current knowledge, stating 
that vaping is at least 95% less harmful than smoking remains a good way to 
communicate the large difference in relative risk unambiguously…”.9 This means 
that e-cigarettes are not totally harmless, but that the appropriate scientific 
approach is to compare their safety (and all SNP) relative to combustible 
cigarettes, rather than examine the absolute safety of the products in isolation.  
In other words, harm reduction, not harm eradication.
5 The Lancet. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and 
occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of 
Disease Study 2016. The Lancet, 2017. Available at 
 https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)32366-8.pdf
6  McNeill, A. et al. Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by 
Public Health England. PHE, 2018
7  Royal College of Physicians. Nicotine without smoke; tobacco harm reduction. A report by the Tobacco Advisory 
Group of the Royal College of Physicians. RCP, 2016
8 World Health Organisation. Electronic nicotine delivery systems: a report by WHO. 201, p.4
9 McNeill, A. et al. Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned 
by Public Health England. PHE, 2018, p.20. Relative risk figure calculated on an estimate that cancer-related 
emissions from e-cigarettes are 0.5% that of combustible cigarettes.
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Figure 5.3 
Continuum of risk for nicotine containing products
“Based on current knowledge, stating that vaping is at least 95% less harmful 
than smoking remains a good way to communicate the large difference in 
relative risk unambiguously”.
There needs to be a commonly accepted and credible assessment process for 
establishing this relative product safety. There are several key elements to the 
process of assessing risk of SNP:
1. Chemical and physical characterisation of emissions: what chemicals and 
toxins are released?
2. In vitro and animal toxicological studies: laboratory studies of potential 
effects of the chemicals and toxins from SNP.
3. Quantification of human exposure to chemicals and toxins: clinical studies 
of changes in biomarkers of exposure when switching from smoking to 
SNP.
4. Substantiation of reduced health risk: clinical studies evaluating short 
and long range impact on health effect indicators when switching from 
smoking to vaping.
5. Long-term epidemiological studies of the health of SNP users over  
time.
Additionally, there are shorter and longer-term impacts on the numbers in the 
population that are smoking – which includes both SNP as an exit route from 
smoking, but also the potential for new nicotine users to be recruited to regular 
smoking (so-called gateway effect).
E-cigarettes
The reason people die prematurely or develop life-threatening diseases from 
smoking cigarettes is due to the toxic chemicals released when a cigarette is lit 
and the fumes inhaled. The composition of cigarette smoke is complex, but the 
main toxins identified as potentially harmful include carbon monoxide (CO), 
volatile organic compounds, carbonyls, aldehydes, tobacco-specific nitrosamines 
(TSNAs) and metal particles. All these are present in e-cigarette and HNB vapour 
but at much lower levels than in cigarettes, often at exposure levels no greater 
than present in the general environment. The relative levels of toxins have been 
demonstrated by mechanically aided puff tests in the laboratory, measuring the 
toxin release when a cigarette, a HNB product or an e-cigarette are puffed.
A visual representation of the relative emissions for smoked cigarettes, 
e-cigarettes and HNB products can be seen Figures 5.4-6. 
These are three dimensional chromatograms of emissions/aerosol generated 
from a single puff of a cigarette, a HNB device and an e-cigarette. The colours 
indicate quantity of chemicals and toxins in each puff; red indicating most 
compounds. The height of peaks illustrates chemical and toxins levels (note 
that the three pictures are not in the same scale). The fewer the peaks, the less 
complex and thus harmful the emissions. The complexity of HNB emissions lies 
between the cigarette smoke and the aerosol from an e-cigarette.10
There are various laboratory tests which can be carried out on cells to 
demonstrate the relative safety of e-cigarette vapour over cigarette smoke. One 
test involves deliberately ‘damaging’ cells to see how long they take to repair 
themselves, depending on whether they are exposed to cigarette smoke or 
e-cigarette vapour. What scientists find is that the cells exposed to e-cigarette 
vapour will repair themselves at nearly the same rate as they would naturally. 
However, when exposed to cigarette smoke, repair will take much longer.
10 Photos used with the permission of BAT Science.
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Another test involves exposing certain lung cells to vapour and smoke. The 
purpose of these cells is to clear mucus and debris from the lungs. They do 
it by a ‘beating’ action, which is not compromised by e-cigarette vapour but 
weakened when exposed to cigarette smoke.
A common test used to assess the safety of emissions is that of cytotoxicity, 
during which the percentage of dying cells (usually epithelial cells from human 
airways) is calculated when exposed to aerosols or smoke. Although some cell 
death can be shown with SNP emissions, these effects are much less than those 
observed with cigarette smoke.11
A major criticism of much laboratory testing of e-cigarette toxicity is that the 
experiments do not match real world use and experience of the devices.  
A good example of this was the concern raised in one study about the levels of 
formaldehyde, acrolein and acetaldehyde released when the propylene glycol 
and glycerine in the e-liquid are heated. Yet the heating temperature in the study 
was much higher than any user would tolerate (so called bad tasting ‘dry puff’) 
and was akin to burning toast that nobody would eat and then claiming that 
toast causes cancer.12 
As the Royal College of Physicians states, “In normal conditions of use, toxin 
levels in inhaled e-cigarette vapour are probably well below present threshold 
limit values for occupational exposure in which case significant long-term harm 
is unlikely. Some harm from sustained exposure to low levels of toxins over many 
years may yet emerge, but the magnitude of these risks relative to sustained 
tobacco smoking is likely to be small”. The RCP goes on to observe that most 
reviews raising concerns about constituents, were related to their presence 
rather than absolute levels which are “generally the more important determinant 
of toxicity”. They commented that all the constituents identified were at lower 
levels than in cigarette smoke, but that long-term use even at these low levels 
could be problematic, although “the magnitude of these risks relative to those 
from sustained tobacco smoking is likely to be small”.13 
Figure 5.4
Cigarette emissions
Figure 5.5
HNB emissions
Figure 5.6
E-cigarette emissions
11 For more explanation of relative emissions and impact on cells, go to BBC iPlayer and the Horizon programme 
broadcast in 2016. Available at https://www.bbc.co.uk/programmes/b07c6ll4
12 The original study was Jensen, R.P et al (2015). Hidden formaldehyde in e-cigarette aerosols. New England 
Journal of Medicine, 372 (4), p. 392-4. This was then replicated at normal temperature by Farsalinos, K. et al 
(2017), E-cigarettes emit very high formaldehyde levels only in conditions that are aversive to users. Food and 
Chemical Toxicology, 109, p. 90-4. It is not just the temperature settings that are a factor. Researchers, not familiar 
with product range and development may be using old-style components in the laboratory that have been 
superseded in the real world. 
13 Royal College of Physicians. Nicotine without smoke; tobacco harm reduction. A report by the Tobacco Advisory 
Group of the Royal College of Physicians. RCP, 2016, p.79
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“A major criticism of much laboratory testing of e-cigarette toxicity is that the 
experiments do not match real world use and experience of the devices”.
The next level of assessment for establishing relative product safety concerns 
exposure. Studies of e-cigarettes,14 HNB15 and snus16 have shown substantial 
reductions in exposure to a wide range of chemicals and toxins relative to 
cigarette smoking.
Substantiation of reduced health risk by evaluating short and long-range impact 
of SNPs on biomarkers that might indicate a health concern is another key 
element for establishing relative product safety. However, given their relatively 
recent introduction, there are no studies of the long-term effects of e-cigarette 
or HNB use, so the areas of concern about long-term exposure remain largely 
hypothetical. The most obvious areas for consideration would be vapour 
constituent deposits in the mouth, upper airway and lungs and the overall effects 
on bodily functions of vapour inhalation. These constituents would include 
nicotine, propylene glycol, glycerine and flavours.
Nicotine is a psychoactive substance that in the extremely rare cases where 
ingestion of high doses happens, whether by accident or on purpose, can be 
fatal. But at commonly used dose levels, short-term nicotine use does not result 
in clinically significant harm17 while the long-term adverse effects are also likely 
to be minimal.18
According to the International Agency for Research on Cancer (IARC) nicotine is 
not a carcinogen19 and a recent US Surgeon General’s report concluded that it 
does not contribute to respiratory diseases.20
Tobacco smoke and e-cigarette vapour follow the same pathway into the mouth 
and upper airway, through the gastrointestinal tract and are then excreted. The 
deposit and absorption of smoke-derived carcinogens increase the cancer 
risk impacting on various organs but, given the very low level of potential 
carcinogens in e-cigarette vapour, the risk either relative or absolute is low.  
In respect of the respiratory system, while the risk of vapour causing lung cancer 
is low, there is the possibility of vapour-induced lung irritation and the attendant 
increased risk of adverse respiratory impact in people with hypersensitivities to 
certain chemicals. That said, many smokers who switch report improvements in 
lung function.21
Regarding propylene glycol in e-cigarettes, this is also the primary ingredient 
generating synthetic ”smoke” at rock concerts and other events and is 
considered to be safe. Apart from possible minor irritation causing a cough, 
there are no other known harmful effects, while animal studies have failed to 
demonstrate any harmful effects on the lungs of inhaling glycerine. By virtue 
of its bactericidal properties, propylene glycol in its aerosol form was used to 
sanitise hospitals and military barracks. Thus, regular vaping of pharma grade 
propylene glycol could have additional theoretical health benefits. Lower 
incidence of airway infections of smokers who had switched to e-cigarettes has 
been reported.22 23
Turning to the flavours added to e-cigarette liquids, there has been much media 
coverage of a condition known as ‘popcorn lung’. This has emerged through 
concerns that some flavours contain diacetyl, an organic compound with an 
intense buttery taste used to flavour products, such as margarine, that might 
cause bronchiolitis obliterans, as suffered by employees working in popcorn 
factories who have been exposed to high levels of this compound. 
14 Shahab L. et al. (2017) Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine 
Replacement Therapy Users: A Cross-sectional Study. Annals of Internal Medicine. 2017 Mar 21;166(6)390-400. 
doi: 10.7326/M16-1107
15 Haziza C. et al. (2017) Assessment of the reduction in levels of exposure to harmful and potentially harmful 
constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes 
and smoking abstinence: a randomize controlled study in confinement. Regulatory Toxicology and Pharmacology 
2017; 81: 489–499
16 Sarkar M. et al. (2010) Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro snus. 
Nicotine and Tobacco Research 2010; 12(2): 105–116
17 Royal College of Physicians. Nicotine without smoke; tobacco harm reduction. A report by the Tobacco Advisory 
Group of the Royal College of Physicians. RCP, 2016, p.58
18 National Institute for Health and Care Excellence. Tobacco harm reduction (PH45). NICE 2013
19 World Health Organisation International Agency for Research on Cancer. IARC monographs on the evaluation of 
carcinogenic risks to humans. In: Cancer IAfRo, editor. Tobacco Smoke and Involuntary Smoking 2004. Geneva: 
World Health Organisation International Agency for Research on Cancer; 2004
20 US Department of Health and Human Services CfDCaP, editor. The health consequences of smoking: 50 years of 
progress: a report of the surgeon general. National Centre for Chronic Disease Prevention and Health Promotion, 
Office on Smoking and Health. Atlanta: US Department of Health and Human Services CfDCaP; 2014
21 Polosa, R. et al (2014). Effect of smoking abstinence and reduction in asthmatic smokers switching to electronic 
cigarettes; evidence for harm reversal. International Journal of Environmental Research and Public Health 11: 
4965-77
22 Polosa, R. et al (2016). Evidence for harm reduction in COPD smokers who switch to electronic cigarettes. 
Respiratory Research 17, 166
23 Miler J.A. et al (2016). Changes in the Frequency of Airway Infections in Smokers Who Switched To Vaping: 
Results of an Online Survey. Journal of Addiction Research 2016, 7:4
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The symptoms such as coughing, shortness of breath and wheezing might be 
indistinguishable from the effects of long-term smoking in an e-cigarette user 
who had switched, while in any event exposure levels would be several orders 
of magnitude lower than a factory environment. This respiratory condition has 
never been reported in vapers, despite widespread e-cigarette use. Even so, 
manufacturers are now avoiding flavours that contain diacetyl. Some flavours like 
cinnamon may be more cytotoxic than other flavours, if there is direct contact 
with the e-liquid, but no studies have demonstrated harmful effects in real world 
vapour situations.
There are other components in e-cigarette liquids that are generated when 
the liquid is heated, including formaldehyde (see above) and acrolein, while 
the device and the device elements can also release aerosolised particles of 
metal, ceramic and rubber when heated. Again, exposure will be well below 
recognised safety thresholds, but could be reduced still further by improved 
manufacturing standards.
HNB products
HNB products are more recent than e-cigarettes and, so far, most of the 
evidence has come from the manufacturers, which is to be expected with any 
new product. However, the body of independent research on these products 
is growing. To date, independent research on heated tobacco products has 
focused on a number of areas including aerosol chemistry, indoor air quality, 
toxicity, exposure to toxicants, and risk. 
Unlike e-cigarettes, these products contain tobacco which is heated at different 
temperatures depending on the device, although never above 350°C, and so 
well below the combustion temperature of cigarettes and below the typical 
combustion temperature of 600 to 900°C. It is crucial to demonstrate that 
no combustion occurs when heated tobacco products are used as intended 
because most of the harm from tobacco is produced under combustion. 
One manufacturer has indicated that while the temperature of the blade that 
heats the tobacco can reach up to 350°C, the tobacco itself never reaches 
this temperature and the temperature of the majority of the tobacco does not 
exceed 250°C.24 Recently, an independent assessment, conducted for New 
Zealand’s Ministry of Health, confirmed that no combustion occurs in the heated 
tobacco product IQOS, when used as intended.25
The scientific assessment process is very similar to that for e-cigarettes i.e. it 
focuses on chemical and physical characterisation of emissions; laboratory 
studies of potential effects of the chemicals and toxins; quantification of human 
exposure to chemicals and toxins; clinical studies of changes in biomarkers of 
exposure; clinical studies evaluating short and long range impact on health 
effect indicators when switching from smoking to using heated tobacco products, 
and long-term epidemiological studies of the health of users. Another important 
aspect of such assessment has to include consumer behaviour at the population 
level, e.g. whether these products create a new generation of tobacco users 
who may or may not eventually move on to smoking cigarettes (the purported 
‘gateway’ effect), and whether at the population level there is long term dual use 
of these products, along with cigarettes among smokers who switch.
PHE and the UK Committee on Toxicity, Carcinogenicity and Mutagenicity of 
Chemicals in Food, Consumer Products and the Environment considered the 
available evidence in 2017.26 The UK Committee on Toxicity (COT) highlighted 
24 Script of Philip Morris International’s Presentation before the Tobacco Products Scientific Advisory Committee 
(TPSAC), 24 January 2018. Available at https://pmiscienceprd.s3.amazonaws.com/docs/default-source/news-
documents/pmi-tpsac_-final-script.pdf?sfvrsn=10dcce06_2
25 Ministry of Health v Philip Morris (New Zealand) Limited [2018] NZDC 4478. Available at  
http://www.districtcourts.govt.nz/assets/unsecure/2018-03-27/2018-NZDC-4478-MOH-v-Morris.pdf
26 UK Committee on Toxicity. Statement on the toxicological evaluation of novel heat-not-burn tobacco products. 
2017. Available at https://cot.food.gov.uk/sites/default/files/heat_not_burn_tobacco_summary.pdf
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significant reductions in levels of harmful and potentially harmful constituents 
(HPHCs) in the aerosol of heated tobacco products compared to cigarette 
smoke and stated that “[t]here would likely be a reduction in risk for conventional 
smokers deciding to use heat-not-burn tobacco products instead of smoking 
cigarettes”.27 COT added that ”[a] reduction in risk would also be experienced by 
bystanders where smokers switch to heat-not-burn tobacco products”.28 
In 2018, PHE reviewed 20 extant studies (12 of which were tobacco company 
research) and reiterated these points based on the available evidence and noted 
the potential of HNB tobacco: “Compared with cigarette smoke, heated tobacco 
products are likely to expose users and bystanders to lower levels of particulate 
matter and harmful and potentially harmful compounds. The extent of the 
reduction found varies between studies. […] The available evidence suggests 
that heated tobacco products may be considerably less harmful than tobacco 
cigarettes and more harmful than e-cigarettes.”29
The conclusions from both reports were necessarily cautious because of limited 
independent evidence at the time of publication and also because the products 
are new to the global market. But the headline data show that because the 
tobacco is not burnt at the same high temperatures as cigarettes, and like e-ciga-
rettes, the level of ’chemicals’ and ’toxins’ emission is greatly reduced. A number 
of independent analytical chemistry studies on HNB products have recently been 
published. These have mostly confirmed manufacturers’ findings by showing 
that HNB products generate much lower levels of harmful constituents compared 
to tobacco cigarettes.30 31 32 In terms of cancer potency a review of extant studies 
of toxicological of risk and likely daily exposure indicated that cancer risk from 
heat-not-burn products is between one and 10 percent that of cigarettes.33
To date PMI’s IQOS is the most widely available HNB product on the market, 
followed by BAT with their glo brand and JTI with their Ploom TECH brand. 
National companies such as KTNG from South Korea have launched their own 
HNB products under the Lil brand. 
PMI and BAT have a product development and assessment programme, which 
includes aerosol chemistry, indoor air quality, toxicology, clinical studies, and 
population studies.
Both BAT and PMI have published scientific papers that describe the operation 
of these products and their assessment in a series of preclinical, clinical and 
population-based studies (for an example refer to reference34). The key findings 
of these studies are that emissions on use correspondingly showed around 
90–95 percent fewer tested toxicants than those measured in cigarette smoke.  
The environmental emissions were substantially reduced when consumers used 
these heated tobacco products compared with when they smoked cigarettes, 
to the extent that for the majority of measured constituents, the environmental 
emissions were at similar levels as those from the baseline measurements, when 
the consumers were not using any products.  
The latest independent study on HNB products was published in June 2018.35 
It compared the levels of carbonyl emissions from IQOS, an E-cigarette, and 
Marlboro Red cigarettes using three puffing regimes. The authors conclude that 
“[t]he IQOS heated tobacco product emits substantially lower levels of carbonyls 
than a commercial tobacco cigarette (Marlboro Red) but higher levels than  
a Nautilus Mini e-cigarette.” However, the authors highlight “that the absolute 
difference in carbonyl emissions between the heated tobacco products and the 
e-cigarette is low when compared to the difference between these products and 
tobacco cigarette smoke.”
27 UK Committee on Toxicity. Statement on heat not burn tobacco products, 12 December 2017. Available at  
https://cot.food.gov.uk/cotstatements/cotstatementsyrs/cot-statements-2017/statement-on-heat-not-burn-
tobacco-products
28 UK Committee on Toxicity. Statement on heat not burn tobacco products, 12 December 2017. Available at  
https://cot.food.gov.uk/cotstatements/cotstatementsyrs/cot-statements-2017/statement-on-heat-not-burn-
tobacco-products
29 McNeill A. et al Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by 
Public Health England. Public Health England, 2018. Available at https://www.gov.uk/government/publications/ 
e-cigarettes-and-heated-tobacco-products-evidence-review
30 Bekki K. et al (2017) Comparison of Chemicals in Mainstream Smoke in Heat-not-burn Tobacco and Combustion 
Cigarettes. Journal of UOEH. 2017;39(3):201-207. doi: 10.7888/juoeh.39.201
31 Li X. et al (2018). Chemical Analysis and Simulated Pyrolysis of Tobacco Heating System 2.2 Compared to 
Conventional Cigarettes. Nicotine and Tobacco Research. 2018 Jan 8. doi: 10.1093/ntr/nty005. [Epub ahead of 
print] PubMed PMID: 29319815
32 Mallock N. et al (2018) Levels of selected analytes in the emissions of ”heat not burn” tobacco products that are 
relevant to assess human health risks. Archives of Toxicology. 2018 May 5. doi: 10.1007/s00204-018-2215-y.[Epub 
ahead of print] PubMed PMID: 29730817
33 Stephens E (2018) The role of emissions in the debate on health effects across the spectrum of nicotine delivery. 
Global Forum on Nicotine. Available at https://gfn.net.co/downloads/2018/PRESENTATIONS/SATURDAY/
Plenary%202/EdStephens.pdf
34 Proctor C (2018) Assessment of tobacco heating product THP1.0. Part 1: Series introduction. Regulatory 
Toxicology and Pharmacology 93, 1-3
35 Farsalinos et al. (2018), Carbonyl emissions from a novel heated tobacco product (IQOS): comparison with an 
e-cigarette and a tobacco cigarette, Addiction. Available at https://doi.org/10.1111/add.14365 
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The toxicological and clinical biomarker studies offer an insight into potential 
reduction to harmful exposures but need to be followed through to examination 
of whether reductions in toxicant exposure occur in real world settings.
Snus
The relatively lower risks from smokeless tobacco products in general and 
Swedish-style snus in particular are well evidenced in the literature backed 
by decades of research. In summary, snus is a safer nicotine delivery product 
because:
» It is pasteurised to remove toxins;
» There is no inhalation, so no risk of respiratory disease which accounts for 
nearly half of all smoking-related deaths;
» There is no significant association with premature deaths, diabetes, pancreatic 
and oral cancers, heart disease or strokes.
In the case of snus – in contrast to e-cigarettes and HNB – there is a large amount 
of long-term epidemiological data. The first indication that there is something 
different about Sweden compared with the rest of Europe is the high level of 
snus use compared with smoking (see also Chapter 3). Sweden has – using 
WHO data – the lowest rate of tobacco-related mortality in Europe – and its 
rate of tobacco-related disease is half that of the EU average. The low levels of 
smoking mean that there will be low levels of respiratory disease linked with 
inhalation. But there remains the possibility that snus has other non-respiratory 
health effects such as on cancers of the mouth and digestive tract, diabetes, and 
cancer of the pancreas. However, the epidemiological evidence is that snus is 
not associated with premature mortality, nor in Sweden with diabetes, oral and 
pancreatic cancers, or cardiovascular disease.
In its 2008 investigation, the EU Scientific Committee on Emerging and Newly 
Identified Health Risks reported several conclusions about the health effects 
of smokeless tobacco products (STP) and snus.  Primarily, it found that there is 
consistent evidence that use of STP does not cause any major respiratory disease 
and that complete substitution of STP for tobacco smoking would ultimately 
prevent nearly all deaths from respiratory disease currently caused by smoking, 
and reduce the cardiovascular mortality that currently arises from smoking by at 
least 50 percent. They also concluded that there was no obvious gateway effect 
from snus to cigarettes among young Swedish people.36 
Health risks of snus
Premature mortality
The Global Burden of Diseases, Injuries and Risk Factor Study provides  
a comprehensive assessment of risk factor exposure and attributable burden 
of disease. For example, the 2016 study states, “for the first time in the GBD 
study, we estimated exposure to and burden attributable to smokeless 
tobacco…RR [Reduced Risk] estimates were derived from prospective 
cohort studies and case-control studies…Based on available evidence, for 
chewing tobacco RRs were significantly higher than one for oral cancer 
and oesophageal cancer, while for snus or snuff we did not find sufficient 
evidence of a RR greater than one for any health outcome”.37
36 Scientific Committee on Emerging and Newly Identified Health Risks. Health effects of smokeless tobacco 
products. Health and Consumer Protection Directorate, European Commission, 2008. Available at  
ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_013.pdf
37 Global, regional and national comparative risk assessment of 84 behavioural, environmental and occupational, 
and metabolic risks or clusters of risks: a systematic analysis for the Global Burden of Disease Study 2016. Lancet; 
2017, 390, 1345–1422
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Diabetes
Five Swedish cohort studies compared never-smokers with snus users and 
concluded that use of snus was associated with a 15 percent increased risk of 
type 2 diabetes or 4.4/100,000 for all causes of diabetes in Sweden.38 But in 
four other studies, the risk was lower for snus users, or close to no difference 
in risk, and in another case control study of people with type 2 diabetes, 
the risk was unrelated to snus use.39 Difference in consumption level, with 
significant associations only reported for heavy users but not for light users, 
can explain some of the disagreement between studies.  
Oral and pancreatic cancers
The conclusion of a meta-analysis of major Scandinavian studies was 
that there was “no overall association [with snus] seen for oropharyngeal 
cancer”,40 while a study into pancreatic cancer conducted by the Karolinska 
Institute concluded that, “compared to never snus use, current snus use was 
not associated with risk of pancreatic cancer after adjustment for smoking”.41
Cardiovascular disease
In one longitudinal study, nearly 17,000 Swedish male twins participating 
in the Screening Across the Lifespan Twin Study, conducted in 1998–2002, 
were followed up for incidence of cardiovascular disease. The researcher 
concluded, “Overall, there was no association between use of snus and risk 
for cardiovascular disease. Current snus users, without a smoking history, 
had a relative risk of 1.00 for cardiovascular disease as compared to non-
users. Corresponding relative risks for ischemic heart disease and stroke 
were 0.85 and 1.18 respectively. In smoking adjusted models, risk estimates 
for ischemic heart disease in relation to snus use were all close to unity 
regardless of timing or intensity of snus use”.42
Adding to these studies, the WHO Scientific Advisory Committee on Tobacco 
Product Regulation reported in 2010 that, “Among the smokeless tobacco 
products on the market, products with low levels of nitrosamines such as 
Swedish snus, are considerably less hazardous than cigarettes”.43
Passive exposure to SNP
When somebody is seen blowing out clouds of vapour from a device, it is 
understandable that passers-by might equate this with cigarette smoke and 
be concerned about the possible effects of their own inhalation. Clouds of 
vapour can irritate the throat in enclosed spaces, however, most people who 
vape are reasonably discrete about their use, adopting ‘stealth vaping’, more 
like sucking on a pen than smoking a cigarette, and so never produce clouds 
of vapour anyway. Although some annoyance might be caused by vaping, as 
we have established above, vapour is not smoke. To quote PHE, “there is no 
side-stream vapour emitted from the end of an e-cigarette, just the exhaled 
vapour entering the atmosphere”.44 In their 2015 review, “we concluded that 
there was no identified health risk to bystanders”. More recent studies leave the 
PHE conclusion from 2015 unchanged.45 46 And obviously since snus is an oral 
product, there is no passive exposure.
Is nicotine addiction a problem?
It is important to consider the issue of nicotine ‘addiction’ because in absence 
of any evidence that SNP carries substantial health risks when compared with 
smoking to either those who use them or to bystanders, warnings on SNP 
packaging generally fall back on the issue of addiction.
Addiction is an ill-defined concept which can be applied to many substances 
and activities; the whole range of psychoactive drugs – both legal and illegal – 
gambling, shopping, sex, eating, or playing video games. When deemed to be 
38 Carlsson, S et al. (2017) Smokeless tobacco (snus) is associated with an increased risk of type 2 diabetes: results 
from five pooled cohorts. Journal of Internal Medicine. 281, 398–406
39 Rasouli, B. et al. (2017) Use of Swedish smokeless tobacco (snus) and the risk of Type 2 diabetes and latent 
autoimmune diabetes of adulthood. Diabetic Medicine; 34, 514–521
40 Lee, P. (2011). Summary of the epidemiological evidence relating snus to health. Regulatory Toxicology and 
Pharmacology, 59 (2), 197–214
41 Araghi, M. et al (2017). Use of moist oral snuff (snus) and pancreatic cancer: pooled analysis of nine prospective 
observational studies. International Journal of Cancer. 141(4):687–693
42 Hansson, J et al (2009). Use of snus and risk of cardiovascular disease; results from the Swedish Twin Registry. 
Journal of Internal Medicine 265(6):717–24
43 World Health Organisation. Scientific Basis of Tobacco Product Regulation. Tobacco Regulation Report 955. 2010
44 McNeill, A. et al. Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by 
Public Health England. PHE, 2018, p.162
45 Glasser, A. M. et al. (2017). Overview of electronic delivery systems: a systematic review. American Journal of 
Preventative Medicine. 52 (2), e33–e66
46 Zwack, et al (2017). Evaluation of chemical exposures at a vape shop. US Department of Health and Human 
Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. 
Available at www.cdc.gov/niosh/hhe/reports/pdfs/2015-0107-3279pdf 
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out of control and adversely affecting other areas of life, all these are classified 
by the medical profession as psychiatric conditions, but from a common sense 
real-world point of view, there is a clear difference between injecting heroin and 
gambling on horses. The question remains: what is ‘addiction’? 
From a neuro-biological standpoint, nicotine is a mild stimulant drug which 
binds to the equivalent receptors in the brain like a key fitting into a lock. Once 
locked in, nicotine stimulates the release of the chemical dopamine which is 
crucial to reward and reinforcement effects that users of many different drugs 
experience. Simply put, it could be called ‘the good time chemical’ in that it is 
responsible not just for the pleasure people derive from intoxication,47 but also 
for sexual gratification and the satisfaction of eating, without which humans as 
a species would die out. So there has to be drug/brain interaction to start the 
process – and the quicker the drug gets to the brain through the blood-brain 
barrier, the stronger the sensations; so injecting would be the quickest route, 
followed very closely by smoking, then snorting, and the slowest route would be 
oral or transdermal use. This explains why many users of NRT find the experience 
unsatisfying because nicotine ingested in this way takes longer to hit the brain 
than smoking. 
But as the recent RCP report points out, the rewards and reinforcement of 
smoking are not just about the specific drug/brain interaction, although of 
course, the brain has a role to play in all our sensory experiences: “Continued 
pairing of the rewarding/reinforcement pairing with specific and sensory and 
environmental stimuli (which for example, could include the smell of tobacco 
or the sight of a packet of cigarettes…) results in these stimuli also acquiring 
reinforcing properties.”48 This would also involve certain rituals like first cigarette 
in the morning, or always having a smoke with a drink or a meal, even the post-
coital cigarette, which has been used as a coy symbol in film and TV to indicate 
that sex had taken place even if not shown.
Hence from that point of view, nicotine is ‘addictive’; people say they crave 
cigarettes, get ‘withdrawal symptoms’, feel agitated and irritable and find it 
hard to concentrate if they run out. Influenced strongly by the psychiatric and 
rehabilitation industries, addiction is viewed in society as an irreducible scientific 
and biological syndrome, a disease caused by the brain being hijacked.
Yet if you match up the criteria for a ‘substance use disorder’ as set out in the 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (2013), the 
American Psychiatric Association’s gold-standard text on the names, symptoms, 
and diagnostic features of every recognised mental illness including addiction, 
you find that nicotine falls short on several counts. For example; taking the 
substance in larger amounts or for longer than you’re meant to; spending a lot 
of time getting, using, or recovering from use of the substance; not managing 
to do what you should at work, home, or school because of substance use; 
continuing to use, even when it causes problems in relationships; giving up 
important social, occupational, or recreational activities because of substance 
use; needing more of the substance to get the effect you want. None of these 
apply to the use of nicotine on a regular, long-term basis.
And more generally, there is a counter-view on the whole notion of addiction 
as a disease.  The psychologist Stanton Peele has written at length as to why he 
regards ‘addiction’ as more of a modern day cultural concept than a medical  
given.49 And he along with others, convincingly challenges the seemingly 
universal assumption that addiction is a disease comparable to cancer or 
diabetes.50
In US medical circles, the word was originally associated simply with the consequ-
ences of heroin use and as such became freighted with all kinds of visceral ima-
gery depicting the worst outcomes of chronic injecting drug use. Prompted by 
films and television, in the public mind, the word conjures up a life in chaos and 
ruin, where the drug becomes all-consuming, where family and friends, school, 
college or job, everything in the person’s life, takes second place behind securing 
the next dose which (in the case of illegal drugs) may also involve criminal activity. 
All this produces a welter of discrimination and prejudice against drug users, 
discussion of which is beyond the scope of this report. But looking at what 
happens in the real world, does this picture of misery and despair map across 
47 See Siegal R., Intoxication: the universal drive for mind-altering substances (reissue) Park Street Press, 2005. The 
author details how not only humans throughout history, but also animals seek to alter their state of consciousness.
48 Royal College of Physicians. Nicotine without smoke; tobacco harm reduction. A report by the Tobacco Advisory 
Group of the Royal College of Physicians. RCP, 2016, p.57
49 Even with heroin, the idea that addiction is inevitable and permanent was challenged in the classic study by Lee 
Robins published in the American Journal of Public Health in 1974 following soldiers returning from Vietnam. 
Many became dependent on heroin while in the midst of war, but gave it up on return, thus confounding fears 
that thousands of new heroin users would be coming back to the USA.
50 For example, Peele, S, The meaning of addiction. Jossey-Bass, 1985; Lewis, M. The biology of desire; why 
addiction is not a disease. Scribe 2015. Szalavitz, M. The unbroken brain: a revolutionary new way of understanding 
addiction. St Martin’s Press, 2016.
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to the person who is ‘addicted’ to nicotine? Because as the clinical literature 
confirms, if there are no significant short or long-term effects from using nicotine, 
and if you take the cigarettes out of the equation by changing the nicotine 
delivery system, the somewhat heretical question becomes – what’s the problem 
with being ‘addicted’ to nicotine? In this specific context, should we even talk 
about ‘addiction’ at all? In the absence of serious clinical or societal harm, isn’t 
this just a pleasurable habit? In which case, does the concept of ‘addiction’ 
become more of a moral or ideological construct than a clinically-based public 
health concern?51 52
“As the clinical literature confirms, if there are no significant short or long-term 
effects from using nicotine, and if you take the cigarettes out of the equation 
by changing the nicotine delivery system, the somewhat heretical question 
becomes – what’s the problem with being ‘addicted’ to nicotine?”
This is an important point because as the evidence accumulates that, in all 
respects, using SNP is far safer than smoking cigarettes, there is still the question 
of ‘addiction’, warnings about which as we say appear on much SNP packaging. 
The risk perception of SNP has actually increased, while smokers often cite the 
guilt and shame of being ‘addicted’ to nicotine as a reason for trying to quit. 
For the many unable to do so, it would be invidious to allow guilt and shame 
about nicotine ‘addiction’ to inhibit quit or switch attempts using SNP, if nicotine 
’addiction’ is being heralded as the worst outcome of using SNP.53
Renormalisation of smoking
Some public health leaders have asserted that SNP will undermine efforts to 
‘denormalise’ smoking by for example, encouraging those who have never 
smoked cigarettes to take up vaping and from there move onto smoking. This 
kind of thinking is grounded in the misconception that there is no difference 
between the two delivery systems, making that transition a real risk.54
Most tobacco control strategies are aimed at engineering a change in social 
norms away from smoking, so ensuring maximum barriers to smoking in 
public, to affording cigarettes, or to be subjected to any form of advertising or 
promotion which encourages smoking, while making every effort to warn of 
the dangers of smoking. And while not the whole story, these strategies have 
contributed to reducing smoking at a population level. But firstly, there is no 
evidence from mature e-cigarette markets around the world that non-smokers 
are taking up vaping in anything other than barely significant numbers.55 
Secondly, the idea of ‘renormalising’ smoking is a very ‘western-centric’ 
approach. Levels of smoking in some low-middle income countries are far 
higher than in the West and the number of smokers is rising in some countries 
due to population growth. Unlike in the West, where the tobacco control policy 
success has also been significantly helped by a general move towards healthier 
lifestyles among large sections of the more well-off population, smoking in low-
middle income countries is far more ‘normal’. These regions of the world would 
clearly benefit from more ready access to SNP.
Gateway effect
The idea that one drug leads to another – classically the supposed transition 
from a ‘soft’ drug (e.g. marijuana) to a ‘hard’ drug (e.g. heroin) – was first 
mooted by the head of the Federal Bureau of Narcotics back in the 1950s, as 
he sought to extract more funding from US Congress when earlier claims of 
‘reefer madness’ were looking highly suspect.56  The idea gained more sustained 
traction in the mid-1980s through Dr Robert DuPont, a psychiatrist and vehement 
anti-marijuana campaigner, who was the White House drugs advisor under 
Presidents Richard Nixon and Gerald Ford. The main problem with the thesis is 
that it grossly over-simplifies the dynamics of drug use and completely ignores 
all the co-founding factors that might lead young people to experiment with one 
drug and then another. As one academic has suggested, once the hypothesis 
51 As an interesting aside, there is evidence that nicotine might be more ‘addictive’ when smoked in cigarettes 
because of other additives in the smoke that aid nicotine delivery and absorption including MAO inhibitors, 
sugars and polysaccharides. Royal College of Physicians. Nicotine without smoke; tobacco harm reduction.  
A report by the Tobacco Advisory Group of the Royal College of Physicians. RCP, 2016, p.61
52 Some clinicians prefer ‘dependence’ to ‘addiction’ and would argue that nicotine ‘enjoyment’ is simply  
a manifestation of dependence keeping the regular use of nicotine within a medical context. 
53 The term ‘hardcore’ in relation to smokers is equally meaningless in research terms as addiction and similarly 
pejorative. See West, R and Jarvis, M. (2017). Is ‘hardcore smoker’ a useful term in tobacco control? Addiction: 
113, p.3–4
54 Voigt, K. (2015). Smoking norms and the regulation of e-cigarettes. American Journal of Public Health.105 (10), 
1967–1972
55 Farsalinos, K.E. et al (2016). Electronic cigarette use in the European Union; analysis of a representative sample of 
27,460 Europeans from 28 countries. Addiction. Nov;111(11) p. 2032-2040. Available at https://www.ncbi.nlm.nih.
gov/pubmed/27338716, and McNeill A. et al (2018). Evidence review of e-cigarettes and heated tobacco products 
2018. A report commissioned by Public Health England. PHE, 2018
72                CHAPTER 5 
had been popularised, “it suffered the death of a thousand qualifications – it 
becomes an empty peg whose removal is long overdue…reflecting the interests 
of certain stakeholders rather than wise social policy”.57
From this it follows that the hypothesis of a gateway from vaping to smoking 
is just as flawed and has just as many caveats as for any other drug, but 
nevertheless does feature heavily in debates about young people and the new 
products. Therefore an important aim of tobacco harm reduction is to ensure 
that while current smokers benefit from a switch to SNP, there are no unintended 
consequences which lead young people who might experiment with SNP to go 
on to become regular smokers. 
 “[The gateway effect theory] suffered the death of a thousand qualifications 
– it becomes an empty peg whose removal is long overdue…reflecting the 
interests of certain stakeholders rather than wise social policy”.
To date, there is no evidence of a gateway effect to regular smoking, although 
some young people will experiment with e-cigarettes because of the novelty 
factor and may also try cigarettes too. Specific studies show that use of 
e-cigarettes among young people is largely experimental58 with the majority 
using flavours that do not even contain nicotine.59 60
But the chances are that they would have tried cigarettes anyway, they will drink 
alcohol and probably smoke a cannabis joint too, go to loud rock concerts, have 
unprotected sex and ride motorbikes. There will be teenagers who do all, some 
or none of these things, but it is a given that this is the age of experimentation, of 
pushing boundaries and indulging in behaviour designed to provoke disappro-
val. Given that e-cigarettes have been on the market for more than a decade, if 
there was going to be a gateway effect, demonstrated by rising prevalence of 
smoking among those young people who had started vaping, it would show up 
in official data – but it doesn’t. Levels of past 30-day smoking prevalence among 
young people in the USA and UK are among the lowest ever recorded.61
From a public health perspective, it is more important to measure prevalence 
of frequent e-cigarette use and to establish whether use occurs in non-smoking 
youth. Data from the US National Youth Tobacco Survey 2015 show that the vast 
majority of e-cigarette use is experimental or infrequent, while regular use is rare 
among never smoking adolescents.62
The National Academy of Sciences report concluded that there was ‘substantial’ 
evidence of a gateway effect, but this was based on mainly US evidence from 
studies with a different methodological approach from other studies. Quite 
simply, studies which conflate ‘ever use’ (which might only mean once) with ‘use’ 
are bound to show quite high levels of ‘use’ by young people.
One recent phenomenon, which has captured media attention in the USA to the 
extent of a ‘moral panic’, is the use of JUUL e-cigarette devices. These devices 
have been extremely successful in the market place and may well feature in 
youthful experimentation, although currently no studies have been published 
and media coverage has been anecdotal. 
The place of SNP in smoking cessation
When surveyed, most smokers say they want to give up or are planning to quit 
and most have tried to quit completely or cut down many times, either going 
‘cold turkey’ or in conjunction with various nicotine replacement therapies 
utilising gum, patches or inhalers. Pharmaco-therapies do not work well for 
many people, whereas SNP are much more promising. The smoker trying to 
quit smoking is still getting the nicotine hit. When surveyed, smokers who have 
switched to vaping cite health concerns as the main reason for a move to vaping. 
Smokers who switch often start with high nicotine content liquid and then reduce 
56 McWilliams, J.C. The protectors: Harry J Anslinger and the Federal Bureau of Narcotics 1930–1962. Associated 
University Presses, 1990
57 Kleinig, J. (2015) Ready for retirement: the gateway drug hypothesis. Substance use and misuse; online 1–5 
58 Bauld, L. et al. (2017). Young people’s use of e-cigarettes across the United Kingdom; findings from five surveys 
2015-2017. Int J Environ Res and Public Health; 14, 973
59 Miech, R. et al. (2017). What are kids vaping? Results from a nationwide survey of US adolescents. Tobacco 
Control. 26: 386–391
60 A very small qualitative study was conducted with existing young Scottish smokers and their experience with 
vaping. While limited in scope, it did suggest that some young people might start vaping as a trial but return to 
cigarettes for a raft of reasons including peer group smoking culture, satisfaction and ease of use. McKeganey, 
N. et al. (2018). Vapers and vaping: e cigarettes users and views of vaping and smoking. Drugs: education, 
prevention and policy. 25 (1), p.13–20
61 Harrell, P.T et al (2016). Patterns of youth tobacco and poly-tobacco usage. The shift to alternative products. 
American Journal of Drug Alcohol Abuse. 1–9
62 Farsalinos K. et al (2018). Frequency of Use and Smoking Status of U.S. Adolescent E-Cigarette Users in 2015. 
American Journal of Preventative Medicine. 2018 Jun;54(6):814-820.doi: 10.1016/j.amepre.2018.03.003. Epub 
2018 Apr 7. PubMed PMID: 29631871
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to very low levels, or no nicotine content at all, while still wanting to replicate the 
cigarette ‘experience’.63
There are divided opinions about the effectiveness of e-cigarettes as smoking 
cessation tools, with evidence pooled from observational studies and 
randomised control studies reaching conflicting conclusions; some showing 
improved success64 and others demonstrating either no efficacy,65 or even 
suggesting that e-cigarettes suppress the chances of successful smoking 
cessation.66
Even though there will be those vapers who have switched with no intention 
of totally quitting, there is no evidence that overall the advent of e-cigarettes 
has slowed quitting rates or caused relapse in long-term quitters. On the 
contrary, studies show a switch to e-cigarettes increases the chance of quitting 
altogether.67 In Europe as a whole, it has been estimated in 2014 that six million 
people have quit smoking using e-cigarettes.68 
Beyond cessation and the ‘pleasure principle’
The medicalisation of any illegal drug use has meant notions of pleasure 
derived from use have been completely written out of the script of public 
policy, leaving a ‘pathology paradigm’ as the dominant discourse.69 70 The 
denormalisation of smoking has created a similar paradigm, where smoking 
is more regarded as an illness that needs to be treated. Not surprising then 
that the use of SNP is only viewed as legitimate by some of the public health 
community, so long as SNP are part of a smoking cessation strategy. But 
some studies have looked into the issue of ‘loss of identity’ when embarking 
on smoking cessation,71 which can arguably be recaptured by a change 
of identity to vaper, rather than smoker, and engaging with a new social 
grouping. This is underlined by recent research revealing that many ex-
smokers embrace the new social context of vaping.72 73 74
One UK study75 asked vapers to rank statements about e-cigarettes along 
a continuum of agree/disagree, and to sort these into groups. The three 
groupings that emerged were:
1. Vaping as pleasure or ‘having your cake and eating it’; 
2. Vaping as medical treatment; 
3. Ambivalent about using e-cigarettes.
The majority of participants signed up to the first group and stated the many 
positives about using e-cigarettes while rejecting the notion of smoking as 
an illness including the following statements:
“I smoked for 53 years and gave up almost immediately after trying an 
e-cigarette”. (Female aged 69)
 “I loved the smoking experience, now the vaping experience”. (Male  
aged 37)
“Vaping is a hobby now. Rebuilding mods, coils, drip tip carving and mixing 
your own juices, there are no ‘NRT’ forums and only a few smokers forums”. 
(Male aged 41)
“Flavours are a big part of the e-cig experience. I vape sweet flavours. Once 
your taste buds come back, tobacco flavours are not nice”. (Male aged 41)
“Flavours are essential for disassociation from smoking”. (Male aged 37)
63 Personal communication with ex-smokers who have switched.
64 Hartmann-Boyce J. et al (2016). Electronic cigarettes for smoking cessation. Cochrane Database of Systematic 
Reviews 2016: 9: CD010216 
65 Khoudigian S. et al (2016). The efficacy and short- term effects of electronic cigarettes as a method for smoking 
cessation: a systematic review and a meta-analysis. International Journal of Public Health 2016: 61(2): 257–267
66 Kalkhoran S. and Glantz S.A. (2016). E-cigarettes and smoking cessation in real-world and clinical settings:  
a systematic review and meta-analysis. The Lancet Respiratory Medicine 2016: 4(2): p.116–128
67 Shu-Hong, Z. et al. (2017) E-cigarette use and associated changes in population smoking cessation: evidence 
from US current population surveys. British Medical Journal 2017;358:j3262
68 Farsalinos, K.E. et al (2016). Electronic cigarette use in the European Union; analysis of a representative sample of 
27,460 Europeans from 28 countries. Addiction. Nov;111(11) p. 2032-2040. Available at  
https://www.ncbi.nlm.nih.gov/pubmed/27338716
69 Moore, D (2007). Erasing pleasure from public discourse on illicit drugs: on the creation and reproduction of an 
absence. International Journal of Drug Policy; 19, p.353–358
70 Duff, C (2007). The pleasure in context. International Journal of Drug Policy; 19, p.384–392
71 Pechacek, T.F et al (2017) Reassessing the importance of ‘lost pleasure’ associated with smoking cessation: 
implications for social welfare and policy. Tobacco Control. Available at: https://tobaccocontrol.bmj.com/content/
early/2017/11/24/tobaccocontrol-2017-053734
72 Keane, H et al (2017) ‘Anytime, anywhere: vaping as social practice. Critical Public Health. 27 (4), p. 465–476.
73 Bevan, I. (2016). E-cigarettes: smoking pleasure reinvented? The many faces of harm reduction in France. 
Contemporary Drug Problems. 43(3), p.228–241
74 Saddleson, M.L et al. (2016). Enjoyment and other reasons for electronic cigarette use: results from college 
students in New York. Addictive Behaviour; 54, p.33–39
75 Farrimond, H. (2017) A typology of vaping: identifying different beliefs, motivations for use, identity and political 
interest among e-cigarette users. International Journal of Drug Policy; 48, p.81–90
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“I absolutely love vaping. My health has improved. No more coughing!”. 
(Female aged 62)
“Medicine? I assume medicine is to treat an illness. I am not ill!!’. (Female 
aged 62)
“I do not smoke anymore. I am not taking medicine. There is no doubt e-cigs 
offered a viable alternative to smoking but in themselves they are not  
a medicine”. (Male aged 60).
“Part of why vaping works is that it doesn’t medicalise smokers or frame 
nicotine consumption as a problem. I think it’s more like caffeine”. (Female 
aged 45)
General product safety
Given the controversial and innovative nature of the new technologies 
associated with e-cigarettes and HNB products, it is in the interests of 
manufacturers to be at the forefront of establishing product safety, through 
development and implementation of product standards. 
The importance of standards was underlined at the WHO Framework 
Convention on Tobacco Control Conference of the Parties (COP) in 2016, in 
India, when its Secretariat was tasked with reporting back to the next COP on the 
development of methods used by regional and international standards bodies 
for the testing and measuring of contents and emissions of the new products. 
A number of international, regional and national bodies are charged with the 
development of standards and many of these are now working on standards 
specific to vaping liquids and devices. Those safety standards cover three key 
areas: the composition of e-liquids and other consumables, the safety of the 
devices and emissions from those devices.
The International Organisation for Standardisation (ISO) is an independent, 
non-governmental organisation, with a membership comprising standards 
organisations of the 162 member countries. It is the world’s largest developer 
of voluntary international standards and facilitates world trade by providing 
common standards between nations. Over 20,000 standards have been set, 
covering everything from manufactured products and technology, to food 
safety, agriculture and healthcare.  The ISO tobacco committee has established 
an e-cigarette sub-committee with two working groups, looking at safety and 
quality requirements for electronic cigarette devices and e-liquids; test methods 
for devices and e-liquids; determination of substances in e-liquids; testing 
conditions, equipment, reference products, emissions, vaping machines and 
user information and services provided by retailing.76
At the regional level there is the European Committee for Standardisation or 
CEN, which has four working groups covering devices, e-liquids and emissions.
In Great Britain, there is the British Standards Institute (BSI) which has produced 
PAS 54115 in 2015, a manufacture, importation, testing and labelling guide 
covering vaping products, including electronic cigarettes, e-liquids, e-shisha 
and directly-related products. Subjects covered include: the purity of e-liquid 
ingredients; potential contaminants from device materials and potential 
emissions from devices; an outline for the toxicological and chemical analysis 
of emissions and the safety of batteries and chargers. The French have a similar 
organisation, the Association Française de Normalisation (AFNOR) which has 
published similar guidance standards.
There is a voluntary product standard for Swedish snus called the Gothiatek 
standard introduced by the snus industry in 2001.77 In 2007, the Gothiatek 
standard was accepted as a standard for all STPs by the European Smokeless 
Tobacco Council (ESTOC), an organisation representing all the major 
manufacturers of snus.
The Gothiatek standard sets maximum permissible levels for several unwanted 
substances. The mandated maximum levels have been lowered on several 
occasions since the introduction of the standard.  In 2010 the WHO Study 
Group on Tobacco Product Regulation proposed maximum levels for some 
nitrosamines (NNN, NNK) and one PAH (BaP, benzo(a)pyrene) in STPs. These 
levels are, however, higher than the maximum levels currently mandated by 
Gothiatek.
76 Tranchard, S. (2016) Vaper and vapour products make their debut in international standardization. International 
Organization for Standardization. https://www.iso.org/news/2016/04/Ref2074.html
77 Rutqvist, L.E. et al (2011). Swedish snus and the Gothiatek standard. Harm Reduction Journal. 8:11 Available at 
https://www.ncbi.nlm.nih.gov/pubmed/21575206 
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The levels of such substances in Swedish snus are well below the levels for 
STPs proposed by the WHO Scientific Advisory Committee on Tobacco Product 
Regulation78 as well as below the maximum levels for snus recently set by the 
Swedish Food Authority in its recent regulation which came into force on  
11 April 2016.79
How to improve the science of SNP
We started this chapter by highlighting the quality of science and of science 
reporting. There are many areas of public life and health where there are 
scientific disputes and questionable media reporting with consequent myths 
and misconceptions. 
The problem with research into SNP
It might seem strange to end with a quote from a philosopher who lived 400 
years ago, but what Francis Bacon had to say in 1620 in his New Organon or True 
Directions concerning the interpretation of nature about approaches to new 
science is still relevant today:
“The human understanding when it has once adopted an opinion draws all 
things else to support and agree with it. And though there be a greater number 
and weight of instances to be found on the other side, yet these it either 
neglects and despises, or else by some distinction sets aside and rejects, in 
order that by this great and pernicious predetermination the authority of its 
former conclusion may remain inviolate.”
This resistance to the paradigm shift in nicotine delivery will most likely be 
manifest in those researchers who have been involved in tobacco research for  
a long time. They would have seen the damage caused by cigarettes, the smoke 
and mirror activities of the big tobacco companies, and so may well come at 
research into new and very different, disruptive products manufactured by so-
called ‘Big Tobacco’ and the much wider independent sector, through the same 
prism of antipathy and suspicion. This in turn can consciously or sub-consciously 
result in ‘confirmation’ bias in research. As policy makers and legislators involved 
in tobacco control will often harbour the same antipathies and suspicions, 
negative research has the potential to exert the most influence in inhibiting the 
progress of tobacco harm reduction. 
The same kind of problem attaches itself to research funding bodies, both public 
and private, who are ill-disposed towards the tobacco industry and would likely 
only be interested in funding research that calls into question SNP as a new harm 
reduction pathway, without fully realising or choosing to ignore the fact that the 
tobacco companies do not have a monopoly on the e-cigarette business.
Then there are the faulty mechanisms of academic publishing. There are 
concerns about the peer review process itself,80 journal editors and editorial 
boards may demonstrate the same biases as the authors of the papers under 
review – and academic careers stand or fall on publishing. Therefore, it is hardly 
surprising that researchers will headline their findings in the most dramatic way, 
in order to increase the chances of publication in the first place (especially in 
high impact journals) and then to capture the media’s attention.  A study in The 
Lancet revealed that those papers demonstrating a null effect for those infants 
whose mothers used crack cocaine during pregnancy were less likely to be 
published than those that showed negative outcomes, even if the methodology 
of the latter was less robust.81
There is a well-worn cliché about the devil being in the detail and this applies 
acutely in the whole new research arena around SNP and tobacco harm 
reduction. With a 24/7 news cycle and new and often conflicting research 
appearing on an almost daily basis, it is impossible for most people to discern 
what research really stands up to scrutiny. 
Professor David Abrams from the College of Global Public Health at New York 
University summarised the issue of bad science and SNP as follows:
“We suggest that current divisiveness that paralyzes policy-making can 
be mitigated by paying close attention to the strongest evolving scientific 
syntheses and not relying on select, isolated studies that exaggerate claims 
of harms and/or omit direct comparisons of harms relative to smoking. 
78 World Health Organisation. WHO Study Group on Tobacco Product Regulation Report on the Scientific Basis of 
Tobacco Product Regulation (2010). Available at www.who.int/tobacco/global_interaction/tobreg/publications/
tsr_955/en/
79 Swedish Match, Snus and the Swedish Food Act. Available at: https://www.swedishmatch.com/Snus-and-health/
snus-and-the-swedish-food-act/
80 Mccook, A (2006) Is Peer Review Broken? The Scientist. Available at https://www.the-scientist.com/?articles.view/
articleNo/23672/title/Is-Peer-Review-Broken-/ 
81 Koren G. et al (1989). Bias against the null hypothesis: The reproductive hazards of cocaine. Lancet; 2:1440–1442
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Strong assertions that go beyond the science (e.g., conflating correlation 
with causation, cherry picking results to highlight a particular viewpoint) are 
troubling trends that feed divisiveness rather than provide a basis for rational 
recommendations. Adhering to good research practices (e.g., research 
integrity; respect, ethics and professional standards; honesty and transparency; 
openness and accountability) is also necessary to reduce these apparent 
conflicts”.82
A research evaluation check-list for SNP83
1 Toxic chemicals have been identified in e-cigarette vapor or e-liquids 
1.1 Did they show potentially harmful exposure not just the presence of  
a chemical? “The dose makes the poison”. 
1.2 How risky is the exposure compared to smoking? 
1.3 How risky is the exposure compared to other risks such as those 
accepted under occupational health limits? 
1.4 Were measurements made in realistic human operating conditions or 
in extreme or unrealistic conditions? 
1.5 Are inappropriate proxies being used for risk – for example effects that 
are also seen with coffee or exercise? 
1.6 Are flawed analogies being used – for example assuming all ultrafine 
particles are equally toxic? 
2 Adverse health effects from e-cigarettes are reported 
2.1 Was vaping the real cause?  
2.2 Was the person suffering from adverse impacts of beings a smoker 
before using e-cigarettes? 
2.3 Is the study just observing the effect of nicotine on the body (though 
no serious disease is caused by nicotine)? 
2.4 Is there evidence of actual harm or is it just a change in the body or 
brain? 
2.5 Is it based on a cell culture study, are the limitations recognized and 
was exposure realistic proxy for human use? 
2.6 Is it based on an animal study and are the limitations recognized?  
3 Claims second-hand vapor is toxic and indoor vaping should be banned 
3.1 Are vapor exposures to bystanders potentially harmful given they pose 
little risk to direct users? 
3.2 Is the difference between risk or harm and nuisance or personal 
preference recognized? 
3.3 Have false choices been proposed? e.g. between a ban and laissez 
faire. 
4 Nicotine damages the adolescent brain 
4.1 What is the specific nature of the detriment to human health? 
4.2 Where is the evidence for the brain damage from nicotine in the 
longstanding human population of smokers? 
4.3 How does this compare to damage from alcohol, cannabis or caffeine? 
5 More children using e-cigarettes and gateway effects 
5.1 Did they characterize use properly? For example, ‘ever use’ of an 
e-cigarette is a marker of experimentation. 
5.2 Could the rising use of e-cigarettes be a good thing if it is displacing 
smoking? 
5.3 High level of smoking associated with vaping – but is this due to 
independent common factors (confounding)? 
5.4 Have they defined a gateway effect? 
5.5 Are they assuming prior behaviour caused the later behaviour? 
6 E-cigarettes keep people smoking and reduce quit rates 
6.1 Has vaping been wrongly conceptualized as though it is a medical 
intervention? 
6.2 Has the importance of product’s consumer appeal been recognized? 
6.3 Was “dual use” described as problematic – any cutting down is 
beneficial and may be part of a longer transition? 
6.4 Did they claim there are no benefits to cutting down? 
6.5 Have the limitations of randomized controlled trials been 
acknowledged?
7 Flavours and e-cigarette marketing aimed at children 
7.1 Do they assume it is just obvious that childish names appeal  
to kids? 
7.2 Why would adolescents try to emphasize their childishness? 
7.3 Have preferences for particular flavours been misrepresented as  
a cause of vaping? 
7.4 Could it be a benefit that some flavours are attractive to adolescents if 
it means they don’t smoke? 
7.5 Is an e-cig advertising in effect an anti-smoking ad?  
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8 Citing uncertainty and appeal to the ‘precautionary approach’ 
8.1 Have they understood what is known and recognized that the physical 
processes in vaping are different to smoking? 
8.2 Are they asking the impossible? E.g., by saying we will only know the 
risks when we have 40 years of data? 
8.3 Do they realize that ‘precautionary approach’ can be harmful if it 
blocks access to beneficial technology? 
9 Tobacco industry involvement implies inevitable harm 
9.1 Is the malign influence of tobacco companies assumed or 
demonstrated? 
9.2 Is there over-reliance on decades old industry statements, documents 
or behaviours? 
9.3 Is there a proper understanding of how the nicotine and tobacco 
market works? 
9.4 Are the authors concerned about the right things? For example, are 
they fighting ill-health or capitalism? 
10 Policy recommendations in a scientific paper 
10.1 Do policy recommendations go beyond what their research justifies? 
10.2 Have policy-making disciplines been followed – options generation, 
impact assessment, consultation etc.? 
10.3 Are the authors’ policy positions revealing their biases and priors?  
10.4 Have unintended consequences been ignored? Many e-cigarette 
policy proposals could lead to more smoking.  
Conclusion
All those working in public health acknowledge the gravity of the global 
smoking epidemic and seek ways to reduce cigarette consumption. Many 
people quit smoking without any intervention and are aided in this by measures 
such as smoking bans and high prices. But this leaves many millions of people 
around the world who for whatever reason, cannot or do not want to stop 
using nicotine. The question then becomes, what more can be done to smooth 
a transition away from deadly cigarettes? New technologies have brought 
e-cigarettes and heated tobacco products to market and refocused attention on 
smokeless tobacco products like snus, all of which present a new pathway to a 
less risky use of nicotine and, for some, complete cessation. The assertions that 
by any measure SNP are less harmful than cigarettes are based on a growing 
body of independent scientific evidence from around the world which we have 
brought together in this chapter. But the watchword here is harm reduction, 
not harm elimination; SNP are not magic bullets, but a valid and potentially 
lifesaving public health option.
Nonetheless, there is an over-cautious approach among many public health 
and medical professionals who warn against SNP because there is not enough 
evidence about the long-term individual and population level effects. At times 
this is used to justify misleading public information on the premise that ‘because 
we don’t know everything, we don’t know anything’, so the only reasonable 
course of action is to guard against some unknown catastrophic future. This is 
known as the precautionary principle, which might be justified, if, as we say, it 
was not already demonstrably clear that there is a potentially huge saving in 
mortality and morbidity to be made by actively encouraging persistent smokers 
to switch to SNP. This holds true even if it turned out 20 years down the line 
that across the board SNP turned out to be just 50 percent safer than smoking 
cigarettes.
“[The precautionary principle] is used to justify misleading public information 
on the premise that ‘because we don’t know everything, we don’t know 
anything’”.
Of more immediate danger to the acceptance of tobacco harm reduction,  
however, is the global drive to over-regulation and control, where those charged 
with the responsibility for tobacco control are similarly influenced by the same 
misunderstandings of the science and the epidemiology, a misreading of 
industry involvement, but also a suspicion of a potentially highly significant  
public health benefit not initiated, funded or controlled by national or  
international public health bodies.  
82 Abrams, D. From a talk entitled, Harm minimisation: reframing societal nicotine to save more lives NOW given at 
Vermont Center on Behavior and Health conference 2017.
83 Check list adapted from submission by Clive Bates for the UK House of Commons Science and Technology 
Committee Enquiry into e-cigarettes 2017
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Chapter 6:
Regulation and control
The advent of new SNP products presents a serious challenge to established 
tobacco regulatory control regimes at both a national and international level. 
As a consequence, the global legislative landscape is highly varied, with many 
countries having no specific controls on different SNP, while others ban some of 
these products. There are also wide differences in the control of older SNP such 
as snus – which is allowed in much of the world but is banned throughout the EU, 
with the exception of Sweden.
National tobacco control measures are well-documented (see for example, the 
WHO Report on the Global Tobacco Epidemic, 2017).1 However, the global legal 
and regulatory profile for SNP is less enumerated. At the end of this chapter we 
summarise the legal situation regarding e-cigarettes, including how they are 
regulated (whether they are banned regulated or if there is simply no specific 
law or regulation). In addition, we cover whether it is legal to sell the devices or 
nicotine, and whether there are restrictions on their use in public places. Further 
information is available in the country profiles at www.gsthr.org. 
Broadly speaking, the global regulatory picture is comprised of a majority of 
countries who have no specific legal or regulatory provision for e-cigarettes, and  
a smaller group that have introduced or are in the process of introducing specific 
legal and regulatory provision (as for example in the EU), as well as those which 
have outright bans. In some countries, such bans are legacies of legislation that 
predate e-cigarettes. For example, in Australia the ban on the unauthorised sale, 
possession or use of nicotine preceded the arrival of e-cigarettes. In some cases, 
countries have introduced bans on e-cigarettes and/or nicotine in response to 
the arrival of these products on the market.
“In Australia the ban on the unauthorised sale, possession or use of nicotine 
preceded the arrival of e-cigarettes”.
The three main approaches to regulation are to control SNPs as tobacco 
products, as consumer products, and/or as medicinal products. However, these 
broad categories hide wide nuances in regulatory provision, and have become 
the focus of legal argument and in some cases legal challenge. The quandary for 
governments is how to categorise these new products, and how to determine 
where they fit in terms of potential risks (and sometimes but more rarely in terms 
of potential benefits) within the dominant tobacco control model that has been 
developed over the last two decades. 
There seems little doubt that contradictory research findings, together with the 
work of individual influential activists and sensationalised media reporting, have 
all served to influence the legal framework within which SNP are supposed to fit. 
However, laws aimed at inhibiting the manufacture, sale and use of SNP should 
also be seen through the prism of the long and complex past of tobacco control. 
Therefore, our discussion needs first to look at the history of tobacco control.
A brief history of tobacco control
Since the French diplomat Jean Nicot and British explorer Sir Walter Raleigh 
first brought tobacco from the Caribbean to the courts of France and England 
respectively in the late 16th century, tobacco has been a controversial drug. 
Initially hailed as a universal panacea for a whole range of ailments, as early as 
1604 James 1st of England published his famous Counterblaste to tobacco in 
which he not only railed against tobacco itself, but also attacked the morality of 
smokers in ways which resonate today among anti-tobacco activists:
“Have you not reason then to bee ashamed, and to forbeare this filthie noveltie, 
so basely grounded, so foolishly received and so grossely mistaken in the right 
use thereof? In your abuse thereof sinning against God, harming your selves 
both in persons and goods, and raking also thereby the markes and notes of 
vanitie upon you: by the custome thereof making your selves to be wondered 
at by all forraine civil Nations, and by all strangers that come among you, to be 
scorned and contemned. A custome lothsome to the eye, hatefull to the Nose, 
harmefull to the braine, dangerous to the Lungs, and in the blacke stinking 
1 World Health Organisation, WHO report on the global tobacco epidemic 2017. WHO, 2017. Available at  
www.who.int/tobacco/global_report/en/
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fume thereof, neerest resembling the horrible Stigian smoke of the pit that is 
bottomelesse”.2
A very early anti-tobacco law was enacted by Pope Urban VII, who in 1590 
threatened to excommunicate anybody who “Took tobacco in the porchway of 
or inside a church, whether it be by chewing it, smoking it with a pipe, or sniffing 
it in powdered form through the nose”.3
Ottoman ruler Sultan Murad IV (1623-1640) went further than any other 
potentate to stamp out tobacco. He banned alcohol, coffee and tobacco in 
Istanbul and reportedly toured the less salubrious districts of the city in disguise, 
personally beheading on the spot anybody he caught smoking.4 Serious physical 
punishments could also befall smoking Muscovites.5 Most authorities, however, 
restricted controls on smoking (for example in some German cities) to personal 
civil penalties for breaking local ordinances, up until the turn of the 20th century.
The first coordinated non-governmental action against tobacco was probably 
the creation of the Anti-Cigarette League in America, founded in 1899. The drive 
behind the League was very closely linked to temperance and anti-drug groups 
spearheaded by coalitions of faith groups and moral and social reformers. The 
Anti-Cigarette League was influential in states-wide tobacco controls. Fifteen 
states enacted laws banning the sale, manufacture, possession, or use of 
cigarettes, and 22 other states considered such legislation, although by 1930 all 
states had repealed these various laws.6 
Most US laws focused on minimum legal age for purchase and similar 
legislation was enacted in the UK, under the Children’s Act 1908. Nazi Germany 
provided an early example of a nationwide anti-tobacco campaign: bans on 
smoking on public transport; limiting cigarette rations for soldiers; and raising 
tobacco tax, as part of the ethos of racial purity and which was no doubt 
inspired by Hitler’s personal disgust of smoking, and nascent research on the 
effects of tobacco.
Although German scientists and an Argentinian Angel Roffo between them first 
made the link between smoking and cancer, it was the work of British professors 
Sir Richard Doll and Sir Austin Bradford Hill, published in 1954,7 which set in 
motion subsequent research leading to two landmark health reports from the 
UK’s Royal College of Physicians (1962) and the US Surgeon-General (1964), 
heralding the first concerted attempts at national tobacco controls. 
But as King James 1st quickly realised, whatever the adverse effects of smoking, 
the drug was a source of vital tax revenues and it was imperative for the 
generation of income. More recently this, coupled with an industry determined 
to maintain profits, politicians fearful of losing votes especially among 
working people, and the general ethos of personal freedom in western liberal 
democracies, meant that progress to enact comprehensive national tobacco 
controls was slow.
The legal tipping point came in 1980-81 with the publication of evidence 
concerning passive smoking. 8 This enabled activists and legislators to frame 
the tobacco control issue as one of environmental health, potentially affecting 
the whole community, especially family members and co-workers – not just 
individual smoker themselves. Partial or full public smoking bans, alongside 
taxation probably now account for the most common form of tobacco control 
across the world.
By the 1990s and subsequently, most countries in the developed world have in 
place a raft of measures which variously include: health warnings on packets; 
bans on media advertising and sports’ sponsorship; bans on sales to minors 
and sales of single cigarettes, or smaller packet cigarettes mainly sold to poorer 
people; and rapidly rising rates of taxation. Significant and effective controls 
have also been enacted against smoking in public places. 
Aside from illegal smuggling and cross-border advertising, smoking was and 
remains largely a matter for domestic laws rather than a transnational issue – one 
nation’s tobacco consumption does not have cross-border health impacts. But 
starting in the late 1960s, the scientists, clinicians, public health officials, and 
especially NGO activist delegates attending world conferences on tobacco, 
2 Texas Liberal Arts, A Counterblaste to Tobacco (2002) http://www.laits.utexas.edu/poltheory/james/blaste/ 
3 Henningfield, J. Nicotine: an old-fashioned addiction. Chambers, 1985
4 Davis, W. A short history of the Far East. MacMillan, 1922 
5 Dr Murray. A general history of the tobacco plant. Parsons, 1836
6 Wikipedia, Anti-Cigarette League of America https://en.wikipedia.org/wiki/Anti-Cigarette_League_of_America
7 Proctor R.N. (2012) The history of the discovery of the cigarette–lung cancer link: evidentiary traditions, 
corporate denial, global toll. Tobacco Control 2012;21:87-91. Available at http://tobaccocontrol.bmj.com/
content/21/2/87?utm_source=njam&utm_campaign=sponsorcontent&utm_medium=display
8 Bayer, R and Colgrove, J. Children and bystanders first; the ethics and politics of tobacco control in the United 
States. In: Feldman, E and Bayer, R eds. Unfiltered: conflicts over tobacco policy and public health. Cambridge, 
Harvard University Press, 2004, p.21
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wanted to move beyond simple information exchange towards an action agenda 
which would demand the legislative glue to help such action hang together 
across countries.9
Increasing evidence of wider health harms was not the only driving force 
towards international action. At one time, some activists thought they could work 
with the industry. That all changed in 1998.
In the face of a growing number of multiple lawsuits across several US states, 
the four largest US tobacco companies: Phillip Morris; R.J Reynolds; Brown 
& Williamson; and Lorillard entered into an agreement in November 1998 
with the Attorney’s General of 46 states called the Tobacco Master Settlement 
Agreement. The states settled their Medicaid lawsuits against the tobacco 
industry for recovery of their tobacco-related health-care costs. In exchange, 
the tobacco companies agreed to curtail or cease certain advertising practices 
as well as to pay, in perpetuity, various annual payments to the states to 
compensate them for some of the medical costs of caring for those with 
smoking-related illnesses.
In the course of concluding this agreement, disclosures from within the industry 
revealed misleading industry publicity over low-tar and ‘light’ cigarettes, the 
suppression of evidence of passive smoking and generally exposed the depth  
of industry deception in all areas of tobacco health risks. As a result, a trust 
deficit opened up between anti-tobacco activists and the industry, which 
remains to this day.10 More broadly, the general spread of smoking came to be 
seen as, “A series of complex developments including trade liberalization, direct 
foreign investment in companies, global marketing, transnational advertising 
and sponsorship and the international movement of contraband or counterfeit 
tobacco”,11 which all played to a view that a global public health response was 
required.  
The Framework Convention on Tobacco 
Control (FCTC)
In fact, ‘global’ became the new watchword; ‘international’ could just mean 
bi-lateral agreements between countries, whereas ‘global’ signified a more 
universally inclusive approach.12 Until the mid-1990s, tobacco control was not 
a priority issue for the WHO, more concerned as it was to tackle infectious 
diseases. But in 1994, at the Ninth World Conference on Tobacco and Health 
in Paris, a resolution was passed on the need to take international legal action 
to combat the global smoking epidemic. The following year, the World Health 
Assembly instructed the Director-General of the WHO, Gro Harlem Brundtland, 
former Prime Minister of Norway, to investigate the feasibility of “Developing 
an international convention on tobacco control to be adopted by the United 
Nations”.13 It took several years of arduous negotiations in six Intergovernmental 
Negotiating Body (INB) meetings, between the 193 WHO member governments 
in Geneva, followed by unanimous adoption at the 56th World Health Assembly 
in May 2003. In February 2005 the FCTC entered into force in international law 
as the world’s first multi-lateral health treaty.
It was a singular event in UN history; the world’s first public health treaty and 
the first example of the WHO using its constitutional authority in global public 
health to develop a legal instrument aimed at improving population health. 
The FCTC became the most accepted and ratified treaty since the formation of 
the UN: it was signed by 168 countries during its year-long initial open period 
and has been ratified or acceded to by 181 countries, known as Parties to the 
FCTC. Parties to the FCTC have legal obligations to implement its provisions 
and to participate in meetings of the Parties, known as the FCTC Conference 
of the Parties (COP). As of July 2017, there were nine UN member states who 
have neither signed nor ratified the Convention: Andorra; Dominican Republic; 
Eritrea; Indonesia; Liechtenstein; Malawi; Monaco; Somalia and South Sudan. 
A further seven Member States have signed but not ratified the Convention: 
Argentina; Cuba; Haiti; Morocco; Mozambique; Switzerland and the USA.14
9 Reubi, D and Berridge, V. (2016) The internationalisation of tobacco control 1950-2010. Medical History. 60 (4), 
2016, p.453.472
10 Reubi, D and Berridge, V. (2016). The internationalisation of tobacco control 1950-2010. Medical History 60 (4), 
2016, p.453.472
11 Sparks, M. (2010). Governance beyond governments: the role of NGOs in the implementation of the FCTC. 
Global Health Promotion; Supp (1), 2010, p. 67-72 
12 Reubi, D and Berridge, V. (2016). The internationalisation of tobacco control 1950-2010. Medical History 60 (4), 
2016, p.453.472
13 Wikipedia, WHO Framework Convention on Tobacco Control. https://en.wikipedia.org/wiki/WHO_Framework_
Convention_on_Tobacco_Control
14 The USA has a long history of not ratifying international treaties. This is partly to do with the definition of the word 
‘treaty’ in US law and it seems also that any treaty which conflicted with the US Constitution would not be ratified. 
For more explanation see: https://www.asil.org/insights/volume/2/issue/5/international-agreements-and-us-law
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FCTC structure
During the establishment and negotiation of the FCTC, the WHO’s 
Tobacco Free Initiative (TFI) was the treaty secretariat and it remains within 
the WHO to administer tobacco-related issues. In addition, the FCTC 
provided in Article 24 for a specialist secretariat to be established by the 
COP, and this body, known as the FCTC COP Secretariat, administers the 
reporting and coordination of all FCTC related matters, provides support 
to developing country Parties, including organising knowledge hubs and 
regional workshops, as well as facilitating the financial resources of the 
implementation of the FCTC. 
The first COP meeting (COP1) was held in 2006 in Geneva. It met again 
in 2007 and 2008, and since then it has met every two years. The meeting 
is open to all 193 WHO members; however, different status categories 
exist. The FCTC Parties, those who have formally ratified or acceded to the 
Convention, have full participation and voting rights. Those WHO members 
who are not Parties, such as the USA and Indonesia, are known as Observers 
and they can participate in the COPs, but sit separately and do not take 
part in informal government working groups, unless special permission 
is granted, which did happen during negotiation of the FCTC guidelines. 
International organisations such as the World Customs Organization or the 
World Trade Organization, also have the status of Observers.  
Although the COP is an intergovernmental meeting of WHO member Parties, 
access is also given to non-governmental organisations (NGOs). NGOs with 
official accreditation to the WHO, as well as NGOs with official accreditation 
to the COP, are also permitted NGO Observer status, such as the Framework 
Convention Alliance (FCA). 
The FCA was formed in 1999 at the start of the FCTC negotiations. It is  
a confederation of nearly 500 organisations from more than 100 countries 
which banded together to support the negotiation, ratification and 
implementation of the FCTC. Compared with some other UN bodies, access 
to COP meetings is difficult for most NGOs, unless they join the FCA and 
agree with its aims and positions.
Members of the public, including industry, students, or NGOs not accredited 
to the WHO are required to apply for access to observe proceedings from 
the public gallery. However, since 2009, the COP has undemocratically made 
provision to close the public gallery, denying the public access, which sets 
the WHO practice apart from most other UN bodies. 
The FCTC is a comprehensive instrument, obliging Parties to implement a wide 
range of tobacco control provisions contained in its 38 articles. The whole 
process, from the earliest days of negotiation to the final agreements on the 
Convention text, were seen through a prism of anti-tobacco sentiment, and 
any considerations that might be deemed to dilute this discourse, such as the 
idea of relative tobacco harm, were brushed aside. At that time (1999–2003) 
e-cigarettes and vaping were unheard of and the only reduced harm product 
known was Swedish snus. The only alternatives to smoking spoken about 
were pharmaceutical nicotine replacement products, as referenced in the 
cessation section of the FCTC contained in Article 14, and this was largely 
due to the significant funding that was provided to tobacco control from the 
pharmaceutical industry at that time. So, the thrust of the FCTC is to reduce all 
tobacco use, rather than to focus in a proportionate way according to the risk of 
different tobacco products. Hence, FCTC is a treaty against tobacco rather than 
a treaty against smoking.  
“The FCTC is a treaty against tobacco rather than a treaty against smoking”.  
The opening Convention statements, known as the treaty Preamble, make 
specific reference to the right to health, a matter to which we return in Chapter 7:
“Recalling Article 12 of the International Covenant on Economic, Social and 
Cultural Rights, adopted by the United Nations General Assembly on 16 
December 1966, which states that it is the right of everyone to the enjoyment of 
the highest attainable standard of physical and mental health.”
Although most tobacco control measures promoted under the FCTC have 
focused on reducing the supply of and demand for tobacco, the Convention 
does in fact specifically refer to harm reduction. This would be viewed as 
a surprising and positive outcome by many drug policy and public health 
reformers who have argued (for a long time unsuccessfully) to have harm 
reduction language in the positions of the United Nations Office on Drugs and 
Crime and the Commission on Narcotic Drugs (the equivalent of the COP).
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In the very first article of the FCTC (Article 1d) it defines tobacco control as:  
“A range of supply, demand and harm reduction strategies that aim to improve 
the health of a population by eliminating or reducing their consumption of 
tobacco products and exposure to tobacco smoke”.
However, harm reduction per se is not defined and in its widest sense, could  
be interpreted as applying to any control intervention. Harm reduction has 
been neglected in subsequent position papers from the FCTC and in discussions 
at COP meetings. It is only recently, since the advent of smoking alternatives, 
that the WHO and the FCTC COP Secretariat has had to begin to consider safer 
nicotine products and initial discussion papers have been put onto the agenda 
at recent COPs.  
The arrival of e-cigarettes and later HNB devices comes after a global tobacco 
control ethos which sees an end to the use of all tobacco products and an end 
to the tobacco industry. It is not surprising then that WHO advisers have tried 
to fit SNP into this existing framework with the inclination to see all SNP as 
potentially problematic both for individual health, and also for the ambitions of 
tobacco control. The WHO has shown little inclination to acknowledge the role 
of SNP in trying to reduce the harm from smoking from a consumers’ point of 
view, using instead the precautionary principle to advise action regarding these 
products. The WHO suggests a range of regulatory actions that states might 
take, including bans.
“The WHO has shown little inclination to acknowledge the role of SNP in 
trying to reduce the harm from smoking from a consumers’ point of view”.
It would appear that the anti-tobacco sentiment was consequent to the 
involvement of major anti-tobacco NGOs. Gregory Jacob is a lawyer who was 
a member of the US delegation involved in negotiating the FCTC. He wrote a 
paper generally criticising the process, but noted especially the very influential 
role of (mainly US) NGOs in assisting government delegates, many of whom 
were inexperienced in international treaty law, coming as they did from health 
ministries. The WHO itself was not well versed in the standard procedures either, 
as this was a first for them too.15 The most active NGOs formed themselves into 
the FCA and since its formation, backed by US philanthropic funding, has helped 
the WHO implement the FCTC around the world, especially in LMIC where 
tobacco control has varied from being very weak to non-existent.16 This was a 
great coup for civil society, as NGOs are usually sidelined in international treaty 
meetings like the Commission on Narcotic Drugs, reduced mainly to providing 
information, giving short speeches at the discretion of the chair or holding fringe 
events of their own.
But perversely the effect of NGO involvement in international tobacco control 
has been counter-productive in terms of benefits to public health. It is these 
influential American NGOs who have been leading the fight the longest against 
the tobacco industry, and who see the advent of SNP as just another ploy to 
boost industry profits in the face of declining prevalence of smoking in the 
developed world.
“Perversely the effect of NGO involvement in international tobacco control has 
been counter-productive in terms of benefits to public health”.
The WHO, the FCTC and the tobacco industry
Wariness of the industry and its intentions is expressed formally, but in quite 
measured terms, in Article 5.3 of the Convention which states that “In setting and 
implementing their public health policies with respect to tobacco control, Parties 
shall act to protect these policies from commercial and other vested interests 
of the tobacco industry in accordance with national law”. These were the words 
that were agreed to by a consensus of the 193 governments drafting the treaty. 
Subsequently, however, during the less formal and legal negotiation of the FCTC 
Guidelines (in COP working groups of only a small number of governments 
together with NGOs), Article 5.3 was extrapolated to a set of Principles. While 
the FCTC text for 5.3 is legally binding and the FCTC Guidelines for 5.3 are 
not binding, NGOs and the WHO itself have pushed the 5.3 principles for 
interpretation to be the norm and they have become almost customary in terms 
of national interpretation and subsequent implementation. 
15 Jacob, G.(2004) Without reservation. Chicago Journal of International Law; 5 (1), Article 19
16 Sparks, M. (2010). Governance beyond governments: the role of NGOs in the implementation of the FCTC. 
Global Health Promotion. Supp (1), 2010, p. 67–72 
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The Guidelines applicable to Article 5.3 state these Principles:
“Principle 1: There is a fundamental and irreconcilable conflict between the 
tobacco industry’s interests and public health policy interests. The tobacco 
industry produces and promotes a product that has been proven scientifically 
to be addictive, to cause disease and death and to give rise to a variety of 
social ills, including increased poverty. Therefore, Parties should protect the 
formulation and implementation of public health policies for tobacco control 
from the tobacco industry to the greatest extent possible”. 
“Principle 2: Parties, when dealing with the tobacco industry or those working 
to further its interests, should be accountable and transparent. Parties should 
ensure that any interaction with the tobacco industry on matters related to 
tobacco control or public health is accountable and transparent”. 
“Principle 3: Parties should require the tobacco industry and those working 
to further its interests to operate and act in a manner that is accountable and 
transparent.  The tobacco industry should be required to provide Parties with 
information for effective implementation of these guidelines”.
“Principle 4: Because their products are lethal, the tobacco industry should 
not be granted incentives to establish or run their businesses. Any preferential 
treatment of the tobacco industry would be in conflict with tobacco control 
policy”. 
Two important points emerge from these principles and the eight 
recommendations that follow. The first is that these Guidelines are in urgent 
need of revising, as it is now clear that SNP are very far from ‘lethal’ or give 
rise to ‘a variety of social ills’. Second, all it requires of Member States is that 
their dealings with the industry are open, accountable and transparent. But this 
has been over-interpreted to mean that any and all kinds of interaction with 
industry personnel – simply holding meetings or being present at events where 
tobacco industry staff are present – is deemed to be in contravention of the 
FCTC. This extends to anybody – and not just Member State officials – 
 with any connection to the industry; they can be banned from attending  
the COP or international tobacco control meetings17 while complaints are 
lodged by NGOs and medical organisations if industry representatives are 
invited to speak to parliamentarians and other public bodies investigating  
the new products.18 
FCTC Article 5.3 seems increasingly problematic when tobacco companies 
manufacture SNP and spotlights the difficult relationship between UN bodies 
such as the WHO and manufacturers of products that contribute positively or 
negatively to individual and population health.
There is a paradox here: in 2014, the WHO published a report, Electronic 
nicotine delivery systems,  which states that public health authorities should 
prioritise research into ENDS, and to invest adequately to develop the evidence 
as soon as possible: “However, the greater responsibility to prove claims about 
ENDS scientifically should remain with the industry”.19 Yet this is problematic 
when industry scientists are denied conference platforms, when leading 
peer-reviewed journals will not accept their papers and where anybody who 
undertakes industry-funded research is  discredited.20
This is reiterated in the WHO’s Time to Deliver report on tackling non-
communicable diseases. In the section dealing with private sector relationships, 
the WHO encourages Member States to engage “constructively” with the private 
sector but specifically excludes the tobacco industry citing Article 5.3. Yet 
regarding alcohol, a major cause of global death and disease and the source 
of much domestic and community violence, governments are encouraged 
to work with the industry by encouraging “economic operators in the area of 
alcohol production and trade to consider ways in which they could contribute to 
reducing the harmful use of alcohol in their core areas”.21
However, there is evidence that antipathy towards tobacco harm reduction goes 
beyond even distrust of the industry. The direction of travel of international 
tobacco control, as expressed in the FCTC, is not just about controlling smoking, 
17 Health 24. Ex-WHO expert banned from tobacco conference after links to Marlboro (2018).   
https://m.health24.com/News/Public-Health/ex-who-expert-banned-from-tobacco-conference-after-links-to-
marlboro-maker-20180307
18 For example, The Australian Parliament Report on the inquiry into the use and marketing of electronic cigarettes 
and personal vaporisers in Australia (2018) 
19 World Health Organisation. Electronic nicotine delivery systems; report by WHO. WHO, 2014. FCTC/COP/6/10 – 
21 July 2014 Paragraph 35 p.10
20 Godlee, F. et al (2013). Journal policy on research funded by the tobacco industry. Thorax, British Medical Journal. 
Available at http://thorax.bmj.com/content/68/12/1090; and The Australian Parliament Report on the inquiry into 
the use and marketing of electronic cigarettes and personal vaporisers in Australia (2018)
21 World Health Organisation. Time to Deliver. WHO, 2018. p.23. Available at http://www.who.int/ncds/management/
time-to-deliver/en/
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or even just controlling tobacco, but a vision to eliminate non-medical nicotine 
use entirely.22
As far back as 1987, influential US tobacco control activist Stanton Glantz 
stated that the evidence for passive smoking meant reframing activism in terms 
of protecting others, “Rather than the rhetoric of protecting smokers from 
themselves or the cigarette companies”.23 In a paper published in Addiction, 
Hall and Kozlowski asserted that, “The policy goal of some US tobacco control 
advocates is the elimination of the recreational use of nicotine”.24  This was 
underscored by the 2014 WHO ENDS report which declared that “While 
medicinal use of nicotine is a public health option under the treaty, recreational 
use is not”,25 denying the possibility of a public health response to smoking 
that was not medicalised. Moreover, there is a definite sense that part of 
the antipathy towards tobacco harm reduction is that from the start it was a 
consumer-led grass roots public health intervention that circumvented the need 
for any involvement in the formal structures of public health itself.
“The direction of travel of international tobacco control…is a vision to 
eliminate non-medical nicotine use entirely”.
The lack of leadership demonstrated by the WHO in refusing to acknowledge 
the role of tobacco harm reduction in helping to deliver FCTC objectives to 
reduce smoking-related death and disease is likely to impact most on those 
countries least able to tackle rampant and growing cigarette consumption. But 
while the WHO does not support tobacco harm reduction, nor does it compel 
member states to regulate SNP, its stated opposition provides an easy ‘get out 
of jail free’ card for health ministries across the world to avoid devising the most 
appropriate national SNP policy.
The current global control landscape for e-cigarettes
Moving on from the FCTC as the most universal tobacco control measure, it may 
come as a surprise to both those in tobacco control and those advocating for 
tobacco harm reduction that at present most countries do not have any specific 
law regulation regarding e-cigarettes: 101 countries have no specific law on 
e-cigarettes. It is possible that if it came to a government or court decision, it 
might be that in some of these countries e-cigarettes would be found to be 
covered by tobacco control legislation. However, this has yet to be determined 
in many countries. This includes many LMIC, where it is likely that e-cigarettes are 
not yet available or are only used by a minority. 
At the other end of the spectrum there are 39 countries where the sale of 
e-cigarettes or nicotine liquids is banned. It is worth noting that rather like the 
failure of bans on recreational drugs to be effective, e-cigarettes are known 
to be available in at least 14 of these 39 countries. For example, e-cigarettes 
and nicotine are widely available and used in Australia. Some of the banning 
countries had pre-existing laws in which e-cigarettes and nicotine liquids were 
caught up – as again for example in Australia where the poisons regulations 
under the jurisdiction of the Therapeutic Goods Administration (TGA) prohibit 
the unauthorised sale, possession and use of nicotine (see box).
Several countries have a legal and regulatory framework for e-cigarettes, and 
this is generally a mix of a legal framework – often within the context of tobacco 
control legislation (as in the USA and Europe), plus product standards and 
legal or voluntary control over access to the products by young people. The 
most usual legislative route is to regard them as tobacco products, and/or as 
consumer products. 
In most jurisdictions manufacturers are only allowed to promote e-cigarettes as 
safer than cigarettes and as aids to quitting if they are registered as medicinal 
products, similar to the regulations governing nicotine replacement therapies. In 
ten countries there is provision for medically regulated products. 
Figure 6.1 
Global e-cigarette regulation as of July 2018 è
22 Kozlowski, L and Abrams, D. (2016) Obsolete tobacco control themes can be hazardous to public health: the need 
for updating views on absolute product risks and harm reduction. Public Health, 16: 432
23 Glantz, S. (1984) ‘Achieving a smoke-free society’ Circulation; 76, 750 1984, and Bayer, R and Colgrove, J. 
Children and bystanders first; the ethics and politics of tobacco control in the United States. In: Feldman, E and 
Bayer, R eds. Unfiltered: conflicts over tobacco policy and public health. Cambridge, Harvard University Press, 
2004, p.23
24 Hall, W and Kozlowski, L (2017). The diverging trajectories of cannabis and tobacco policies in the United States: 
reasons and possible implications. Addiction 113, p.595-601
25 World Health Organisation. Electronic delivery systems; report by WHO. WHO, 2014. FCTC/COP/6/10–21 July 
2014 Paragraph 35 p.14 
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Global e-cigarette
regulation as of
July 2018
101
14
62
59
41
39
Number of countries where
there is no specific law
covering e-cigarettes
Number of countries where, although banned
e-cigarettes are known to be widely available
Number of countries where
e-cigarettes are controlled as
a ‘tobacco product’
At least
countries have restrictions
on vaping in public areas
In at least countries there are age restrictions for purchasing
e-cigarettes. Ranging from 15 in Ivory Coast to 21 in Honduras
49
Number of the above countries
where in theory e-cigarettes can also be regulated as
a medicinal product, but no products are available.
Number of countries that ban the sale
of e-cigarettes and or nicotine liquids
Antigua and Barbuda, Argentina, Australia, Bahrain,
Bhutan, Brazil, Brunei, Cambodia, Colombia, East
Timor, Egypt, Ethiopia, Gambia, Indonesia, Japan,
Jordan, North Korea, Lebanon, Malaysia, Mauritius,
Mexico, Nepal, Nicaragua, Oman, Panama, Qatar,
Saudi Arabia, Seychelles, Singapore, Sri Lanka,
Suriname, Syria, Thailand, Turkmenistan, Uganda,
United Arab Emirates, Uruguay, Vatican City,
Venezuela
no information no law allowed banned
But the pharmaco-diligence bar for bringing a medicinal product to market is set 
far higher and is significantly more expensive than for tobacco products. With 
the possible exception of BAT’s VOKE inhaler (since discontinued),26 and the 
E-Voke inhaler27, no SNP devices have been granted a medical licence. 
Figure 6.2 
Global status of e-cigarettes
Source: see Figure 6.7
Because of the rapid development of e-cigarettes globally, the legal landscape 
is complex, as Ryan Kennedy and colleagues of the John Hopkins School of 
Public Health discovered when they conducted a review of global approaches 
to e-cigarette control. In 2017, they identified 68 countries that regulate 
26 Vaped, The only medically licensed e-cig axed by BAT (2018) https://www.totallywicked-eliquid.co.uk/vaped/the-
only-medically-licensed-e-cig-is-axed/
27 Vape Ranks, E-Voke Becomes First E-Cigarette to Be Awarded Medicine License in the UK (2016) http://vaperanks.
com/first-e-cigarette-to-be-awarded-medicine-license-in-the-uk-is-not-really-an-e-cigarette/ 
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e-cigarettes, of which “22 countries regulate e-cigarettes using existing 
regulations, 25 countries enacted new policies to include e-cigarettes; seven 
countries made amendments to existing regulations, 14 countries use  
a combination of new/amended and existing regulations [and] many countries 
regulate e-cigarettes using legislation not written for e-cigarettes”.28
Australia and the ban on nicotine29 
Australia has a strict regulatory environment for vaping with a complex mix 
of federal and state laws. The possession and use of nicotine for vaping is 
effectively banned under federal poisons regulation. The laws governing 
the sale, use in public places, age limits on sale, display and promotion of 
vaping products are managed by the states and territories and are generally 
covered under each state and territories’ tobacco control legislation. 
Australia Commonwealth regulation of nicotine
Medicines and poisons are listed in the Poisons Standard and are classified 
into Schedules which determine how they are regulated. Nicotine is  
a Schedule 7 ’dangerous poison’ (S7) which also includes arsenic, cyanide 
and strychnine, and it is therefore illegal to buy, possess or use nicotine for 
vaping without prescription from a registered Australian medical practitioner. 
Nicotine in tobacco for smoking and approved nicotine replacement 
products are specifically exempt and are freely available.
Australian states can make variations to the Poisons Standard and could 
legalise the sale and possession of nicotine e-liquid on an individual state 
basis. However, none have chosen to do so.
There are three main ways to legally access nicotine e-liquid, all requiring  
a prescription from a registered Australian medical practitioner:
1. Smokers can import nicotine from overseas under the Therapeutic Goods 
Administration (TGA) Personal Importation Scheme.30 Users can import 
three months’ supply at a time for personal use, up to a total of 15 months’ 
supply per year. 
2. An approved Australian compounding pharmacy can prepare nicotine 
liquid for individual patients, under the extemporaneous compounding 
exemption of the Therapeutic Goods Regulations 199031 (Item 6 of 
Schedule 5). This service is currently only available through Nicopharm,  
an e-cigarette company, which provides an online prescribing service 
which includes a nicotine prescription.
3. Use of a nicotine-containing product approved for therapeutic  
use by the medicines regulator, the TGA. There are currently no 
nicotine-containing e-cigarettes approved. The approval process  
is expensive, onerous and time-consuming and not feasible for most 
manufacturers. 
In reality, few vapers use these methods. Although it is legal to do so, very 
few Australian doctors will write prescriptions for nicotine due to the lack of 
official endorsement and knowledge about vaping.
Most users import nicotine illegally without a prescription, or purchase it 
from the unregulated black market. There are harsh penalties for possessing 
or using nicotine e-liquid, which vary from state to state, including jail 
sentences of up to two years and fines of up to AU$45,000. So far, no vapers 
have been convicted although the threat is clear and is advertised on 
some state government websites, for example, this notice appears on the 
Queensland state website:
“Under the Health (Drugs and Poisons) Regulation 1996 it is an offence for  
a person to manufacture, obtain, possess, prescribe, dispense, sell, 
advertise, use or destroy nicotine, unless the person is specifically 
authorised or holds an approval under the HDPR. This includes importing 
electronic cigarettes containing nicotine for personal or therapeutic 
use.  The maximum penalty is $9,108”.
It is not an offence to import nicotine e-liquid into Australia under the 
Customs (Prohibited Imports) Regulations 195632 and an import permit  
28 Kennedy, R.D et al (2017). Global approaches to regulating electronic cigarettes. Tobacco Control; 26, p.440–445
29 Text by Colin Mendelsohn, Associate Professor, School of Public Health and Community Medicine, University of 
New South Wales. Chairman, Australian Tobacco Harm Reduction Association. Available at www.athra.org.au
30 Therapeutic Goods Administration Personal Importation Scheme, Department of Health, Australian Government. 
Available at  https://www.tga.gov.au/personal-importation-scheme
31 Therapeutic Goods Regulations 1990. Federal Register of Legislation, Australian Government . Available at 
https://www.legislation.gov.au/Details/F2017C00528
32 Federal Register of Legislation, Australian Government. Customs (Prohibited Imports) Regulations. Available at 
https://www.legislation.gov.au/Details/F2016C00795 
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is not required. However, it is an offence to take possession of it, unless  
a prescription is held and the TGA Personal Importation Scheme criteria are 
met.
State and territory regulation
Legislation varies from state to state. Generally, vaping is managed under 
tobacco control laws rather than consumer legislation. There are currently 
no regulations for vaping in South Australia (although a Bill is before the 
Parliament) or the Northern Territory. As well as the state and territory 
governments, the Australian Competition and Consumer Commission 
(ACCC) has a role in regulating the marketing of vaping devices and product 
safety:
» Sale of vaporisers 
Sale of vaping devices is legal in all states and territories except Western 
Australia where a retailer was prosecuted for selling nicotine-free vaping 
devices online in 2014 (upheld on appeal in 2016) on the basis that they 
resemble tobacco products. Sale to minors is an offence in most states. 
Products must not make a therapeutic claim, such as ‘this product will help 
you quit or reduce smoking’ unless approved by the TGA (see above).
» Vaping in smoke-free areas 
Banned in Victoria, Queensland, Tasmania and the Australian Capital 
Territory (ACT) but allowed in New South Wales (NSW), South Australia, 
Western Australia and the Northern Territory. NSW currently has a Bill 
before the Parliament to ban vaping in smoke-free areas.
» Advertising of vaping products 
Banned in Victoria, Queensland, Tasmania and the ACT. 
» Retail display, free samples, sponsorship or shopper loyalty programmes 
Banned in NSW, Victoria, Queensland, Tasmania and the ACT.
» Vaping in cars with minors present 
Banned in NSW and Victoria (<18 years); Queensland and ACT (<16 years); 
Tasmania (any age).
» Sampling e-liquids in stores 
Banned in Victoria.
This is just an idea of how mixed the picture is. Each state has its own 
particular regulations.33
Country approaches to e-cigarette regulation – snapshots from around the world
Brazil: E-cigarettes cannot be sold in Brazil. According to Resolution 46 
issued from the National Health Surveillance Agency, if they are presented 
as smoking cessation devices, toxicology reports and scientific proof of the 
health and environmental effects are required in order to obtain a licence. 
However, no detailed process is in place for obtaining a licence. Vapers 
buy online as they do in other countries where they are banned such as 
Argentina and Uruguay.
Chile: Nicotine-containing e-liquid cannot be sold without a pharmaceutical 
licence.
Canada: The Canadian federal government legalised vaping on May 23, 2018 
with the introduction of the Tobacco and Vaping Products Act (TVPA). The law 
regulates tobacco products as well as now providing a legal framework for 
adults to legally obtain vaping products with nicotine as a less harmful option 
than smoking. There are four separate laws that govern vaping products. 
The TVPA governs how vape products are to be sold, produced, labelled, 
and promoted. This new Act will continue to govern tobacco products but 
adds the new dimension to cover vaping products. Youth appeal and access 
restrictions form a significant part of the new law – sales are not to be permit-
ted to under 18s and flavours that may appeal to youth are to be restricted.  
E-cigarettes that make a health claim will need to be approved by Health 
Canada and will be regulated by the Food and Drugs Act (FDA), and 
this includes e-cigarettes imported into Canada. The Canada Consumer 
Product Safety Act (CCPSA) will govern all e-cigarettes that do not make 
a health claim classified as consumer products. The CCPSA regulates 
ingredients, health warning labels, packaging as well as all health and safety 
requirements. In addition, vaping liquids are to be subject to the existing 
Consumer Chemicals and Containers Regulations, 2001 (CCCR, 2001) which 
include provisions for labelling and child resistance.
33 Sydney Vape Co, Australian Vaping Laws https://sydneyvapeco.com.au/blogs/news/australian-nicotine-laws
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The Non-smokers Health Act (NSHA) addresses second-hand smoke and 
vapor. This Act applies to federally regulated workplaces, including banks, 
ferries, aircraft and government offices. There are also new provincial, 
territorial, and municipal laws to regulate vaping products and their use. 
The government has established a scientific advisory board to review science 
on vaping products and provide evidence on a regulatory basis to ensure 
legislations remain current and applicable. 
Georgia: Adopted comprehensive restrictions and bans for the marketing, 
sale, labelling and public use of cigarettes, which also apply to vaping and 
heated tobacco products.
Hong Kong: Nicotine is classified as a ‘poison’ under the Pharmacy and 
Poisons Ordinance. E-cigarettes with nicotine are considered pharmaceutical 
products, which are required to be registered with the Department of Health.
Japan: E-cigarettes and e-liquids with nicotine cannot be sold in Japan 
without a pharmaceutical licence; however, limited imports for personal use 
are allowed. HNB products are available and not subject to advertising and 
marketing restrictions.
Malaysia: The manufacture, distribution or sale of nicotine-containing 
e-cigarettes and e-liquids requires a pharmaceutical or medical licence. 
Non-nicotine e-cigarettes and e-liquids are treated as consumer products. 
Products are widely available.
Mexico: The Federal Commission for the Protection Against Health 
Risks (COFEPRIS), part of the Health Ministry, has an obligation to seize 
e-cigarettes because they are considered to be under the scope of article 
16 of the Mexican Tobacco Control Act which forbids the sale of any product 
that resembles tobacco, but is not tobacco. The Mexican Supreme Court 
declared Article 16 of the Tobacco Control Act unconstitutional for being 
disproportionate against e-cigarettes. But decisions only apply to this case, 
and only the e-cigarette retailer that appealed will benefit from this decision 
and is now authorised to sell e-cigarettes.
New Zealand: E-cigarette and HNB products can be legally imported and 
sold in New Zealand under the Smoke-free Environments Act 1990. All the 
requirements of the Act also apply to vaping and heated tobacco products, 
including banning advertising these products and making it illegal to sell them 
to young people under the age of 18. The smoking ban in indoor workpla-
ces only applies to smoked tobacco and does not apply to vaping or other 
products that are not smoked. Individual employers and business owners can 
decide whether they want to include vaping in their smoke-free policies.
Singapore: Banned all new tobacco and nicotine products in 2015 – this 
applies to e-cigarettes, HNB products, smokeless tobacco products and any 
other new alternatives to cigarettes.
Turkey: A licence is required to sell nicotine-containing e-cigarettes in Turkey. 
This measure, while not strictly outlawing retail sale of e-cigarettes, has made 
it virtually impossible to sell e-cigarettes legally. The government recently 
decided not to allow the importation of HNB products (and e-cigarettes).
Tobacco harm reduction and e-cigarettes in India34
India is one of the fastest growing large economies of the world, is the 
second most populous country, and 65% of its over 1.34 billion strong 
population is under the age of 35 years. Two thirds of the population are 
rural, agrarian, economically marginalised and educationally weak. All this 
makes the Indian population highly vulnerable to tobacco use, not least 
because India is the second largest cultivator of tobacco in the world.
Besides having about 12 percent of the world’s cigarette smokers, large 
sections of the Indian population smoke tobacco in its alternative or local 
forms (e.g., bidis, hookah, chilam, etc.) or chewing it in the form of smokeless 
tobacco such as khaini, zarda, gutkha, etc. 
In addition, a large section of the population chew areca nut in various forms 
(e.g., supari, kwai, tambul, betel quid, paan masala, mouth-fresheners, etc.). 
The alkaloids, tannins, polyphenols of areca nuts, alone or in combination 
with other additives, potentially form ultimate carcinogens in the body 
and have been strongly associated with high incidence of oral and 
gastrointestinal cancers in India. 
34 Text provided by Professor R Sharan, of the North-Eastern Hill University
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These products are relatively inexpensive, minimally regulated, produced 
in home and small industrial set ups and are widely available in convenient, 
small, single-use packaging. Further complicating this situation is that there 
are ‘mixed’ users who chew areca nut products, chew or smoke other forms 
of tobacco and smoke cigarettes. India’s complex usage pattern have roots 
in its prevailing cultural ethos and diversity, agrarian orientation, and socio-
economic inequalities, as well as in its political prudence.  Similar patterns of 
diverse tobacco usage prevail in other regional LMIC especially Indonesia, 
Thailand, Sri Lanka, Pakistan, Bangladesh and Afghanistan. 
The idea of tobacco harm reduction is hardly developed at all in India, 
especially among the disadvantaged and most vulnerable sections of the 
population, who are at the same time the highest at-risk group for tobacco-
related death and disease.
This is not helped by the legislative climate surrounding e-cigarettes. Currently, 
they are banned in six provinces of India. Punjab was the first to do so in 2015 
followed by Karnataka (2016), Mizoram (2016), Kerala (2017), Jammu and 
Kashmir (2017) and Bihar (2018). Maharashtra and Delhi are also considering 
bans. In addition, the central government is considering a ban on e-cigarettes 
and has recently filed an affidavit in the Delhi High Court to this effect.35
“The idea of tobacco harm reduction is hardly developed at all in India, 
especially among the disadvantaged and most vulnerable sections of 
the population, who are at the same time the highest at-risk group for 
tobacco-related death and disease”.
Professor Sharan, of the North-Eastern Hill University considers that different 
SNP should be made available to suit different economic, educational and 
cultural backgrounds. For example, while e-cigarettes or HNB products can 
help consumers using all forms of tobacco, a smokeless oral product such 
as Swedish snus might be more effective and appropriate for masticators 
and chewers of the more dangerous smokeless forms currently used. An 
appropriate regulatory framework for all such products, strict enforcement of 
quality standards, and affordability would be essential components to bring 
about a successful penetration of these alternatives into the tobacco using 
population. Simultaneously, he says for this report, ”we need to speedily 
initiate and strengthen scientific endeavours to develop new safer products 
that are relevant to the world’s poorer populations in order to ensure that 
solutions to this problem are truly global”. 
Regulation of Swedish snus
The EU stands out prominently as the only region to have a comprehensive ban 
on the sale of snus, which was implemented in 1992 and then incorporated into 
subsequent Tobacco Products Directives (TPD). 
Figure 6.3 
Global status of snus
Source: see Figure 6.8
35 Deccan Herald, Considering ban on e-cigarettes, Centre tells HC (2018) https://www.deccanherald.com/national/
considering-ban-e-cigarettes-centre-tells-hc-666088.html
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The UK started the ban when, in 1989, it outlawed oral snuff in response to the 
introduction of ‘Skoal Bandits’. When the first TPD was drafted, the EU legislators 
included a ban on snus as part of market harmonisation, in that three EU 
countries had implemented a ban, and the ‘market harmonisation’ reasons were 
used to enforce this across all EU countries:
» 1992, EU Directive 92/41 banned sales of snus;
» 1995, on accession to the EU, Sweden obtained an exemption;
» 2001, EU Tobacco Products Directive continued the ban;
» 2014, EU Tobacco Products Directive continued the ban.
The wording in the TPD is carefully constructed so that it does not apply to snuff, 
or to chewing tobaccos such as South Asian tobaccos: 
“No person may produce or supply tobacco for oral use. 
Tobacco for oral use is:
A tobacco product which is – 
(a) intended for oral use, unless it is intended to be inhaled or chewed; and 
(b) in powder or particulate form or any combination of these forms, whether 
presented in a sachet portion or a porous sachet, or in any other way”.
The sale of snus is allowed in 79 countries in total and banned in 39 countries 
including the EU 28. The sale of snus is allowed in the non-EU Norway and 
although officially banned in Iceland, Icelanders import a slightly different 
’cut’ of what is officially known as ’nasal tobacco’. This is used either in a small 
lump under the lip or made into a snus-like parcel using separate paper like 
the Swedish snus packaging. Despite being much less harmful than cigarettes 
this Icelandic ’snus’ is taxed at the same level and the tax level has increased 
over the last eight years (over 140%). The same rules apply as for cigarettes – 
age restricted sales (18+), no advertising, health warnings on packets, and no 
claims of health benefits such as help quitting cigarettes. Notwithstanding the 
restrictions, snus sales have increased by 330% since 2001.36
Figure 6.8 shows for each country whether snus is allowed, banned or whether 
there is no specific legislation. However, as will be seen even in countries where 
its sale is banned, importation for personal use is often not banned. 
Figure 6.8 shows 31 countries where the use of snus is legal, even where its sale 
is banned. In most countries where import for commercial purposes is banned, 
importation for personal use is allowed. Online forums also indicate that people 
often import snus for personal use, although in some cases incur tax or duty 
charges where these are intercepted at customs.
Information about the specific legal regulation of snus is sparse, however two 
countries where reasonably detailed information has been gathered are Israel 
and Norway. In Israel snus can be imported commercially and advertised fairly 
freely, however, health claims are not allowed and health warnings are required 
on the packaging. There is no restriction on nicotine content or the flavours 
available and snus is taxed at the general taxation rate.
In Norway importation and online sales are allowed, however, advertising is 
restricted. Health claims are not allowed and health warnings are required. 
Authorities have to be notified of new products on the market and tax rates are 
lower than other tobacco products.
On 31 May 2018, New Zealand permitted the online sale of snus and removed 
its earlier ban as part of its aims to be smoke-free by 2025,37 although the exact 
details of the hew legislation await clarification. 
HNB regulation
HNB products are available in more than 37 countries, including Japan, Korea, 
New Zealand, Italy, Portugal, Switzerland, Spain, Ukraine, Russia, the United 
Kingdom, Guatemala, Colombia, and South Africa. Many of these countries,  
and others, regulate these products differently than cigarettes and other 
combustible tobacco products. 
European Union
In the EU, these products are regulated as novel smokeless tobacco products 
under Article 19 of the European Union TPD.38 Article 19 establishes a separate 
regulatory category for novel tobacco products that do not fall within the 
tobacco product categories as defined in Article 2. Novel tobacco products can 
36 Personal communication, Dr Karl Snaebjornsson. 
37 Ministry of Health. Vaping, smokeless, including heated tobacco. New Zealand Government, 2018. Available at 
https://www.health.govt.nz/our-work/preventative-health-wellness/tobacco-control/vaping-smokeless-including-
heated-tobacco
38 Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014. Available at  
https://ec.europa.eu/health/sites/health/files/tobacco/docs/dir_201440_en.pdf
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either be products for smoking or smokeless; the key differentiator being the 
presence or absence of combustion. However, the electronic part of an HNB 
device is not subject to regulation under the TPD.
In addition to receiving a separate regulatory category under the TPD, HNB 
products are also regulated differently than combustible tobacco products. For 
example, health warnings for these products are different from those required 
for cigarettes, both in terms of size and content. Other elements in the TPD also 
treat these products differently, such as the use of additives and ingredients 
necessary to produce products that operate differently from combustible 
cigarettes. 
Under the TPD, Member States must establish a system of notification or autho-
risation, with which manufacturers must comply before placing a product on the 
market, consisting of available scientific studies on a number of topics and other 
available and relevant information, such as risk/benefit analysis of the product. 
Italy
In Italy, regulators have developed a regulatory scheme39 that authorises 
manufacturers to communicate information about product toxicity. The 
ministerial decree defines the rules and procedures whereby research is 
submitted by a manufacturer and is evaluated by government “In order to 
recognise the reduction of toxic components and the potential risk reduction of 
novel tobacco products, compared to combustible tobacco products”.
Japan
In Japan, heated tobacco is regulated as pipe tobacco. Mandatory health 
warnings relate to addiction, smoking, smoking-related diseases, the risks of 
smoking during pregnancy, and the health effects of second-hand smoke. 
These warnings do not differentiate between combustible and non-combustible 
products. Point of sale advertising is allowed. Regarding indoor use, legislation 
states that managers of indoor spaces must try to prevent second-hand smoke but 
there are no penalties for non-compliance.40 Amendments have been proposed to 
allow the use of heated tobacco in areas where smoking is prohibited.41
Switzerland
Switzerland follows an approach similar to the EU TPD with respect to health 
warnings. HNB products are sold with different and smaller health warnings than 
those required for cigarettes. Furthermore, cigarettes must bear graphic health 
warnings, whereas HNB products do not. Indoor public use of HNB products is 
not prohibited in the same way it is for cigarettes, but is left to the discretion of 
the owner or manager of the premises. 
Russia
The Russian Tobacco Technical Regulation Law does not contain any specific 
provisions regulating HNB products and devices, only general consumer goods 
39 Gazzetta Ufficiale Della Repubblica Italiana, Ministero Della Salute (2017). Available at  
http://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario;jsessionid=kpWuzjXuemHEWj9L
C7yjnA__.ntc-as5-guri2a?atto.dataPubblicazioneGazzetta=2017-08-12&atto.codiceRedazionale=17A05676&elen
co30giorni=true
40 Feldman, E.A. (2018) IQOS, E-Cigarettes, and Tobacco Control, Harm Reduction the Japanese Way. Available at 
https://www.e-cigarette-summit.us.com/files/2018/05/Eric-Feldman.pdf
41 Feldman, E.A. (2018) IQOS, E-Cigarettes, and Tobacco Control, Harm Reduction the Japanese Way. Available at 
https://www.e-cigarette-summit.us.com/files/2018/05/Eric-Feldman.pdf
Figure 6.4 
Countries where HNB products are sold
Source: Philip Morris International website. Available at: https://www.pmi.com/smoke-free-products/iqos-our-
-tobacco-heating-system
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regulations are applied to them. A specific standard, known as the National 
Standard GOST R 57458-2017 Heated Tobacco Technical Specifications, 
has been established for HNB. Although voluntary, the standard establishes 
definitions for HNB products and sets basic design and performance 
requirements that differentiate the category from combustible tobacco products, 
including the maximum permissible CO yield (0.3 mg per 100 cm3 of aerosol) 
as the criteria to determine absence of combustion. The standard also 
introduces packaging and labelling requirements, including health warning 
requirements.
Ukraine
In Ukraine, HNB products are generally not subject to the same regulations as 
cigarettes. For example, there is no specific health warning for HNB products, 
and the only product on the market today voluntarily applies the EU TPD novel 
smokeless tobacco product health warning.
New Zealand
In December 2016, PMI started sales of IQOS in New Zealand and was taken to 
court by the New Zealand Ministry of Health in May 2017. The Ministry argued 
that the tobacco plug used with IQOS, known as HEETS, is a smokeless tobacco 
product and therefore, banned under the Smoke-free Environments Act 1990 
(SFEA), which provides: “No person shall import for sale, sell, pack, or distribute 
any tobacco product labelled or otherwise described as suitable for chewing, or 
for any other oral use (other than smoking)”. In March 2018, the District Court of 
Wellington dismissed the charge brought by the Ministry.
Among other things, the Court considered an independent assessment 
conducted at the request of the Ministry, aimed to determine whether 
combustion occurs when IQOS is operated. Ultimately, the report concluded: 
“Based on the literature surveyed and the analytical results of the investigation it 
is my opinion that no combustion is taking place during normal operation of the 
IQOS system”.  
The Ministry decided not to appeal the court decision and said that whilst 
HNB and other reduced-harm products are subject to the Act’s controls on 
advertising, they are not subject to the ban on indoor use in workplaces and that 
this would be up to individual property owners to decide. 
Following the case, the NZ Ministry clarified the legal position:42
“Therefore, the same SFEA regulatory controls apply to smoked tobacco, 
heated tobacco and vaping products that are manufactured from tobacco. This 
includes the ban on sales to minors and restrictions on advertising. 
The ban on smoking in indoor workplaces, early childhood centres and schools 
only applies to smoking. It does not apply to vaping or products that are not 
smoked, such as heated tobacco products. Individual employers and business 
owners decide whether or not to include vaping in their smoke-free policies.
The Ministry of Health is considering how best to apply risk-proportionate 
regulation across all tobacco products including smoked tobacco, smokeless 
tobacco and vaping products. 
Until the SFEA is amended, retailers should continue to trade responsibly and, 
in particular, not to advertise or sell vaping products to children and young 
people under 18 years of age.
Consumers of vaping products should not notice any difference as nicotine 
vaping liquid has been available for purchase in retail shops for some time. 
Heated tobacco products might also become available for sale in New Zealand”.
United Kingdom
Regulation of HNB products is covered by the EU TPD. For HNB products, UK law 
does not require the same plain packaging with graphic health warnings as it 
does for cigarettes. Regarding indoor use, e-cigarettes and HNB are considered 
smoke-free products. In practice this means that as elsewhere, allowing indoor 
use of HNB is at the discretion of premises owners. 
United States
On 28th July, 2017, the US Food and Drug Administration (FDA) announced  
a comprehensive regulatory plan for tobacco and nicotine-containing products. 
The plan will apply risk-based product-specific regulation – increasing 
restrictions on the riskiest forms of nicotine delivery (cigarettes) and allowing 
“greater flexibility” for non-combustible products. 
On January 24th-25th, 2018, the Tobacco Products Scientific Advisory 
Committee (TPSAC) discussed PMI’s IQOS Modified Risk Tobacco Product 
42 Ministry of Health. Vaping, smokeless, including heated tobacco. New Zealand Government, 2018. Available at 
https://www.health.govt.nz/our-work/preventative-health-wellness/tobacco-control/vaping-smokeless-including-
heated-tobacco 
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(MRTP) applications. The TPSAC is a body established by the US Tobacco Control 
Act (see below), comprised of nine public health experts and three non-voting 
tobacco industry representatives, appointed by the Commissioner of the FDA to 
provide nonbinding recommendations to FDA on tobacco matters from a public 
health perspective. TPSAC voted eight to one that IQOS “Significantly reduces  
a person’s exposure to harmful or potentially harmful chemicals”.
* * *
Having considered the FCTC to which most countries in the world are 
signatories, nevertheless as we have seen, every country handles the challenge 
of regulating SNP differently. By any metric, the two largest SNP markets in the 
world are the USA and the 28 countries that collectively make up the European 
Union. Both markets have their own comprehensive tobacco regimes. So for 
this final section we look at the history and development of the regulatory 
frameworks of these two jurisdictions. This is not to endorse the approach of 
either of  these two regimes, but rather to highlight the complexities, and some 
of the consequences of these two very different regulatory models. 
Overview of USA Federal and State 
law relating to SNP
Background
In 1938, Congress passed the Federal Food, Drug and Cosmetic Act (FDCA) under 
the jurisdiction of the FDA. The FDCA covered a range of provisions aimed at 
consumer safety including food colouring and additives, cosmetics and medical 
devices. There were no provisions in the FDCA for the FDA to have jurisdiction 
over tobacco products, save for issues around import and export. Traditionally 
the US Bureau of Alcohol, Tobacco, Firearms and Explosives was responsible for 
enforcing laws against any criminal activities involving tobacco, such as smuggling, 
while the Federal Communications Commission had jurisdiction over tobacco 
broadcast advertising. Federal tobacco control was housed at the Center for 
Disease Control and Prevention (CDC) Office on Smoking and Health (OSH) which 
is responsible for convening the Interagency Committee on Smoking where no 
less than eleven Federal agencies and institutions are involved, including the FDA.
In 1995 the FDA decided that it did have overall jurisdiction over tobacco 
products insofar as nicotine was a ‘drug’ and the cigarette was a ‘drug delivery 
system’, and so fell under the provisions of the FDCA. The tobacco company 
Brown & Williamson challenged the FDA on this and won on the grounds that 
the FDA had never tried to claim jurisdiction before and that it was never the 
intention of Congress back in 1938 to grant it this power. The judgement was 
handed down in 2000, but it kick-started a process which led to the Family 
Smoking Prevention and Tobacco Control Act 2009, which finally gave the FDA 
the legislative power to regulate tobacco that it had been seeking.
Federal law43
The FDA has long held the authority to regulate nicotine replacement therapies 
such as gum, patch, and lozenges through the Center for Drug Evaluation and 
Research (CDER). In 2009, with the passage of the Family Prevention Smoking 
and Tobacco Control Act,44 the FDA gained the authority to regulate tobacco 
products and marketing for cigarettes, cigarette tobacco, roll-your-own tobacco, 
and smokeless tobacco. On May 10, 2016, the FDA published a final ‘deeming 
rule’ allowing the agency to begin regulating all tobacco products, including 
cigars, pipe tobacco, waterpipes (or hookahs), dissolvable products, e-cigarettes, 
and other electronic nicotine delivery systems.45
The deeming rule requires that any new product (any tobacco product not 
commercially marketed in the US as of February 15, 2007) must go through 
a Pre-Market Tobacco Application (PMTA) process to stay on the market (the 
deadline to submit a PMTA is August 8, 2022 for non-combustible products and 
August 8, 2021 for combustible products), and a Modified Risk Tobacco Product 
Application (MRTPA) in order to make any health claims about relative risk 
compared to continuing to smoke cigarettes.46 
Products that have been subjected to small changes from the original 
“grandfathered product” (products on the market before February 15, 2007) 
must submit a Substantial Equivalence Report (SE) or an Abbreviated SE report 
43 Text for the US section provided by Amy Arthur of Pinney Associates.
44 Govtrack, H.R. 1256 (111th): Family Smoking Prevention and Tobacco Control Act, 2009. Available at  
https://www.govtrack.us/congress/bills/111/hr1256/summary#libraryofcongress
45 Federal Register, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as 
Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution  
of Tobacco Products and Required Warning Statements for Tobacco Products, 2016. Available at
 https://www.federalregister.gov/documents/2016/05/10/2016-10685/deeming-tobacco-products-to-be-subject-
to-the-federal-food-drug-and-cosmetic-act-as-amended-by-the
46 Food and Drug Administration, Pipe, Cigar, and Vape Shops that Are Regulated as Both Retailers and 
Manufacturers. Available at https://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/
ucm514606.htm 
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so the product can stay on the market without a PMTA. (See Figure 6.547 for all 
the pathways a nicotine containing product can take to get to market).
The PMTA pathway requires that the applicant proves that the product would be 
appropriate for the protection of the public health. The statute does not define 
that standard further. The FDA has released draft guidance documents, however, 
at the time of writing, none of them have been finalised meaning that they are 
not enforceable and the agency can change them at any time. To date, only eight 
PMTA orders have been granted for Swedish Match’s General Snus products.48 
Figure 6.5 
Center for Tobacco Products (CTP) map49 50
There are two types of MRTPA orders. The Risk-Modification standard requires that 
the product significantly reduces the harm and risk of tobacco-related disease to 
individual tobacco users, and benefits the health of the population as a whole. The 
Exposure-Modification order asks applicants to prove that the “Reduction in expo-
sure to substance is substantial, substance is harmful, and the product as actually 
used exposes consumers to a specified reduced level of the substance”. As manu-
facturers seek to understand how to navigate proving this, an extensive and costly 
application is necessary. To date, no MRTPA order has been issued.51 
The deeming rule extends several provisions of the federal Tobacco Control Act to 
these new tobacco products. For example, these products are now subject to the 
federal prohibition on sales to minors, the federal prohibition on free sampling, fe-
deral warning label requirements, and the requirement that tobacco manufacturers 
register with the FDA and seek the agency’s review of new tobacco products. 
In July, 2017, the FDA announced a new, comprehensive regulatory framework 
aimed at further reducing tobacco-related disease and death in the US. The plan 
has two major objectives: 
1. To reduce the nicotine levels in combustible cigarettes and other tobacco 
products to levels that minimise their addictiveness – known as Very Low 
Nicotine Cigarettes – or VLNC, and;
2. To encourage the development and broader use of innovative nicotine 
replacement products that can help more smokers quit.52
The FDA’s new tobacco strategy has two primary parts: reducing the addicti-
veness of combustible cigarettes while recognizing and clarifying the role that 
potentially less harmful tobacco products could play in improving public health.
Scott Gottlieb and Mitch Zeller (2017)53
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47 Figure originally presented by Dr. Michael Hufford at FDLI’s Introduction to US Tobacco Law and Regulation 
workshop in 2017. Available at https://www.fdli.org/2018/10/introduction-u-s-tobacco-law-regulation-2/
48 Food and Drug Administration, Tobacco Product Marketing Orders  https://www.fda.gov/TobaccoProducts/
Labeling/TobaccoProductReviewEvaluation/ucm339928.htm#1 
49 The CTP is the Center for Tobacco Products which oversees the implementation of the Family Smoking Prevention 
and Tobacco Control Act. Some of the Agency’s responsibilities under the law include setting performance 
standards, reviewing premarket applications for new and modified risk tobacco products, requiring new warning 
labels, and establishing and enforcing advertising and promotion restrictions.
 The TPSAC is the Tobacco Products Scientific Advisory Committee who review and evaluate safety, 
dependence, and health issues relating to tobacco products and provides appropriate advice, information and 
recommendations to the Commissioner of Food and Drugs.
50 The Center for Drug Evaluation and Research is a division of the U.S. Food and Drug Administration (FDA) 
that monitors most drugs as defined in the Food, Drug, and Cosmetic Act. Some biological products are also 
legally considered drugs, but they are covered by the Center for Biologics Evaluation and Research. The Center 
reviews applications for brand name, generic, and over the counter pharmaceuticals, manages US current Good 
Manufacturing Practice (cGMP) regulations for pharmaceutical manufacturing, determines which medications 
require a medical prescription, monitors advertising of approved medications, and collects and analyses safety 
data about pharmaceuticals that are already on the market.
51 Food and Drug Administration, Modified Risk Tobacco Products https://www.fda.gov/TobaccoProducts/Labeling/
TobaccoProductReviewEvaluation/ucm304465.htm#4
52 Food and Drug Administration. Protecting American Families: Comprehensive Approach to Nicotine and 
Tobacco. Speech by Scott Gottlieb, M.D., Commissioner of the FDA, July 28th 2017. Available at  https://www.
fda.gov/NewsEvents/Speeches/ucm569024.htm?utm_source=CTPPartnerTwitter&utm_medium=social&utm_
term=gov&utm_content=speech&utm_campaign=ctp-728regplan
53 Gottlieb, S. and Zeller, M. (2017) A Nicotine-Focused Framework for Public Health. New England Journal of 
Medicine 2017; 377:1111-1114. Available at www.nejm.org/doi/full/10.1056/NEJMp1707409
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The FDA approach to SNP created a raft of critical media comment and opinion 
which focused on the premise that to over-regulate SNP was not only counter-
productive in health terms but would benefit the major tobacco companies, not 
only by protecting cigarette businesses but also through the onerous licensing 
and testing requirements, which would mean that compliance would only be 
possible for the major tobacco companies with large resources.54
US state and local regulation
The deeming rule makes clear that state and local governments can continue 
to adopt and enforce laws relating to tobacco product sales, use, distribution, 
and advertising (within constitutional limitations). These state and local laws 
can be “In addition to, or more stringent, than, the requirements of the Tobacco 
Control Act and its implementing regulations”. States and localities have taken 
many different approaches in terms of bans, taxation, restriction, purchase age, 
and other regulations, which all adds to the legislative confusion over SNP in the 
USA. Readers are referred to the Public Health Law Center overview of state and 
local regulations cited below with the obvious caveat that the laws are in  
a seemingly constant state of flux. For example, San Francisco recently voted for 
a ban on flavoured tobacco products including e-liquids.55  
European Union Tobacco Control Directive (TPD)
The TPD is a Directive of the EU which means that all EU countries must 
‘transpose’ or incorporate the TPD requirements into their national laws. The 
only flexibility permitted is the ability to enact additional regulations. The current 
Directive entered into force on 19th May 2014 and became applicable in the EU 
Member States on 20th May 2016.
Figure 6.6 
The European Union (EU) Tobacco Products Directive (TPD) 
2016 changes to the EU TPD  è
Figure adapted from https://ec.europa.eu/health/tobacco/products_en
54 For example, Fortune, Feds cracked down on e-cigarettes, vaping industry (2016) http://fortune.com/2016/05/05/
fda-e-cigarettes-cigar-tobacco/; and National Review, Promote health by not defending the e-cigarette ban (2017) 
https://www.nationalreview.com/2017/05/cigarette-smoking-vaping-ban-bad/
55 Park, M. and Selig, R. (2018) San Francisco bans sales of flavoured tobacco products, CNN. Available  
at https://edition.cnn.com/2018/06/06/health/san-francisco-flavored-cigarettes-proposition-e/index.html
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Background
The EU has been active in tobacco control policy since 1985 when the Milan 
Council announced its intention to establish a Europe Against Cancer (EAC) 
Programme, although the EU had previously adopted several Directives on 
aspects of tobacco taxation. Shortly after the adoption of the EAC’s first action 
plan, the European Commission presented its first legislative proposals on 
tobacco control. The proposals on labelling became Directives by 1992, and the 
proposal on tobacco advertising became law in 1998. 
In 1996 the Commission published a Communication on the future of EU to-
bacco control and in 1999 at the second European Conference on Tobacco and 
Health, the Social Affairs Commissioner announced his intention to bring forward 
further legislative proposals to amend and consolidate existing EU legislation 
in this sector.56 This led eventually to the Directive on Tobacco Products (2001), 
the first major European legislation specifically related to tobacco products. The 
Directive required manufacturers to put health warnings on tobacco products; 
banned the use of descriptive terms such as ‘light’, ‘mild’ or ‘low tar’; forced 
producers to provide full information on all ingredients utilised in their products, 
and set maximum limits for nicotine and carbon monoxide in cigarettes.
The Directive on Tobacco Advertising (2003) banned cross-border advertising 
of tobacco products in printed media, radio and on-line services and banned 
sponsorship of cross border events if it had the effect of promoting tobacco 
products. Tobacco advertising and sponsorship on television was already 
prohibited since 1989.
The first attack on what turned out to be a significant tobacco harm reduction 
product was the EU wide ban on the sale of snus in 1992 as a response to the 
attempt in the UK to introduce Skoal Bandits oral tobacco from the USA.57 
Directive 2001/37/EC reaffirmed that prohibition, but Sweden was exempted 
by Article 51 of the European Act of Accession because snus was in widespread 
use in Sweden and the ban was introduced before Sweden joined the EU. Only 
a narrow majority of Swedes supported their country’s accession to the EU and 
there was a strong request to be excluded from the snus ban.
However, in Commission reports from 2005 and 2007, new areas were identified 
“In which further action was considered useful for the ‘smooth functioning 
of the internal market’”.58 The preamble to the 2014 TPD noted “Substantial 
differences” in the way member states dealt with “Tobacco and related products” 
and “In the light of scientific, market and international developments, these 
discrepancies are expected to increase”. These ‘discrepancies’ also extended in 
the Commissions’ remit to include e-cigarettes.
As the sale of e-cigarettes was growing throughout the EU, member states were 
seeking advice and clarification from the Commission. In May 2008 an Orienta-
tion Note from the Commission Directorate in charge of Health and Consumer 
Protection suggested that an e-cigarette which did not contain nicotine was not 
a tobacco product but could be regarded as a medicinal product. 
In 2010, the consultants Rand Europe produced a massive 345-page report on 
the impact of revising the 2001 Directive. The report made few references to 
e-cigarettes other than to point out that very little was known about any aspect 
of their use, manufacture or health effects and outlined regulatory options of 
harmonising regulation as tobacco products, pharmaceutical products or simply 
banning them altogether.59
In 2012, the Health and Consumer Directorate produced a proposal for the 
revision of the TPD in which, under Article 18, products with a nicotine content 
over a certain level – including most e-cigarettes currently on the market - would 
have to be authorised as medicines.60 When the proposal came before the 
EU Parliament in 2013, numerous amendments to the Article were proposed 
including deleting Article 18 altogether so that all e-cigarettes could only 
be sold as medicines under pharmaceutical regulations. Significant to these 
deliberations were major objections from e-cigarette consumers. Eventually 
in December 2013, a compromise text was agreed between the European 
Parliament and the Council of Ministers.61
56 Godfrey, F (2000). An overview of European tobacco control legislation. Central European Journal of Public 
Health; 8(2), p.128-31
57 Skoal Bandits were banned in the UK in 1989. The Herald, Safety ban on Skoal Bandits (1989)  
http://www.heraldscotland.com/news/11972277.Safety_ban_on_Skoal_Bandits/
58 European Union, Directive 2014/40/EU of The European Parliament and of The Council (2014)
 http://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32014L0040&from=EN
59 Tiessen, J. et al (2010) Assessing the Impacts of Revising the Tobacco Products Directive. Rand Europe.  
Available at https://ec.europa.eu/health/sites/health/files/tobacco/docs/tobacco_ia_rand_en.pdf
60 European Commission, Directive of the European Parliament and of the Council. EC, 2012. Available at  
https://ec.europa.eu/health/sites/health/files/tobacco/docs/com_2012_788_en.pdf
61 European Parliament, Tobacco directive: MEPs reach agreement with Council Ministers. European Parliament, 
2013. Available at http://www.europarl.europa.eu/news/en/press-room/20131216IPR31001/tobacco-directive-
meps-reach-agreement-with-council-of-ministers
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Key provisions of TPD2 2014 
In 2014 a revised Tobacco Products Directive known as TPD 2 was issued by the 
EU to update the 2001 Tobacco Products Directive. 
TPD2 regulates all tobacco products in the European Union and its scope 
is wide. It covers product regulation in terms of reporting obligations of 
ingredients and emissions for all tobacco products. It includes product 
packaging and labelling including the size and appearance of products, 
traceability features to be fixed onto packaging as well as health warnings. It 
covers cross-border advertising of tobacco products; it reinforces the ban on 
oral tobacco products (snus), but importantly it provides for the placing on 
the market of e-cigarettes and refill containers, as well as making provision for 
notification of novel tobacco products. It also provides for herbal cigarettes. 
Smokeless Tobacco Products
TPD2 regulates smokeless tobacco products and contains a specific requirement 
for the labelling of smokeless tobacco products including a specific health 
warning text in Article 12: “This tobacco product damages your health and is 
addictive”. The provisions on Traceability and Security features also apply to 
“Tobacco products other than cigarettes and RYO” – only at a later date for 
implementation. 
TPD2 defines a ‘Smokeless tobacco product’ as “A tobacco product not involving 
a combustion process, including chewing, tobacco, nasal tobacco and tobacco 
for oral use”. ‘Tobacco for oral use’ is defined as “Tobacco products for oral 
use, except those intended to be inhaled or chewed, made wholly or partly of 
tobacco, in powder or in particulate form or in any combination of those forms, 
particularly those presented in sachet portions or porous sachets” – it is clear 
they are referring to snus. So, while smokeless tobacco products are permitted 
and regulated in TPD 2, snus remains banned except in Sweden. This is made 
clear in the very short Article 17: “Members States shall prohibit the placing on 
the market of tobacco for oral use, without prejudice to Article 151 of the Act 
of Accession of Austria, Finland and Sweden”. The outcome is a questionable 
one on reduced harm grounds, as Swedish snus is known worldwide as the 
least harmful tobacco product backed up by more than 50 years of scientific 
and epidemiological research, and Sweden has the lowest number of tobacco 
related deaths in Europe. 
Novel tobacco products
TPD 2 provides for new and modified products in Article 19 through a notifica-
tion system. Manufacturers of novel tobacco products, defined as products that 
do not fall into the categories of: cigarettes, roll-your-own tobacco, pipe to-
bacco, waterpipe tobacco, cigars, cigarillos, chewing tobacco, nasal tobacco, or 
tobacco for oral use, are required to give six months’ notice before putting  
a product on the market.  
What is required is a detailed description of the novel product, instructions 
for its use, information about ingredients and any emissions it may have. In 
addition, other information that can be provided should be provided, including: 
any available scientific studies on toxicity, addictiveness and attractiveness 
of the novel product; any available studies or market research, including any 
information known about preferences of consumer groups, including from 
young people and current smokers; any available risk/benefit analysis of the 
product; its expected effects on cessation; its expected effects on initiation of 
tobacco consumption; and any predicted consumer perceptions. Member States 
may require manufactures to carry out additional tests if they believe there is  
a need for more information. 
Any novel products placed on the market must respect the TPD2 in terms of its 
other provisions where applicable, and depend on whether the novel product is 
defined as a smokeless product or a tobacco product for smoking. 
In addition to the notification system for novel products, TPD2 allows 
Member States to introduce an authorisation system and charge fees for that 
authorisation. In the UK, this option is available via the MHRA.  
E-cigarettes 
There were high expectations placed on the outcome of the TPD regarding 
e-cigarette regulation. Although some would argue that the regulations are 
not optimal in terms of nicotine levels, or with the requirements of the refill 
containers, most would agree that the ultimate regulation of e-cigarettes in 
Europe as consumer products far outweighs the pharmaceutical medicinal 
outcome or a complete ban, which were both possible options. The driving force 
behind the TPD seemed less to do with public health and is more concerned 
with legislative harmonisation and “The smooth running of the internal market”.
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E-cigarettes, and refill containers, can only be placed on the market as consumer 
products in the EU if they comply with the TPD2, although e-cigarettes that take 
the medicinal authorisation route do not have to comply. Just like novel products, 
a manufacturer of e-cigarettes must notify the authorities of the intention to put  
a product on the market six months prior and provide a further new notification 
for any modifications. Notification needs only to include the name of 
manufacturer, a list of ingredients and emissions, by name, brand, and type. The 
notification must also include the nicotine dose and uptake information. There 
must be a description of the components of the product, such as how the refill 
container opens and how the mechanisms work. A description of the production 
process and its conformity with the TPD is also required, as well as a declaration 
taking full responsibility for the product’s safety and quality is needed. 
Other requirements of the e-cigarette provisions of the Directive: 
» The capacity of e-cigarette refill tanks is restricted to no more than 2ml and 
a maximum volume of e-liquids containing nicotine for sale for one refill 
container to 10 ml;
» The nicotine strength of e-liquids is restricted to no more than 20mg/ml; 
» Products containing nicotine and their packaging must be tamper proof and 
resistant to child tampering;
» The use of certain ingredients including taurine, colourings, and caffeine, are 
prohibited;
» The mandatory use of new labelling and health warning signs on the packaging;
» Packages include a leaflet with information on instructions for use and 
storage; warnings for young people and non-smokers; possible side effects; 
addictiveness and toxicity; and contact details for the manufacturer or importer 
within the EU;
» Labelling for both e-cigarettes and refill containers must include a list of 
ingredients in descending order of weight;
» Products must carry a health warning that says either: “This product contains nico-
tine which is a highly addictive substance. It is not recommended for use by non-
-smokers” or “This product contains nicotine which is a highly addictive substance”;
» Commercial communications are prohibited except in trade publications and 
in specialist tobacco outlets.
In relation to the best interests of tobacco harm reduction, treating e-cigarettes 
as if they were tobacco products is problematic ,and, in effect, TPD2 dealt with  
a public health problem the EU did not have. Some of the most significant issues 
highlighted by former UK ASH Director Clive Bates are:
» Banning advertising hampers the development of trusted brands, 
communication of innovation and the aspirational messages that help new 
products succeed in encouraging a switch away from cigarettes. It means, for 
example, that a tobacco company cannot put a leaflet in a cigarette packet 
suggesting a smoker switch to an e-cigarette;
» Limiting the strength of nicotine liquid to 20mg/ml (two percent) is a potential 
problem because: 
¦ Stronger liquids may be more important for more heavily dependent 
smokers to switch;
¦ They are important for smokers in the process of switching – new users 
may not have acquired the skill or familiarity to find vaping a satisfactory 
alternative to smoking in the early days – the strength limit is likely to cause 
more to relapse; 
¦ In a market that values miniaturisation it may be a barrier to innovation – 
allowing more nicotine to be kept in a smaller volume may be important in 
future product design;
¦ For those users who would prefer stronger e-liquids, it will mean they will 
need to inhale more vapour to get the nicotine they want – if there are any 
hazardous substances in vapour, this policy will increase exposure. If the 
concern is poisoning, then child-resistant containers are the answer;
» Limiting the size of nicotine liquid containers to 10ml and tanks or cartridges to 
2ml is probably based on a misunderstandings of nicotine toxicity and overstated 
LD50 (lethal dose). What it means for consumers is more frequent refilling, more 
spillage possibilities, more chance of running out, and high costs for users etc.;
» The need for warnings is debatable as there is nothing like the risk inherent in 
cigarettes. In addition, each pack is required to contain a leaflet – even though 
nothing similar is required for cigarettes.
» The procedure for bringing a product to market is far more onerous than for 
a new cigarette brand which requires minimal testing of crude metrics (TAR, 
nicotine and carbon monoxide) with long established protocol”.62
62 The counterfactual, What is wrong with the Tobacco Products Directive for vapour products? (2015)  
https://www.clivebates.com/what-is-wrong-with-the-tobacco-products-directive-for-vapour-products/
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“In relation to the best interests of tobacco harm reduction, treating 
e-cigarettes as if they were tobacco products is problematic and in effect dealt 
with a public health problem the EU did not have”.
A brief note on taxation
A central tenet of tobacco harm reduction is to make those products which are 
demonstrably safer than cigarettes as easy as possible for existing smokers to 
access, in order to encourage them to switch away from cigarettes. An important 
factor in promoting that switch is the price of products compared to cigarettes 
including tax levied by local and national governments.63
As a commodity, tobacco along with alcohol and gambling are subject to what is 
often called a ‘sin tax’, an extra levy which represents society’s disapproval of  
a commodity or activity or at least a behaviour or activity which is not necessa-
rily ‘disapproved’ of, but where the state wants to ‘nudge’ people in a different 
direction.  Recently the UK introduced a ‘sugar tax’ on soft drinks and there is a 
US proposal that would block pornography on devices unless consumers paid a 
tax,64 while those states which have legalised or are planning to legalise marijua-
na expect to raise significant ‘sin’ tax revenues.65 Regulators like sin taxes as they 
aim to discourage unhealthy behaviours like smoking and excessive drinking, 
they help pay for the health costs of those behaviours, and they are popular with 
voters because only those who indulge have to pay. Regulators also like this type 
of tax because, so long as the tax is not unduly onerous, people will continue to 
buy the commodity despite tax increases thus securing a tax revenue stream. 
However, in their article published in the New England Journal of Medicine, 
Frank Chaloupka and colleagues argued there should be differential tax levies 
to signal differential risk in nicotine products.66 But the authors acknowledged 
that a balancing act needs to be achieved, “To alleviate concerns that low 
prices on [SNP] might encourage uptake among young people, taxes on such 
products could be set high enough to discourage initiation. At the same time, 
taxes on combustible products could be further increased in order to raise their 
prices relative to less harmful non-combustible products. Such a strategy would 
maximize the likelihood of current smokers switching to lower-risk products while 
deterring users of lower-risk products from switching to more harmful ones. 
Higher prices for combustible products would have the added benefit of further 
reducing the likelihood that young people would take up smoking”.67
The current state of play regarding SNP taxation is very fragmented. At the 
global level, the FCTC has little to say about tax excepting a WHO report on SNP 
that suggested Member States should tax SNP “At a level that makes the devices 
and e-liquids unaffordable to minors in order to deter its use in this age group”.
However, the WHO has commended the World Customs Organization (WCO) 
to confirm a proposal to move e-liquids from their current categorisation under 
Chemicals to a new sub-section under Tobacco to be designated as non-
tobacco products containing nicotine.
The WCO, established in 1952, is an independent intergovernmental body 
representing around 200 Member State customs administrations across the 
globe that collectively process approximately 98 percent of world trade. Among 
many functions, the Brussels-based organisation maintains the international 
Harmonised System (HS) of naming goods. HS codes are used by customs 
authorities, statistical agencies, and other government regulatory bodies, to 
monitor and control the import and export of commodities. And the penalties for 
mis-classifying a product can be punitive, including import bans and seizures.
In November 2016 the WCO Member States unanimously decided to classify 
e-liquids as Chemical Products in the HS. Now they are looking at reclassifying 
e-liquids under ‘Tobacco and manufactured tobacco substitutes’.
The WCO published a document in which it discussed shifting e-cigarettes 
and e-liquids out of the chemicals category and into the tobacco category. 
Despite the actions of many Member States, for the purposes of international 
trade, e-cigarettes are not classified as tobacco products. But there are some 
potentially serious consequences for tobacco harm reduction and affordability 
of products:
63 There is also the issue of the cost of the devices, so that cigarettes need to be taxed at a level which still 
encourages switching, even taking into account the costs of purchasing the device. Liber, A.C et al (2017). 
Combustible cigarettes cost less to use than e-cigarettes: global evidence and tax policy implications. Tobacco 
Control; 26 (2), 158–163
64 AZFamily.com, Bill would block porn on new phones, computers unless consumers pay a tax (2017) http://www.
azfamily.com/story/35195078/bill-would-block-porn-on-new-phones-computers-unless-consumers-pay-a-tax
65 ZeroHedge, Marijuana Expected To Be California’s Largest ‘Sin Tax’ As Jerry Brown Set To Release Surplus Budget 
(2018) https://www.zerohedge.com/news/2018-01-10/marijuana-expected-be-californias-largest-sin-tax-jerry-
brown-set-release-surplus
66 Chaloupka, F. et al. (2015). Differential taxes for differential risks — toward reduced harm from nicotine-yielding 
products. New England Journal of Medicine; 373:594–597
67 WHO (2016).Electronic delivery systems and electronic non-nicotine delivery systems: report for the COP 
meeting 2016, p.6
100           CHAPTER 6 
Kentucky’s General Assembly recognised that “Increasing taxes on tobacco 
products should reduce consumption, and therefore result in healthier lifestyles 
for Kentuckians. The relative taxes on tobacco products […] reflect the growing 
data from scientific studies suggesting that although smokeless tobacco poses 
some risks, those health risks are significantly less than the risks posed by other 
forms of tobacco products. Moreover, the General Assembly acknowledges that 
some in the public health community recognize that tobacco harm reduction 
should be a complementary public health strategy regarding tobacco products. 
Taxing tobacco products according to relative risk is a rational tax policy and 
may well serve the public health goal of reducing smoking-related mortality 
and morbidity and lowering health care costs associated with tobacco-related 
disease”.
“Taxing tobacco products according to relative risk is a rational tax policy”.
Conclusion
The advent of new SNP products presents a serious challenge to established 
tobacco regulatory control regimes at both a national and international level. As 
a result, far too many regulatory anomalies exist in the global SNP space.  
It is an odd regulatory world where the safest tobacco product is banned, as 
snus is in the EU, and yet the most lethal (cigarettes) can be bought freely almost 
anywhere. E-cigarettes and HNB – are they different categories? Or are they both 
e-cigarettes producing vapor where in one the nicotine is derived from liquid, 
while in the in the other the nicotine is derived from tobacco? Should they be 
regulated equally or differently? Should all non-combustible SNPs be allowed, 
and consumers be the ones that choose what works? If all are deemed safer 
compared to cigarettes, should the regulator decide what a consumer should 
have access to, or should the consumer be permitted to decide what he/she 
prefers? These are the regulatory questions that must be addressed as a matter 
of urgency for the sake of global public health.
68 Velvet Glove, Iron Fist, E-cigarettes to be re-classified as tobacco? (2018) https://velvetgloveironfist.blogspot.
com/2018/05/e-cigarettes-to-be-re-classified-as.html
69 Personal communication, E Cig Intelligence
70 Public Health Law Center. US e-cigarette regulation: a 50-state review. Mitchell Hamline School of Law, 2017
71 Tobacco Truth, Kentucky Adopts a Rational Tobacco Tax Plan (2018) https://rodutobaccotruth.blogspot.
com/2018/05/kentucky-adopts-rational-tobacco-tax.html
» Some regions apply a 100 percent additional tax on tobacco products in 
addition to import tariffs;
» Tobacco products are left out of trade deals, so if classified as tobacco 
products, there could be no tariff discount deals struck on behalf of safer 
nicotine products;
» Tobacco products are excluded from foreign investor protection under most 
new trade deals. So if somebody started an e-cigarette business in one country 
and found that the government in that country changed all its policies to 
become highly anti-vaping, the owners would not be protected by foreign 
investor protection treaties.68
Outside of the EU and some US states, only Bangladesh, Indonesia, Kenya, 
Russia, Serbia and South Korea levy tax on e-cigarettes with Kazakhstan set to 
levy a tax.69 Within the EU, the TPD, like the FCTC, does not instruct on domestic 
tax matters leaving it to Member States to decide on whether or not to tax SNP. 
Currently 13 EU countries have opted to tax. However, the EU’s Directorate-
General for Taxation and Customs Union has been considering proposals for 
a harmonising Europe-wide tax on e-cigarettes and HNB products recently 
launching the second of two consultations.
In the US, while there is a Federal tax on snus-type products, there is no tax on e-
-cigarettes again leaving individual states to decide on whether or not to impose  
a tax. Most states have chosen not to impose a tax, but around ten states have a tax 
regime in place. Minnesota was the first state to impose a volume tax in 2010 on 
‘other tobacco products’ at 70 percent of the wholesale price which leapt to 95% in 
2013. Other state wholesale taxation levels include the District of Columbia (70 per-
cent), California (65 percent) and Pennsylvania (40 percent). However, some states 
like North Carolina and Kansas have adopted taxation by volume per ml of liquid 
which is to the advantage of closed cig-a-like systems whose liquid level is 1–2ml 
and to the disadvantage of open systems which have much higher liquid levels in 
turn favouring some larger manufacturers over smaller, independent companies.70
On the other hand, Kentucky has taken a ground-breaking tobacco harm 
reduction approach. In May, the Kentucky legislature passed a tax reform bill 
that increased cigarette excise taxes from $0.60 to $1.10, while leaving taxes on 
smokeless products unchanged with no excise tax at all on e-cigarettes. This was 
in line with the tax regime proposed by Kentucky University’s Brad Rodhu and his 
colleague Nantaporn Plurphanswat71.
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But significant barriers exist to evidence-based proportionate regulation. In their 
deliberations over legal controls on SNP, legislators and politicians are no less 
immune than health professionals or ordinary consumers from being confused 
by contradictory research findings, or influenced by the work of individual 
influential activists and sensationalised media reporting. Regulatory outcomes 
also need to be viewed from the prism of the complex story of tobacco control 
and the infamous and well documented history of the tobacco industry attempts 
to undermine those control efforts.
However, this understandable antipathy toward the industry has been wildly 
over-interpreted by the WHO to make it impossible for there to be any 
meaningful dialogue about SNP and tobacco harm reduction between an 
industry, by no means dominated by the major tobacco companies, and those 
charged with determining international global tobacco policy. Exclusion from 
the debate also extends to a wide range of academics, clinicians, public health 
analysts and consumer groups. This particularly impacts on LMIC, which both 
suffer from the highest levels of death and disease from smoking and are at the 
same time least able to implement FCTC provisions through lack of resources 
and other political and bureaucratic obstacles.
It is perfectly valid for there to be laws and regulations to protect consumers 
through the raft of general product safety standards and regulations that exist 
in many countries. However, to use the law to deny or inhibit access to SNP, 
through outright bans to cumbersome, bureaucratic and cripplingly expensive 
processes for bringing products to market, is not only to deny the current robust 
and independent evidence base. It also squanders the opportunities for major 
public health benefit. To repeat, paradoxically, it simply perpetuates use of the 
cigarettes (which are freely available the world over) and ensures continuing 
profits for major international corporations.
To act in this way against SNP also puts global tobacco control at odds with 
many internationally agreed treaties focusing on the fundamental right to the 
best possible health for all citizens. This takes us to the last chapter of this report. 
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Figure 6.7 
E-cigarette legal/regulatory status
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Sources: see also www.gsthr.org for more details on sources and methods. 
1 Vapetrotter. Available at: https://www.vapetrotter.com/laws/ 
2 Tobacco Control Laws website. Available at: https://www.tobaccocontrollaws.org/legislation/   
3 E-cigarette Politics website. Available at: http://www.ecigarette-politics.com/why-snus-is-important.html  
4 Global tobacco control website. Available at: http://globaltobaccocontrol.org/e-cigarette/   
5 Appiah P. (2018). Ghana to ban Shisha, electronic cigarette by June . Joy Online. Available at: https://www.myjoy-
online.com/lifestyle/2018/march-12th/ghana-to-ban-shisha-electronic-cigarette-by-june.php 
6 Information also provided by in-country experts      
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Figure 6.8 
Snus legal/regulatory status
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Sources: see also www.gsthr.org for more details on sources and methods.
1. Vice.com website available at: https://www.vice.com/en_uk/article/ywz5ek/meet-the-17-year-old-getting-rich-
-dealing-snus-illegally 
2. Tobacco Tactics website available at: http://tobaccotactics.org/index.php/Snus:_EU_Ban_on_Snus_Sales 
3. Snusdirect website available at: https://www.snusdirect.com/articles/eu-snus-ban   
4. Peeters S.and Gilmore A.B. (2013) How online sales and promotion of snus contravenes current European Union 
legislation. Tobacco Control. 22. 266-273.       
5. Snuscentral website available at: https://www.snuscentral.com/blog/snus-users-in-switzerland-can-legally-buy-
-snus-from-snuscentralcom-n44        
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Chapter 7:
Human rights, public 
health and tobacco harm 
reduction 
This section brings us back to the heart of the matter – the right to health for all, 
as enshrined in international conventions and in public health policies. Linked to 
that are issues of personal autonomy, the obligations of the state to give people 
the information they need to make informed choices about personal health, and 
how advocacy groups have taken matters into their own hands when the state is 
seen not to be acting in their best interests.
The notion of public health was born during the 19th century in newly 
industrialised cities across Europe and North America, to combat the appalling 
toll of death and disease suffered by those living in dire poverty. This moved into 
more individualised areas of public health, with the discovery of germ theory 
and the benefits of immunisation, vaccination and family planning. But as poor 
sanitation, which caused diseases like cholera to ravage cities, was improved, 
the drive towards public health gave way to a greater emphasis on medical 
intervention. The medical profession enjoyed increasing power, underpinned by 
the discovery of drugs such as insulin and antibiotics. John Ashton and Howard 
Seymour argue in their book The New Public Health1 that public health rose even 
higher up the health policy agenda following the publication of a Canadian  
report in 1974, which demonstrated that much of the premature death and 
disability in Canada was preventable. This created an environment which 
acknowledged that there were many factors associated with ill-health, not just 
individual pathology. This in turn opened the door to a new era of public health, 
centred on proactive health promotion. The process whereby mortality in higher-
income countries has ceased to be linked primarily to infectious disease and 
has instead been linked to degenerative disease has been described as the 
‘epidemiological transition’.2 
“There is a fundamental right for all people – including smokers – to the 
enjoyment of the highest attainable standard of health, and to have the right 
to information, services and products that may assist them to achieve that 
objective”. 
Jeannie Cameron – international consultant in advocacy and public affairs
Many of these health-related rights are enshrined in international agreements, 
some of which are outlined below. There are many factors globally that may 
prevent the desired level of health being achieved due to differing levels of 
prosperity and stability in the countries of the world, which leads therefore to 
inequality. However, where information, services and products do exist, then 
there is a corresponding obligation for the providers of that information, service 
and product to make it available to those that want it.
In the context of smoking, it should be the right of smokers to gain access to 
information, services and products that can reduce the harm from smoking to 
enable them to achieve a higher quality of health and life should they wish to 
do so. Governments should perform their obligations in this regard by creating 
policy, regulation and legislation that enables smokers to have information about 
and access to services and products that can reduce the harm from smoking. 
At present, only a few governments are allowing and facilitating these rights. 
Equally, it is important that companies, including tobacco companies, which 
can provide products that are less harmful than smoking, are permitted, indeed 
encouraged, to produce them for consumers and put them on the market. At 
this point in the global debate on SNP, these two elements are not aligned. 
Products are available, but governments are not providing access to them 
or information about them. Scientific evidence is available, from some of the 
world’s leading scientific and medical institutions such as the UK Royal College 
of Physicians, and yet there is a resistance to accept it from some of the world’s 
most significant tobacco control activists. This is especially the case for Swedish 
snus, where there is approximately 50 years of epidemiological evidence to 
prove the issue. From a human rights perspective, smokers should be allowed 
to have information about and access to snus, and yet it is banned in many 
1 Ashton J.R. and Seymour H. The New Public Health. Open University Press, 1988
2 Omran, A.R. (1971). The epidemiologic transition: a theory of the epidemiology of population change. Milbank Q. 
49 (4) p. 509–538
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countries in the world. This makes no sense when the most harmful of nicotine 
delivery devices, a cigarette, is freely available almost everywhere in the world. 
The FCTC itself is very clear about health rights and its text reminds and recalls 
the world’s most significant human rights agreements. “The FCTC makes 
clear that harm reduction strategies are part of tobacco control. It provides an 
obligation on FCTC parties to not only allow reduced-risk products but actively 
promote them as part of implementing their tobacco control policies based on 
the most current and relevant scientific, technical and economic considerations 
— so as to provide for the universal right to the highest attainable standards of 
health, politically, practically or otherwise.”3
Human rights, the right to health, smoking and SNP
Framework Convention on Tobacco Control 2005: Article 1d refers to harm 
reduction as one of the defining strategies of tobacco control: “A range of 
supply, demand and harm reduction strategies that aim to improve the health 
of a population by eliminating or reducing their consumption of tobacco 
products and exposure to tobacco smoke”.
The International Covenant on Economic, Social and Cultural Rights 
1966: Article 12 recognises: “the right of everyone to the enjoyment of the 
highest attainable standard of physical and mental health” and that States 
Parties must take steps regarding “The prevention, treatment and control of 
epidemic, endemic, occupational and other diseases”. 
World Health Organization Constitution 1946: The preamble states that 
“The enjoyment of the highest attainable standard of health is one of the 
fundamental rights of every human being without distinction of race, religion, 
political belief, economic or social condition.” 
European Social Charter 1965: “Everyone has the right to benefit from any 
measures enabling them to enjoy the highest possible standard of health 
attainable”. Article 11 requires states to take measures to prevent disease and 
to encourage individual responsibility in matters of health.
The EU Charter on Fundamental Rights 2000. Article 35 stipulates that a 
high level of human health protection shall be ensured in the definition and 
implementation of all the Union’s policies and activities. 
The momentum for a new approach to public health found its expression in the 
WHO Global Strategy of Health for All by the Year 2000 published in 1981.4 Its 
guiding principle was that “All people in all countries should have at least such a 
level of health that they are capable of working productively and of participating 
actively in the social life of the community in which they live”.
The key question was, how do states deliver on this? And the answer was a 
commitment to health promotion enshrined in the 1986 Ottawa Charter for 
Health Promotion.5 The Charter stressed, at the top of the list, the imperative 
to build public policies which support health, such that health promotion is 
an agenda item in all areas of government and organisational policy-making: 
“Any obstacles to health promotion should be removed with the aim of making 
healthy choices the easiest choices”. The Charter makes clear that: “Health 
promotion policy requires the identification of obstacles to the adoption of 
healthy public policies in non-health sectors, and ways of removing them. The 
aim must be to make the healthier choice the easier choice for policy-makers as 
well”. Furthermore, it puts people at the centre of this: “People cannot achieve 
their fullest health potential unless they are able to take control of those things 
which determine their health”.
Harm reduction, drugs and HIV
At the time the Ottawa Charter was published, the USA was in the grip of an 
HIV/AIDS epidemic. There were all kinds of myths and misinformation about 
AIDS, ranging from a public perception that you can ‘catch’ AIDS from toilet 
seats, or touching sufferers, through to pulpit rantings about God’s revenge on 
homosexuals. But once it was established that the AIDS virus was transmitted 
through bodily fluids, gay activists in the most affected cities of San Francisco 
and New York began a grass roots, community-based, self-help initiative to 
educate and support their peers about safer sexual practices. 
3 Tobacco Reporter, By the Book (2015) https://www.tobaccoreporter.com/digital/december2015/html5/index.
html#
4 World Health Organisation, Global Strategy of Health for All by the Year 2000. WHO, 1981. Available at http://
apps.who.int/iris/handle/10665/38893
5 World Health Organisation, Ottawa Charter for Health Promotion. WHO, 1986. Available at http://www.who.int/
healthpromotion/conferences/previous/ottawa/en/
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It soon became apparent that those who were injecting drugs were similarly 
at risk and this created a new arena for community-based self-help. It is hard 
to imagine a more marginalised and despised group in society than injecting 
drug users. They were on nobody’s public health or even primary care agenda, 
while drug treatment services were patchy and poorly funded in all western 
countries. By the mid-1980s, there was already a Dutch drug-using group who 
were offering help and peer support to users in the Netherlands. It was there, 
in the wake of the AIDS crisis, that the idea of encouraging people not to share 
needles and syringes by giving out clean equipment first took root. This was very 
much in the context of what might be termed ‘guerrilla public health’, initially 
undertaken with no support from health professionals.
The UK took this further: a partnership of user activists and enlightened  
public health officials and clinicians offered both practical support and secured 
critical political backing. This created a safe environment for injecting drug 
users, who had access to opiate substitute prescribing and needle exchange 
facilities. This led to the UK registering the lowest prevalence of drug-related 
HIV in Europe.6 
And it was in the UK that the term ‘harm reduction’ was first coined,7 
becoming not only a health intervention but taking on the colour of a social 
movement.8
Notwithstanding the WHO commitment to ‘health for all’, this did not initially 
extend to accepting health interventions for drug users that would help keep 
them alive. There was no attempt to encourage Member States to empower and 
strengthen these individuals and their communities to make healthier choices. 
Instead, the WHO and the UN Office of Drugs and Crime (UNODC) were 
staunchly opposed to the whole concept of harm reduction. Public health was 
viewed through a prism of abstinence, prevention, treatment and regulation.9 
As far as the WHO, UNODC (and their primary funder, the US Government) 
were concerned, harm reduction was simply a mechanism for condoning drug 
use and a stalking horse for those who were campaigning for drug law reform. 
Fortunately, these international bodies came to endorse drug harm reduction 
interventions such as needle exchange.
While drug harm reduction has gained some acceptance at an international 
level, unfortunately, at a global level, tobacco harm reduction has not done well. 
In 1998, the UN declared “A drug-free world. We can do it”, the idea being that 
as the drugs being referenced were illegal, drug enforcement policies would 
deliver on this political ambition. With the entry into force of the FCTC in 2005, 
we now have the political ambition of a tobacco-free world, built on a similar 
premise of enforcement and control. 
However, given the evidence of the relative safety of non-combustible nicotine 
products, opposition to tobacco harm reduction directly contravenes all of 
the international human rights agreements and basic principles of the Ottawa 
Charter of making the healthier choice the easiest choice. It does this not only 
by using stigma as health policy, and/or by restricting access to the healthier 
choice, but (as outlined in Chapter 5) to the extent of deliberately circulating 
misinformation and sowing public confusion about the potential health benefits 
of switching to SNP.
“Opposition to tobacco harm reduction directly contravenes all of the 
international human rights agreements and basic principles of the Ottawa 
Charter”.
For nearly 20 years now, US Professor Lynn Kozlowski has been writing about the 
rights of smokers to be properly informed about harm reduction options. One of 
his earliest papers framed this premise as follows:
“The right to information derives from the principle of respect for autonomy 
[…]. If people are deprived of information relevant to their health, they 
will necessarily be deprived of choices that might protect their health. In a 
tradition deriving from the Nuremberg Code (1949)10 and the United Nations 
Declaration of Human Rights (1948), the American Public Health Association 
concluded, ‘Human rights must not be sacrificed to achieve public health 
6 Stimson, G.V. (1995). AIDS and injecting drug use in the United Kingdom 1988-93: the policy response and the 
prevention of the epidemic. Social Science and Medicine; 41 (5) p.699-716
7 Newcombe, R. (1987) High time for harm reduction. Druglink Jan/Feb
8 Stimson, GV (2016). A tale of two epidemics: drugs harm reduction and tobacco harm reduction in the United 
Kingdom. Drugs and Alcohol Today; (16) 3, p.203–211
9 MacCoun, R.J. (2012). Moral outrage and opposition to harm reduction. Goldman School of Public Policy. 
Available at https://gspp.berkeley.edu/research/selected-publications/moral-outrage-and-opposition-to-harm-
reduction
10 A ten-point code concerned with the rights and safety of those volunteering to take part in medical research.
125CHAPTER 7HUMAN RIGHTS, PUBLIC HEALTH AND TOBACCO HARM REDUCTION
goals, except in extraordinary circumstances in accordance with internationally 
recognised standards’”.11
Figure 7.1
Right to use safer nicotine products = Individual and public health benefit
Kozlowski’s paper, published in 2002 before the first e-cigarette was available 
anywhere, focused on the harm reduction potential offered by snus and 
medicinal nicotine. He concluded that there was no evidence that these 
products presented a risk sufficient to negate the rights of smokers to access 
relevant public health information.
More recent papers published by Professor Kozlowski and colleagues suggest 
that little has changed in terms of the withholding of truthful information and 
communication of misinformation to the public about tobacco harm reduction 
options:12 13 “Ethical and effective public health campaigns need to respect and 
work with consumers to facilitate better informed choices. Campaigns that fail to 
address existing misinformation that may be leading to much more hazardous 
behaviours, and worse, campaigns that continue deceptions, can be expected to 
impose a real cost.”14
He goes onto assert that, as the tobacco companies have been ordered to come 
clean about past lies and deceptions, the same obligations of openness and 
transparency should apply to government agencies and health campaigning 
groups.
Ironically, while the US Government has failed to make it clear that smokeless 
tobacco is much safer than combustible tobacco, as Kozlowski and colleagues 
have also highlighted, the opioid crisis which has hit the USA in the past 10–15 
years has changed official thinking on drug harm reduction.
Funding is now available for opiate substitute treatment and the provision of the 
drug naloxone which immediately reverses the effect of opioid overdose, while 
the Surgeon General has publicly supported the provision of needle exchange.15 
Over the same period (2000–16), around 7.5 million Americans have died from 
a smoking-related disease. From a health perspective, the same US government 
agencies are responsible for both drugs and tobacco, and it would be a very 
significant step forward if they were now to apply the principles of harm 
reduction across the board.
Figure 7.1 
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11 Kozlowski, L.T. (2002). Harm reduction, public health, and human rights: smokers have a right to be informed of 
significant harm reduction options. Nicotine and Tobacco Research s.67–72
12 Kozlowski, L. T and Edwards, B.Q. (2005) ‘Not safe’ is not enough; smokers have a right to know more than there is 
no safe tobacco product. Tobacco Control; 14, 3–7
13 Kozlowski, L.T. and Sweanor, D. (2016). Withholding differential risk information on legal consumer nicotine/
tobacco products; the public health ethics of health information quarantines. International Journal of Drug Policy; 
32, p.17-23 
14Kozlowski, L. T. and Sweanor, D. (2017) Young or adult users of multiple tobacco/nicotine products urgently 
need to be informed of meaningful differences in product risk. Addictive Behaviour: 76, p. 376–381.  Follow up 
commentary (2018). ‘Not harmless’ messages without comparisons disserve consumers, potential consumers and 
pubic health approaches to tobacco/nicotine products. Addictive Behaviour, 76, p.390–391 
15 Meehan, M. (2018) Surgeon General Supports Needle Exchanges To Limit Disease From Opioid Crisis. 89.3 WFPL. 
Available at: http://wfpl.org/surgeon-general-supports-needle-exchanges-to-limit-disease-from-opioid-crisis/ 
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Special populations
Smokers who are thinking of quitting or want information on a healthier option 
for consuming nicotine are often poorly served by public health authorities. But, 
some groups of smokers are in the greatest need of easy access to SNP. These are: 
smokers who belong to those mainly lower-income groups with a higher smoking 
prevalence than the general population; who have disproportionate tobacco-
-related health disparities; who are more likely to have enduring drug, alcohol or 
mental health problems; and have less access to smoking cessation services.
Special populations of smokers, especially those living in the poorer countries, 
potentially face several disadvantages in trying to access SNPs. These include: 
outright domestic bans (which further impact on those living in public housing 
or institutions such as prisons and mental health hospitals); internet only access 
where a credit card or address is needed for purchase and delivery; the initial 
cost of the products themselves compounded by onerous taxation; and the 
simple inability to charge a device due to lack of ready access to electricity.
Figure 7.3
Smoking prevalence among US special population groups16
Schizophrenia   64–74%
Depression   34–60%
Alcohol dependence  67.9%
Bipolar disorder  69%
Generalised anxiety  54%
Drug use   74–88%
Native American  32.4%
Mobility impaired  32.5%
HIV/AIDS   40–65%
Homeless   70–78%
Below poverty level  30%
Men who have sex with men   33%
Military    33%
Average prevalence of those with serious heart and respiratory conditions  37%
Source: Borelli, B. (2010). Smoking cessation; next steps for special populations research and innovative treatments. 
J Consulting and Clinical Psychology. 78 (1), p.1–12
Although Figure 7.3 focuses on US data, the list of those groups containing 
smokers in special need of other routes out of smoking is reasonably similar to 
other countries. For example, a WHO report on tobacco and inequities observed 
“In general terms, lower socioeconomic groups in Europe have higher rates of 
smoking than higher socioeconomic groups. Lower socioeconomic groups also 
commonly start smoking at a younger age, smoke more cigarettes per day and 
stop smoking less often than people in higher socioeconomic groups. Low-
income smokers are more intensely addicted to nicotine and are likely to require 
more support to stop smoking”.17 Smoking prevalence among these vulnerable 
groups in the UK is considerably higher than in the general population.18 In New 
Zealand, 38 percent of Maori women smoke. This is at an even higher level than 
Maori men (32 percent), which itself is double that of New Zealand men in the 
general population.19 In 2018, the Australian Parliament conducted a review 
of e-cigarettes and heard evidence from academics and clinicians about the 
smoking toll among vulnerable groups. One witness focused on the risks of 
smoking posed to Aboriginal and Torres Straits islanders, while another stated 
that 70 percent of those with a diagnosis of schizophrenia and 61 percent of 
bipolar patients smoked.20 In Bangladesh, tobacco use is higher in the most 
vulnerable groups. Greater percentages of slum and illiterate Bangladeshis use 
smokeless tobacco (26 percent and 24 percent, respectively) compared to urban 
and highly-educated Bangladeshis (eight percent and six percent, respectively). 
A greater percentage of urban (46 percent) and highly-educated (52 percent) 
Bangladeshis did not use any tobacco at all compared to slum residents (36 
percent) and illiterate Bangladeshis (32 percent). Moreover, the study concluded 
that the poorest people had the least awareness of the risks of tobacco.21
Why is smoking prevalence so high among these various groups? At one level, 
people in these groups simply enjoy nicotine the same as anybody else. But 
16 Borelli, B. (2010). Smoking cessation; next steps for special populations research and innovative treatments. 
Journal of Consulting and Clinical Psychology. 78 (1), p.1–12
17 World Health Organisation. Tobacco and inequities; guidance for inequities in tobacco-related harm. WHO, 2014
18 Szatkowski, L and McNeill, A (2015). Diverging trends in smoking behaviours according to mental health status. 
Nicotine and tobacco research. 17; 356–60
19 Personal communication, Professor Marewa Glover, Massey University, New Zealand.
20 Parliament of the Commonwealth of Australia. Report on the inquiry into the use and marketing of electronic 
cigarettes and personal vaporisers in Australia. 
21Driezen, P. et al (2016). Awareness of tobacco-related health harms among vulnerable populations in Bangladesh: 
findings from the international tobacco control (itc) Bangladesh survey. International Journal of Environmental 
Research and Public Health. 13 (9), 848. 
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there is some evidence that, for example, nicotine can help those suffering from 
schizophrenia by enabling them to be more focused.22 For other groups, such 
as homeless people on the streets, smoking and sharing cigarettes can be an 
aspect of social glue or a way of coping with both stress and boredom for a 
group of otherwise isolated and marginalised people. This is also the case for 
those inside prison, another venue for very high smoking prevalence, or those 
generally living a poor and disadvantaged life and living alongside generations 
of smokers. 
But why people in special or vulnerable groups smoke more than the general 
population, while not exactly irrelevant, is nevertheless simply a fact. All the 
incumbent ill-health which follows should be a driver to open all the available 
pathways for people to switch away from smoking.
Tobacco harm reduction advocacy
Just like the gay and drug user activist groups, SNP consumers have not sat 
on the sidelines waiting for governments to act reasonably over consumer 
health protection. Consumers have also banded together to offer help and 
peer support, to provide accurate information about SNP, campaign against 
restrictions on access to the widest range of SNP choices, write opinion pieces 
and run blog sites, supply written and oral evidence to government enquiries 
into SNP, track legislative developments and embark on legal challenges. 
One of the earliest groups formed was the American Consumer Advocates 
for Smoke-Free Alternatives Association (CASAA) founded in 2009.23 Since 
then, similar groups have sprung up all over the world and now many such 
organisations form the membership of the International Network of Nicotine 
Consumer Organisations (INNCO).24 Activists in Europe bombarded their 
Members of the European Parliament with communications expressing concerns 
over the Tobacco Products Directive, while those in Australia have been 
campaigning hard to challenge the intransigence of the government over the 
SNP ban. And gradually, the consumer advocacy groups are being consulted by 
policy makers and invited to high level meetings, as well as banding together 
with independent industry companies and associations to fight against anti-
tobacco harm reduction legislative proposals especially in the USA. One high-
profile activity was undertaken by the UK National Nicotine Alliance (NNA).25 
They joined the challenge to the EU ban on snus.
UK – a challenge to the EU ban on snus – a right to health argument
In 2016, Swedish Match, the main European manufacturer of snus, started a 
legal action in the UK High Court against the ban on snus. The New Nicotine 
Alliance (NNA), a consumer advocacy charity, was given leave by the UK 
High Court to join the challenge as a third-party intervenor acting in the 
public interest. Because UK tobacco law is based on the European TPD, the 
case was referred to the European Court of Justice (ECJ). The NNA made 
its case in January 2018. It was the first time that a ‘right to health’ argument 
has been used to challenge a bad tobacco control law and could prove 
a template for other similar actions around the world. The NNA argued 
comprehensively that the ban contravened all the EU and international 
health rights and so was disproportionate and inimical to the goals of public 
health.
The evidence was presented in the ECJ in January 2018. In April, the 
Advocate General Saugmandsgaard Øe issued his opinion upholding 
the ban. He agreed that the evidence showed snus is less hazardous than 
cigarettes but was of the opinion that it was not up to the ECJ to evaluate the 
evidence, simply to ascertain whether or not the ban was lawful. 
At the E-Cigarette Summit held in London in November 2017, Sarah Jakes from 
the NNA made some key points that from a consumer point of view, smoking is 
not a disease, but a pleasurable activity that nonetheless presents serious health 
risks which smokers should be able to mitigate through personal choice access 
to SNP.
“The word ‘pleasure’ seems to be something of an anathema to some in public 
health. One of the biggest challenges for consumers is in getting regulators, 
and those who advise them, to understand that for a great many people vaping 
is not a medicine, or simply a smoking cessation intervention, it works precisely 
because it isn’t those things. It works because they enjoy it. They love the 
22 Schizophrenia.com, Schizophrenia and Smoking, Cigarettes, and Nicotine www.schizophrenia.com/smokereport.
htm#pos
23 Consumer Advocates for Smoke-Free Alternatives Association (CASAAA) www.csaaa.org
24 International Network of Nicotine Consumer Organisations (INNCO) www.innco.org
25 National Nicotine Alliance (NNA) www.nnalliance.org
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personalisation that’s made possible by the diversity of the market in devices, 
and the thousands of flavours available. They enjoy the identity of being a vaper 
and the sense of community that that entails. They love that vaping is similar to 
smoking, but at the same time a million miles away from it.
“But vaping is more than just a pro-choice campaign. Whilst many vapers do 
regard it simply as a more pleasurable alternative to smoking, many others 
place more importance on the reduction in harm to their health, or the ability to 
use e-cigarettes to stop smoking.
“We want to be able to make our own choices based on accurate information [but] 
we see the choices that are taken away from people by the arbitrary and counter-
productive restrictions on reduced risk products in [for example] the TPD. We see 
our smoking friends being put off vaping by the appalling media coverage”. 
Conclusion
What this report has tried to do is enumerate and explain the advantages of 
embracing tobacco harm reduction as a legitimate approach to help tackle the 
global smoking epidemic. Apart from being founded on the well-established 
principles of the right to health for the world’s citizens, as enshrined in many 
international documents, it is also grounded in evidence-based pragmatism. 
The tobacco cigarette is the most dangerous nicotine delivery device. Safer 
Nicotine Products deliver nicotine with a significant reduction in risk as 
compared to combusted tobacco products – there is ‘No Fire, No Smoke’ . All 
the independent science points to SNP being just that – not just safer, but much 
safer, than smoking cigarettes. 
To reiterate: this is harm reduction, not harm elimination, although on current 
evidence, the reduction seems so significant that we should not distracted by 
concerns about ‘gateway’ effects or ‘re-normalising’ smoking. There is simply 
no robust evidence to support these concerns, despite e-cigarettes being on 
the market for more than a decade. Nor should we be overly swayed by talk 
of nicotine ‘addiction’, a word freighted with the worst images of serious and 
chaotic drug and alcohol use, but which simply does not apply to nicotine.
SNP have been disruptive commodities in all ways imaginable, but it is 
imperative to keep the eyes on the prize – an end to smoking. We must not allow 
over-proscriptive regulation and control to deny access to products that have the 
potential to be one of the most dramatic public health coups of modern times. 
We make no apologies for repeating this point – whereas all other global public 
health interventions come at great financial cost, this one costs governments, 
international agencies and NGOs nothing.
